



428 Rec'd PCT/PTO 19 JAN 2001

FORM PTO-1390H S DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE (REV 5-93) TRANSMITTAL LETTER TO THE UNITED STATES DESIGNATED/ELECTED OFFICE (DO/EO/US) CONCERNING A FILING UNDER 35 U.S.C. 371		ATTORNEY'S DOCKET NUMBER 3477-91 U.S. APPLICATION NO. 09/744167
INTERNATIONAL APPLICATION NO.	INTERNATIONAL FILING DATE	PRIORITY DATE CLAIMED
PCT/CA99/00656	20 July 1999	20 July 1998
TITLE OF INVENTION		
SARA PROTEINS		
APPLICANT(S) FOR DO/EO/US		
Jeffrey L. WRANA		
Applicant herewith submits to the United States Designated/Elected Office (DO/EO/US) the following items and other information:		
<ol style="list-style-type: none"> 1. <input checked="" type="checkbox"/> This is a FIRST submission of items concerning a filing under 35 U.S.C. 371. 2. <input type="checkbox"/> This is a SECOND or SUBSEQUENT submission of items concerning a filing under 35 U.S.C. 371. 3. <input checked="" type="checkbox"/> This express request to begin national examination procedures (35 U.S.C. 371(f)) at any time rather than delay examination until the expiration of the applicable time limit set in 35 U.S.C. 371(b) and PCT Articles 22 and 39(I). 4. <input checked="" type="checkbox"/> A proper Demand for International Preliminary Examination was made by the 19th month from the earliest claimed priority date. 5. <input checked="" type="checkbox"/> A copy of the International Application as filed (35 U.S.C. 371(c)(2)) <ol style="list-style-type: none"> a. <input checked="" type="checkbox"/> is transmitted herewith (required only if not transmitted by the International Bureau). b. <input type="checkbox"/> has been transmitted by the International Bureau. c. <input type="checkbox"/> is not required, as the application was filed in the United States Receiving Office (RO/US). 6. <input type="checkbox"/> A translation of the International Application into English (35 U.S.C. 371(c)(2)). 7. <input type="checkbox"/> Amendments to the claims of the International Application under PCT Article 19 (35 U.S.C. 371(c)(3)) <ol style="list-style-type: none"> a. <input type="checkbox"/> are transmitted herewith (required only if not transmitted by the International Bureau). b. <input type="checkbox"/> have been transmitted by the International Bureau. c. <input type="checkbox"/> have not been made; however, the time limit for making such amendments has NOT expired. d. <input type="checkbox"/> have not been made and will not be made. 8. <input type="checkbox"/> A translation of the amendments to the claims under PCT Article 19 (35 U.S.C. 371(c)(3)). 9. <input type="checkbox"/> An oath or declaration of the inventor(s) (35 U.S.C. 371(c)(4)). 10. <input type="checkbox"/> A translation of the annexes to the International Preliminary Examination Report under PCT Article 36 (35 U.S.C. 371(c)(5)). 		
Items 11. to 16. below concern other document(s) or information included:		
<ol style="list-style-type: none"> 11. <input type="checkbox"/> An Information Disclosure Statement under 37 C.F.R. 1.97 and 1.98. 12. <input checked="" type="checkbox"/> An assignment document for recording. A separate cover sheet in compliance with 37 CFR 3.28 and 3.31 is included. 13. <input checked="" type="checkbox"/> A FIRST preliminary amendment. <input type="checkbox"/> A SECOND or SUBSEQUENT preliminary amendment. 14. <input type="checkbox"/> A substitute specification. 15. <input type="checkbox"/> A change of power of attorney and/or address letter. 16. <input checked="" type="checkbox"/> Other items or information: PCT Request; International Search Report; International Preliminary Examination Report; PCT Demand; Sequence Listing (paper and computer copy) 		

1002 Rec'd PCT/PTO 19 JAN 2001

U.S. APPLICATION NO. (If known) 09/7744167 INTERNATIONAL APPLICATION NO. PCT/CA99/00656		ATTORNEY'S DOCKET NUMBER 3477-91	
17. <input checked="" type="checkbox"/> The following fees are submitted: Basic National Fee (37 CFR 1.492(a)(1)-(5)): Search Report has been prepared by the EPO or JPO \$860.00 International preliminary examination fee paid to USPTO (37 CFR 1.482). \$690.00 No international preliminary examination fee paid to USPTO (37 CFR 1.482) but international search fee paid to USPTO (37 CFR 1.445(a)(2)) \$710.00 Neither international preliminary examination fee (37 CFR 1.482) nor international search fee (37 CFR 1.445(a)(2)) paid to USPTO. \$1,000.00 International preliminary examination fee paid to USPTO (37 CFR 1.482) and all claims satisfied provisions of PCT Article 33(1)-(4). \$100.00 ENTER APPROPRIATE BASIC FEE AMOUNT = \$860.00		CALCULATIONS	PTO USE ONLY
Surcharge of \$130.00 for furnishing the oath or declaration later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(e)).		\$	
Claims	Number Filed	Number Extra	Rate
Total Claims	44 - 20 =	24	X \$18.00
Independent Claims	18 - 3 =	15	X \$80.00
Multiple dependent claim(s) (if applicable)			+ \$270.00
TOTAL OF ABOVE CALCULATIONS =			\$2,492.00
Reduction by 1/2 for filing by small entity, if applicable. Applicant qualifies as Small Entity under 37 CFR 1.27.			\$1,246.00
SUBTOTAL =			\$1,246.00
Processing fee of \$130.00 for furnishing the English translation later than <input type="checkbox"/> 20 <input type="checkbox"/> 30 months from the earliest claimed priority date (37 CFR 1.492(f)).			\$
TOTAL NATIONAL FEE =			\$1,246.00
Fee for recording the enclosed assignment (37 CFR 1.21(h)). The assignment must be accompanied by an appropriate cover sheet (37 CFR 3.28, 3.31). \$40.00 per property +			\$ 40.00
TOTAL FEES ENCLOSED =			\$1,286.00
			Amount to be refunded \$
			charged \$
a. <input checked="" type="checkbox"/> A check in the amount of \$1,286.00 to cover the above fees is enclosed. b. <input type="checkbox"/> Please charge my Deposit Account No. _____ in the amount of \$ _____ to cover the above fees. A duplicate copy of this sheet is enclosed. c. <input checked="" type="checkbox"/> The Commissioner is hereby authorized to charge any additional fees which may be required, or credit any overpayment to Deposit Account No. 50-0220.			
NOTE: Where an appropriate time limit under 37 CFR 1.494 or 1.495 has not been met, a petition to revive (37 CFR 1.137(a) or (b)) must be filed and granted to restore the application to pending status.			
SEND ALL CORRESPONDENCE TO: Karen A. Magri Myers Bigel Sibley & Sajovec Post Office Box 37428 Raleigh, North Carolina 27627			
<div style="border: 1px solid black; padding: 5px; width: fit-content;"> "Express Mail" mailing label number EL682675105US Date of Deposit: January 19, 2001 I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Box PCT, Commissioner for Patents, Washington, DC 20231. <div style="text-align: center;">  Marjorie J. Pfeiffer Date of Signature: January 19, 2001 </div> </div> <div style="margin-top: 20px; text-align: right;"> SIGNATURE  Karen A. Magri 41,965 REGISTRATION NUMBER </div>			

09/744167
J002 Rec'd PCT/PTO 19 JAN 2001

Attorney's Docket No. 3477-91

PATENT

IN THE UNITED STATES DESIGNATED OFFICE (DO/US)

In re: Application of Jeffrey L. Wrana
Serial No.: To be Assigned
Filed: Concurrently Herewith
For: *SARA PROTEINS*

Date: January 19, 2001

BOX PCT
Commissioner for Patents
Washington, DC 20231

PRELIMINARY AMENDMENT

Sir:

Please amend the above-referenced application as follows prior to substantive examination.

In the Specification.

After the title, please insert the following:

--Related Application Information

This application claims the benefit under 35 U.S.C. § 371 from PCT Application No. PCT/CA99/00656, filed July 20, 1999, the disclosure of which is incorporated by reference herein in its entirety, which claims the benefit of Canadian Application Serial No. 2,237,701, filed July 20, 1998 and Canadian Application Serial No. 2,253,647, filed December 10, 1998, the disclosures of which are incorporated by reference herein in their entirety.--

In the Claims.

Please amend the claims as follows.

13. (Amended) The isolated polynucleotide of claim 6 [any one of the preceding claims] wherein the polynucleotide is a polydeoxyribonucleotide.
14. (Amended) The isolated polynucleotide of claim 6 [any one of claims 1 to 11] wherein the polynucleotide is a polyribonucleotide.

In re: Application of Jeffrey L. Wrana
Serial No.: To be Assigned
Filed: Concurrently Herewith
Page 2 of 2

16. (Amended) A recombinant vector comprising the isolated polynucleotide of claim 6 [any one of claims 1 to 15].

43. (Amended) The transgenic animal of claim 42 [L01] wherein the polynucleotide encodes a human SARA protein or a portion thereof.

Remarks

Claims 1-44 are pending in this application. Claims 13, 14 and 16 have been amended herein to remove multiple dependencies from the claims. Claim 43 has been amended to correct a typographical error. It is submitted that this application is now in condition for substantive examination, which action is respectfully requested.

Respectfully submitted,




Karen A. Magri
Registration No. 41,965

Myers Bigel Sibley & Sajovec
Post Office Box 37428
Raleigh, NC 27627
Tel. (919) 854-1400
Fax (919) 854-1401

"Express Mail" mailing label number EL682675105US
Date of Deposit: January 19, 2001

I hereby certify that this paper or fee is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 on the date indicated above and is addressed to Box PCT, Commissioner for Patents, Washington, DC 20231.



Marjorie J. Pfeiffer
Date of Signature: January 19, 2001

SARA PROTEINS

Field of the Invention

The invention relates to a family of proteins, the SARA proteins, which
5 bind to receptor-regulated Smad proteins and are involved in appropriate
localization of these Smad proteins for receptor activation.

Background of the Invention

The Transforming Growth Factor-beta (TGF β) superfamily, whose
10 members include TGF β s, activins and bone morphogenetic proteins (BMPs),
have wide ranging effects on cells of diverse origins (Attisano and Wrana, 1998;
Heldin et al., 1997; Kretschmar and Massagué, 1998). Signaling by these
secreted factors is initiated upon interaction with a family of cell-surface
transmembrane serine/threonine kinases, known as type I and type II receptors.
15 Ligand induces formation of a typeI/typeII heteromeric complex which permits
the constitutively active type II receptor to phosphorylate, and thereby activate,
the type I receptor (Wrana et al., 1994). This activated type I receptor then
propagates the signal to a family of intracellular signaling mediators known as
Smads (Attisano and Wrana, 1998; Heldin et al., 1997; Kretschmar and
20 Massagué, 1998).

The first members of the Smad family identified in invertebrates were the
Drosophila MAD and the *C. elegans* sma genes (sma-2, sma-3 and sma-4; Savage
et al., 1996; Sekelsky et al., 1995). Currently, the family includes additional
invertebrate Smads, as well as nine vertebrate members, Smad1 through 9
25 (Attisano and Wrana, 1998; Heldin et al., 1997; Kretschmar and Massagué,
1998). Smad proteins contain two conserved amino (MH1) and carboxy (MH2)
terminal regions separated by a more divergent linker region. In general, Smad
proteins can be subdivided into three groups; the receptor-regulated Smads,
which include Smad 1, 2, 3, 5 and 8, Mad, sma-2 and sma-3; the common
30 Smads, Smad4 and Medea, and the antagonistic Smads, which include Smad6, 7

and 9, DAD and daf-3 (Heldin et al., 1997; Nakayama et al., 1998; Patterson et al., 1997).

Numerous studies with vertebrate Smad proteins have provided insights into the differential functions of these proteins in mediating signaling. Receptor-regulated Smads are direct substrates of specific type I receptors and the proteins are phosphorylated on the last two serines at the carboxy-terminus within a highly conserved SSXS motif (Abdollah et al., 1997; Kretzschmar et al., 1997; Liu et al., 1997b; Macias-Silva et al., 1996; Souchelnytskyi et al., 1997). Interestingly, Smad2 and Smad3 are substrates of TGF β or activin receptors and mediate signaling by these ligands (Liu et al., 1997b; Macias-Silva et al., 1996; Nakao et al., 1997a), whereas Smad1, 5 and 8 appear to be targets of BMP receptors and thereby propagate BMP signals (Chen et al., 1997b; Hoodless et al., 1995; Kretzschmar et al., 1997; Nishimura et al., 1998). Once phosphorylated, these Smads bind to the common Smad, Smad4, which lacks the carboxy-terminal phosphorylation site and is not a target for receptor phosphorylation (Lagna et al., 1996; Zhang et al., 1997). Heteromeric complexes of the receptor-regulated Smad and Smad4 translocate to the nucleus where they function to regulate the transcriptional activation of specific target genes. The antagonist Smads, Smad6, 7 and 9 appear to function by blocking ligand-dependent signaling by preventing access of receptor-regulated Smads to the type I receptor or possibly by blocking formation of heteromeric complexes with Smad4 (reviewed in Heldin et al., 1997).

Analysis of the nuclear function of Smads has demonstrated that Smads can act as transcriptional activators and that some Smads, including *Drosophila* Mad, and the vertebrate Smad3 and Smad4, can bind directly to DNA, albeit at relatively low specificity and affinity (Dennler et al., 1998; Kim et al., 1997; Labbé et al., 1998; Yingling et al., 1997; Zawel et al., 1998).

Localization of Smads is critical in controlling their activity and Smad phosphorylation by the type I receptor regulates Smad activity by inducing nuclear accumulation (Attisano and Wrana, 1998; Heldin et al., 1997; Kretzschmar and Massagué, 1998). However, little is known about how Smad

localization is controlled prior to phosphorylation and how this might function in modulating receptor interactions with its Smad substrates.

Summary of the Invention

5 Smad proteins (Smads) transmit signals from transmembrane ser/thr kinase receptors to the nucleus. Mammalian and non-mammalian proteins have been identified which interact directly with Smads and are designated the Smad Anchor for Receptor Activation or SARA proteins.

The invention provides cDNA sequences encoding this previously
10 undescribed family of SARA proteins which bind to receptor-regulated Smad proteins and ensure appropriate localization of these Smad proteins for activation by a Type I receptor of a TGF β , activin or BMP signaling pathway.

For example, TGF β signaling induces dissociation of Smad2 or Smad3 from a SARA protein with concomitant formation of Smad2/Smad4 or
15 Smad3/Smad4 complexes and nuclear translocation. In the absence of signaling, SARA functions to recruit a particular Smad (eg. Smad2 or Smad3) to distinct subcellular sites in the cell and interacts with the TGF β superfamily receptor complex in cooperation with the particular receptor regulated Smad. Mutations in hSARA1 that cause mislocalization of Smad2, and interfere with receptor
20 association, inhibit receptor-dependent transcriptional responses, indicating that regulation of Smad localization is essential for TGF β superfamily signaling. The invention provides a novel component of the signal transduction pathway that functions to anchor Smads to specific subcellular sites for activation by the Type I receptor of the TGF β , activin or BMP signaling pathways.

25 The SARA proteins are characterised by the presence of three domains, a double zinc finger or FYVE domain responsible for the subcellular localisation of the SARA protein or SARA-Smad complex, a Smad-binding domain which mediates the interaction or binding of one or more species of Smad protein and a carboxy terminal domain which mediates association with the TGF β
30 superfamily receptor. The FYVE domain may bind phosphatidyl inositol-3-phosphate.

In accordance with one embodiment, the invention provides isolated polynucleotides comprising nucleotide sequences encoding SARA proteins.

In accordance with a further series of embodiments, the invention provides an isolated polynucleotide selected from the group consisting of

- 5 (a) a nucleotide sequence encoding a human SARA protein;
- (b) a nucleotide sequence encoding a mammalian SARA protein;
- (c) a nucleotide sequence encoding a non-mammalian SARA protein;
- (d) a nucleotide sequence encoding the human SARA amino acid
10 sequence of Table 2 (hSARA1: Sequence ID NO:2);
- (e) a nucleotide sequence encoding the human SARA amino acid sequence of Table 4 (hSARA2: Sequence ID NO:4);
- (f) a nucleotide sequence encoding the *Xenopus* SARA amino acid sequence of Table 6 (XSARA1: Sequence ID NO:6);
- 15 (g) a nucleotide sequence encoding the *Xenopus* SARA amino acid sequence of Table 8 (XSARA2: Sequence ID NO:8).

In accordance with a further embodiment, the invention provides the nucleotide sequences of Table 1 (human SARA1 or hSARA1), Table 3 (human SARA2 or hSARA2), Table 5 (*Xenopus* SARA1 or XSARA1) and Table 7 (*Xenopus*
20 SARA2 or XSARA2).

In accordance with a further embodiment, the invention provides recombinant vectors including the polynucleotides disclosed herein and host cells transformed with these vectors.

The invention further provides a method for producing SARA proteins,
25 comprising culturing such host cells to permit expression of a SARA protein-encoding polynucleotide and production of the protein.

The invention also includes polynucleotides which are complementary to the disclosed nucleotide sequences, polynucleotides which hybridize to these sequences under high stringency and degeneracy equivalents of these
30 sequences.

In accordance with a further embodiment, the invention provides antisense molecules which may be used to prevent expression of a SARA protein. Such antisense molecules can be synthesised by methods known to those skilled in the art and include phosphorothioates and similar compounds.

5 The invention further includes polymorphisms and alternatively spliced versions of the disclosed SARA genes and proteins wherein nucleotide or amino acid substitutions or deletions do not substantially affect the functioning of the gene or its encoded protein.

The invention also enables the identification and isolation of allelic
10 variants or homologues of the described SARA genes, and their corresponding proteins, using standard hybridisation screening or PCR techniques.

The invention provides a method for identifying allelic variants or homologues of the described SARA genes, comprising

15 choosing a nucleic acid probe or primer capable of hybridizing to a SARA gene sequence under stringent hybridisation conditions;

mixing the probe or primer with a sample of nucleic acids which may contain a nucleic acid corresponding to the variant or homologue; and

detecting hybridisation of the probe or primer to the nucleic acid corresponding to the variant or homologue.

20 In accordance with a further embodiment, the invention provides fragments of the disclosed polynucleotides, such as polynucleotides of at least 10, preferably 15, more preferably 20 consecutive nucleotides of the disclosed polynucleotide sequences. These fragments are useful as probes and PCR primers or for encoding fragments, functional domains or antigenic determinants
25 of SARA proteins.

In accordance with a further embodiment, the invention provides substantially purified SARA proteins, including the proteins of Table 2 (hSARA1), Table 4 (hSARA2), Table 6 (XSARA1) and Table 8 (XSARA2).

In accordance with one embodiment, a SARA protein has a FYVE domain,
30 a Smad binding domain (SBD) and an amino acid sequence having at least 50% overall identity with the amino acid sequence of hSARA1 (Sequence ID NO:2).

In accordance with a preferred embodiment, a SARA protein has a FYVE domain having at least 65% identity of amino acid sequence with the FYVE domain of hSARA1 and a C-terminal sequence of 550 consecutive amino acids which have at least 50% identity with the C-terminal 550 amino acid residues of hSARA1.

In accordance with a more preferred embodiment, a SARA protein has a FYVE domain having at least 65% identity of amino acid sequence with the FYVE domain of hSARA1 and wherein the portion of the SBD corresponding to amino acid residues 721 to 740 of hSARA1 has at least 80% identity with that portion of hSARA1.

The invention further provides a method for producing antibodies which selectively bind to a SARA protein comprising the steps of administering an immunogenically effective amount of a SARA immunogen to an animal; allowing the animal to produce antibodies to the immunogen; and obtaining the antibodies from the animal or from a cell culture derived therefrom.

The invention further provides substantially pure antibodies which bind selectively to an antigenic determinant of a SARA protein. The antibodies of the invention include polyclonal antibodies, monoclonal antibodies and single chain antibodies.

The invention includes analogues of the disclosed protein sequences, having conservative amino acid substitutions therein. The invention also includes fragments of the disclosed protein sequences, such as peptides of at least 6, preferably 10, more preferably 20 consecutive amino acids of the disclosed protein sequences.

The invention further provides polypeptides comprising at least one functional domain or at least an antigenic determinant of a SARA protein.

In accordance with a further embodiment, the invention provides peptides which comprise SARA protein Smad binding domains and polynucleotides which encode such peptides.

In accordance with a further embodiment, the invention provides a Smad binding domain peptide selected from the group consisting of

(a) SASSQSPNPNPAEYCSTIPPLQQAQASGALSSPPPTVMVPVGV
LKHPGAEVAQPREQRRVWFADGILPNGEVADAAKLTMNGTSS; and

5 (b) amino acids 589 to 672 of the XSARA1 sequence of Table 9.

The invention includes fragments and variants of these Smad binding domain peptides which retain the ability to bind a Smad protein.

In accordance with a further embodiment, the invention provides peptides which comprise SARA protein FYVE domains and polynucleotides
10 which encode such peptides.

In accordance with a further embodiment, the invention provides a FYVE domain peptide selected from the group consisting of

(a) amino acids 587 to 655 of the hSARA1 sequence of Table 9;
(b) amino acids 510 to 578 of the XSARA1 sequence of Table 9; and
15 (c) the consensus amino acid sequence of Table 10.

The invention includes fragments and variants of these FYVE domain peptides which retain the function of the parent peptide.

In accordance with a further embodiment, the invention provides peptides which comprise SARA protein TGF β receptor interacting domains and
20 polynucleotides which encode such peptides.

In accordance with a further embodiment, the invention provides a TGF β receptor interacting domain peptide comprising amino acids 751 to 1323 of the hSARA1 sequence of Table 9.

The invention includes fragments and variants of these TGF β receptor
25 binding domain peptides which retain the binding ability of the parent peptide.

The invention further provides methods for modulating signaling by members of the TGF β superfamily which signal through pathways which involve a SARA protein.

Modulation of signaling by a TGF β superfamily member through such a
30 pathway may be effected, for example, by increasing or reducing the binding of the SARA protein involved in the pathway with its binding partner.

In accordance with a further embodiment, TGF β superfamily signaling, including TGF β signaling, by a pathway involving a SARA protein described herein may be modulated by modulating the binding of the SARA protein to a Smad binding partner, by modulating the binding of its FYVE domain to its binding partner or by modulating the binding of the SARA protein to a TGF β superfamily receptor, such as the TGF β receptor.

For example, the binding of a SARA protein to a Smad binding partner may be inhibited by a deletion mutant of the protein lacking either the SBD domain or the FYVE domain or by the SARA protein Smad binding domain peptides or FYVE domain peptides described herein, and effective fragments or variants thereof. The binding of a SARA protein to a TGF β superfamily receptor may be inhibited by a deletion mutant of the protein lacking a C terminal portion or by the SARA protein TGF β receptor binding domain peptides described herein, and effective fragments and variants thereof.

In accordance with a further embodiment, TGF β superfamily signaling, including TGF β signaling, by a pathway involving a SARA protein may be modulated by modulating the binding of the SARA protein FYVE domain to phosphatidyl inositol-3-phosphate, by increasing or decreasing the availability of phosphatidyl inositol-3-phosphate or by administration of agonists or antagonists of phosphatidyl inositol-3-phosphate kinase.

The invention also provides a method of modulating a TGF β superfamily signaling pathway involving phosphatidyl inositol-3-phosphate, including a TGF β signaling pathway, by increasing or decreasing the availability of SARA protein or by modulating the function of SARA protein.

The invention further provides methods for preventing or treating diseases characterised by an abnormality in a TGF β superfamily member signaling pathway which involves a SARA protein, by modulating signaling in the pathway, as described above.

TGF β signaling is important in wound healing, and excessive signaling is associated with scarring, with arthritis and with fibrosis in numerous diseases, including fibrosis of the liver and kidney. TGF β signaling is also involved in

modulating inflammatory and immune responses and can contribute to tumour progression.

The invention thus provides methods for modulating TGF β -dependent cell proliferation or fibrogenesis.

5 The BMP signaling pathways are important in tissue morphogenesis and in protecting tissues and restoring or regenerating tissues after tissue damage, for example in bone, kidney, liver and neuronal tissue (see, for example, (Reddy, A.H. (1998), *Nature Biotechnology*, v. 16, pp. 247-252).

10 The invention further provides methods for modulating BMP-dependent phenotypic marker expression by modulating the interactions of SARA proteins involved in these BMP signaling pathways.

15 In accordance with a further embodiment, modified versions of a SARA protein may be provided as dominant-negatives that block TGF β superfamily signaling. These modified versions of SARA could, for example, lack the Smad binding domain and thereby prevent recruitment of Smad or could lack the FYVE domain and thereby inhibit signaling by interfering with translocation.

20 These modified versions of SARA may be provided by gene therapy, for example using transducing viral vectors. Expression may be driven by inclusion in the vector of a promoter specific for a selected target cell type. Many examples of such specific promoters are known to those skilled in the art.

 In a further embodiment, a normal version of a SARA protein such as hSARA1 could be provided by gene therapy to restore function in a disease wherein SARA is mutated or non-functional.

25 In a further embodiment, the invention provides a pharmaceutical composition comprising a purified SARA protein as active ingredient.

 In accordance with a further embodiment, the invention provides non-human transgenic animals and methods for the production of non-human transgenic animals which afford models for further study of the SARA system and tools for screening of candidate compounds as therapeutics. For example, knock
30 out animals, such as mice, may be produced with deletion of a SARA gene.

10

These animals may be examined for phenotypic changes and used to screen candidate compounds for effectiveness to reverse these changes.

In a further example, transgenic animals may be produced expressing a dominant negative mutant of a SARA protein, as described above, either
5 generally or in specific targeted tissues.

The invention provides many targets for the development of small molecule drugs, including peptides and peptidomimetic drugs, to interfere with the interaction of the various binding partners described herein and thereby modulate signaling by members of the TGF β superfamily, including TGF β and
10 BMPs.

The invention further provides methods for screening candidate compounds to identify those able to modulate signaling by a member of the TGF β superfamily through a pathway involving a SARA protein.

For example, the invention provides screening methods for compounds
15 able to bind to a SARA protein which are therefore candidates for modifying the activity of the SARA protein. Various suitable screening methods are known to those in the art, including immobilization of a SARA protein on a substrate and exposure of the bound SARA protein to candidate compounds, followed by elution of compounds which have bound to the SARA protein. The methods
20 used to characterise the binding interactions of the SARA proteins disclosed herein, as fully described in the examples herein, may also be used to screen for compounds which are agonists or antagonists of the binding of a SARA protein.

This invention also provides methods of screening for compounds which modulate TGF β superfamily signaling by detecting an alteration in the
25 phosphorylation state of a SARA protein.

In accordance with a further embodiment, the invention provides a method for reducing or preventing TGF β , activin or BMP signaling by inhibiting the activity of SARA. SARA activity may be inhibited by use of an antisense sequence to the SARA gene or by mutation of the SARA gene.

30

Summary of the Drawings

Certain embodiments of the invention are described, reference being made to the accompanying drawings, wherein:

- Figure 1 (top panel) shows interaction of full length hSARA1 with
- 5 bacterially expressed Smads. Full length SARA protein was produced in an *in vitro* transcription/translation system in the presence of [³⁵S]methionine and was incubated with glutathione-sepharose beads coated with bacterially-expressed GST fusion proteins of the indicated Smads or Smad2 subdomains. Bound material was resolved by SDS-PAGE and visualized by autoradiography.
- 10 Migration of full length hSARA1, and a translation product that initiates from an internal methionine located upstream of the Smad binding domain (asterisk) are indicated. The presence of approximately equivalent amounts of GST fusion proteins was confirmed by SDS-PAGE and coomassie staining of a protein aliquot (bottom panel).
- 15 Figure 2 shows interaction of hSARA with Smads in mammalian cells. COS cells were transfected with Flag-tagged hSARA1 (Flag-SARA) either alone or together with the indicated Myc-tagged Smad constructs. For Smad6, an alternative version lacking the MH1 domain was used (Topper et al., 1997). Cell lysates were subjected to an anti-Flag immunoprecipitation and coprecipitating
- 20 Smads detected by immunoblotting with anti-Myc antibodies. The migration of anti-Flag heavy and light chains (IgG) are marked. To confirm efficient expression of hSARA1 and the Smads, aliquots of total cell lysates were immunoblotted with the anti-Flag and anti-Myc antibodies (bottom panel). The migrations of hSARA1 and the Smads are indicated.
- 25 Figures 3-6 show immunoblots of lysates from COS cells transiently transfected with various combinations of Flag or Myc-tagged hSARA1, wild type (WT) or mutant (2SA) Myc or Flag-tagged Smad2, Smad4/HA and wild type (WT) or constitutively active (A) T β RI/HA, cell lysates being subjected to immunoprecipitation with anti-Flag or anti-Myc antibodies, as indicated.
- 30 Confirmation of protein expression was performed by immunoblotting total cell

lysates prepared in parallel for the indicated tagged protein (totals, bottom panels).

Figure 3: Transfected cells were metabolically labelled with [32 P]PO₄ and cell lysates subjected to immunoprecipitation with anti-Flag antibodies for visualization of hSARA1 phosphorylation (top panel) or with anti-Myc antibodies for Smad2 phosphorylation (middle panel). Immunoprecipitates were resolved by SDS-PAGE and visualized by autoradiography. The migrations of hSARA1 and Smad2 are indicated.

Figure 4: Lysates from transiently transfected COS cells were subjected to immunoprecipitation with anti-Flag antibodies and Smad2 bound to hSARA1 was analyzed by immunoblotting with anti-Myc antibodies (IP: α -flag; blot: α -Myc).

Figure 5: Lysates from transiently transfected COS cells were subjected to immunoprecipitation with anti-Flag antibodies and Smad2 bound to hSARA1 was analyzed by immunoblotting with anti-Myc antibodies (IP: α -flag, blot: α -Myc). Partial dissociation of hSARA1/Smad2 complexes induced by TGF β signaling was enhanced by expression of Smad4.

Figure 6: Cell lysates from transiently transfected COS cells were subjected to immunoprecipitation with anti-Flag antibodies directed towards Smad2. Immunoprecipitates were then immunoblotted using anti-Myc or anti-HA antibodies which recognize hSARA1 or Smad4, respectively. Coprecipitating SARA (α -myc blot) and Smad4 (α -HA blot) are indicated.

Figure 7, panels A to E, shows photomicrographs of Mv1Lu cells transiently transfected with various combinations of Flag-Smad2, Myc-hSARA1, and constitutively active T β RI (T β RI*) as indicated (Tx). hSARA was visualized with the polyclonal Myc A14 antibody and Texas-Red conjugated goat-anti-rabbit IgG (red) and Smad2 was detected with an anti-Flag M2 monoclonal antibody followed by FITC-conjugated goat anti-mouse IgG (green). The subcellular localization of the expressed proteins was visualized by immunofluorescence and confocal microscopy.

13

Panels A, B, C, Mv1Lu cells singly transfected with hSARA1 (A) or Smad2 (B) are shown. Cotransfection of Smad2 with the constitutively active T β RI (T β RI*) results in its accumulation in the nucleus (C).

Panel D, Mv1Lu cells were transfected with hSARA1 and Smad2 and the
5 localization of hSARA1 (red, left photo) and Smad2 (green, centre photo) is shown. Colocalization of SARA and Smad2 is shown (right photo) and appears as yellow.

Panel E, Mv1Lu cells were transfected with hSARA1, Smad2 and activated
10 T β RI (T β RI*) and the localization of hSARA (red, left photo) and Smad2 (green, centre photo) is shown. Colocalization of SARA and Smad2 is indicated (right photo). Note the shift to an orangy-red colour in the punctate spots and an intensification of Smad2 nuclear staining, indicative of dissociation of Smad2 from SARA and nuclear translocation.

Figure 7, panel F, shows photomicrographs of Mv1Lu cells stained with
15 rabbit, polyclonal anti-SARA antibody (left photo, green), goat, polyclonal anti-Smad 2/3 antibody (centre photo, red) and with both antibodies (right photo, yellow), showing co-localization of hSARA1 and Smad2.

Figure 8A shows photomicrographs of Mv1Lu cells transfected with either
hSARA1 alone (panel i), T β RII alone (panel ii) or hSARA1 and T β RII together
20 (panel iii), then treated with TGF β and the localization of hSARA1 (red) and T β RII (green) determined by immunofluorescence and confocal microscopy. In cells coexpressing hSARA1 and T β RII, superimposing the staining revealed colocalization of the proteins as indicated by yellow staining in panel iii.

Figure 8B shows affinity labelling of COS cells transiently transfected with
25 various combinations of Flag-hSARA1, Myc-Smad2, wild type (WT) T β RII and either wild type or kinase-deficient (KR) versions of T β RI. Cells were affinity-labelled with [¹²⁵I]TGF β and lysates immunoprecipitated with anti-Flag antibodies. Coprecipitating receptor complexes were visualized by SDS-PAGE and autoradiography. Equivalent receptor expression was confirmed by
30 visualizing aliquots of total cell lysates (bottom panel).

Figure 9A shows COS cells transiently transfected with wild type T β RII and kinase-deficient T β RI and various combinations of wild type Flag-hSARA1 (WT), a mutant version lacking the Smad2 binding domain (Δ SBD) and Myc-Smad2. The amount of receptor bound to SARA was determined by anti-Flag immunoprecipitation followed by gamma counting. Data is plotted as the average of three experiments \pm S.D. Protein expression was analyzed by immunoblotting aliquots of total cell lysates and the results from a representative experiment are shown (bottom panel).

Figure 9B shows COS cells transiently transfected with wild type T β RII and kinase-deficient T β RI and Flag-tagged wild type (WT) or mutant versions of hSARA1 with (black bars) or without (open bars) Myc-Smad2. The amount of receptor bound to hSARA1 was determined by anti-Flag immunoprecipitation followed by gamma counting. Protein expression was analyzed by immunoblotting aliquots of total cell lysates (bottom panel).

Figure 10 is a schematic representation of mutant versions of SARA. The FYVE domain (shaded bar) and the Smad binding domain, SBD (striped bar), are indicated. COS cells transiently transfected with Flag-hSARA1 and Myc-Smad2 were immunoprecipitated with anti-Flag antibodies followed by immunoblotting with anti-Myc antibodies. The presence (+) or absence (-) of a hSARA1/Smad2 interaction is indicated (Smad2 interaction). Mutants used for the subsequent localization study are marked on the left (i-vi).

Figure 11A shows an immunoblot of lysates from COS cells expressing Flag-tagged Smad2 or Smad3 incubated with GST alone or with GST-hSARA1 (665-750), which corresponds to the SBD; bound proteins were immunoblotted using anti-Flag antibodies. The presence of Smad2 and Smad3 bound to GST-hSARA1 (665-750) is indicated.

Figure 11B shows an immunoblot of lysates, from COS cells expressing Flag-tagged Smad2 together with wild type (WT) or activated (A) type I receptor, incubated with GST-hSARA1 (665-750) (GST-SBD) and immunoblotted with anti-Flag antibodies. The expression levels of Smad2, each receptor and GST-

hSARA1 (665-750) were determined by immunoblotting aliquots of total cell lysates.

Figure 12 shows the subcellular localization of hSARA1 mutants. Mv1Lu cells were transiently transfected with wild type (panel i) or mutant versions of Flag-hSARA1 (panels ii-viii, as marked on the left in Figure 10). Proteins were visualized by immunofluorescence and confocal microscopy using a monoclonal anti-Flag M2 monoclonal antibody followed by FITC-conjugated goat anti-mouse IgG.

Figure 13 shows photomicrographs of Mv1Lu cells transiently transfected with mutant versions of Myc-hSARA1 and Flag-Smad2 (panel A) or with wild type Myc-hSARA1, HA-Smad2 and mutant versions of hSARA1 (panel B). Protein subcellular localization was visualized by immunofluorescence and confocal microscopy. hSARA1 was visualized with the polyclonal Myc A14 antibody and FITC-conjugated goat anti-rabbit IgG (green), while Smad2 was detected with monoclonal antibodies followed by Texas Red-conjugated goat anti-mouse IgG (red). In B, overlaying the images reveals mislocalization of Smad2 as green speckles of SARA over red, diffuse Smad2 staining (panels ii and iii) and colocalization of hSARA1 and Smad2 appears as yellow spots (panels i and iv).

Figure 14 shows luciferase activity of Mv1Lu cells transfected with 3TP-lux alone or together with the indicated amounts of wild type (WT) or mutant (Δ 1-664 or Δ 1-704) versions of hSARA1 and incubated in the presence (black bars) or absence (open bars) of TGF β . Luciferase activity was normalized to β -galactosidase activity and is plotted as the mean \pm S.D. of triplicates from a representative experiment.

Figure 15 shows luciferase activity of HepG2 cells transfected with ARE-Lux alone (v), or ARE-Lux and FAST2 alone or together with the indicated amounts of wild type (WT) or mutant versions of hSARA1. Transfected cells were incubated in the presence (black bars) or absence (open bars) of TGF β and luciferase activity was normalized to β -galactosidase activity and is plotted as the mean \pm S.D. of triplicates from a representative experiment.

16

Figure 16 shows a Northern blot of expression of hSARA1 (upper panel) and Smad2 (lower panel) in the indicated tissues.

Figure 17 shows an immunoblot of a HepG2 lysate immunoprecipitated (IP) with preimmune serum (PI), anti-hSARA1 polyclonal antibody (SARA) with
5 and without pretreatment with TGF β (- and +), or N19 anti-Smad2/3 antibody (S2), followed by immunoblotting with an anti-Smad2 antibody. The migration position of Smad2 is indicated (Smad2).

Figure 18 shows a diagram of a model of the interaction of a SARA
10 protein with a receptor regulated Smad, as exemplified by the interaction of hSARA1.

Detailed Description of the Invention

This invention provides a family of proteins that play key roles in TGF- β , activin and bone morphogenetic protein (BMP) signal transduction pathways. In
15 particular, the proteins of this family interact with specific Smad proteins to modulate signal transduction. These proteins are therefore designated as "Smad Anchor for Receptor Activation" or "SARA" proteins. SARA proteins are characterised by three distinct domains (1) a double zinc finger or FYVE domain responsible for the subcellular localization of the SARA protein or SARA-Smad
20 complex, possibly through its association with PtdIns(3)P, (2) a Smad binding domain ("SBD") which mediates the interaction or binding of one or more species of Smad protein with the particular member of the SARA family and (3) a carboxy terminal domain which mediates interaction of SARA with members of the TGF β superfamily of receptors.

25 FYVE domains have been identified in a number of unrelated signaling molecules that include FGD1, a putative guanine exchange factor for Rho/Rac that is mutated in faciogenital dysplasia, the HGF receptor substrate Hrs-1 and its homolog Hrs-2, EEA1, a protein involved in formation of the early endosome and the yeast proteins FAB1, VPS27 and VAC1 (reviewed in Wiedemann and
30 Cockcroft, 1998). Recently, analysis of a number of FYVE domains from yeast and mammals has revealed that this motif binds phosphatidyl inositol-3-

phosphate (PtdIns(3)P) with high specificity and thus represents a novel signaling module that can mediate protein interaction with membranes (Burd and Emr, 1998; Gaullier et al., 1998; Patki et al., 1998; Simonsen et al., 1998; Wiedemann and Cockcroft, 1998). Comparison of the FYVE domains from the

5 vertebrate proteins with that from SARA revealed extensive conservation of residues throughout the domain (Table 10). Thus, SARA contains a FYVE domain that may function to bind PtdIns(3)P, which has been implicated in intracellular vesicle transport.

For example, deletion of the FYVE domain in hSARA1 causes

10 mislocalization of Smad2 or Smad3, interferes with TGF β receptor interaction and inhibits TGF β -dependent transcriptional responses.

Thus, the SARA proteins of the invention define a component of TGF β superfamily signaling that fulfills an essential role in anchoring receptor regulated Smads to specific subcellular domains for activation by a TGF β

15 superfamily receptor.

Cloned DNA coding sequences and corresponding amino acid sequences for representative human and Xenopus SARA protein family members are shown in the Tables, as follows:

Tables 1 and 2 – human SARA1 (hSARA1) cDNA (Sequence ID NO:1)

20 and amino acid sequence (Sequence ID NO:2) respectively;

Tables 3 and 4 – human SARA2 (hSARA2) cDNA (Sequence ID NO:3)

and amino acid sequence (Sequence ID NO:4) respectively;

Tables 5 and 6 – Xenopus SARA1 (XSARA1) cDNA (Sequence ID NO:5)

and amino acid sequence (Sequence ID NO:6) respectively; and

25 Tables 7 and 8 – Xenopus SARA2 (XSARA2) cDNA (Sequence ID NO:7)

and amino acid sequence (Sequence ID NO:8) respectively.

Table 9 shows a comparison of the amino acid sequences of XSARA1 and hSARA1. Identical residues (dark grey) and conservative changes (light grey), the FYVE domain (solid underline) and the Smad binding domain (dashed

30 underline) are indicated. The sequences in XSARA1 used to design degenerate PCR primers for identifying hSARA1 are shown (arrows). The amino-terminal

end of the partial *Xenopus* cDNA obtained in the expression screen is marked (asterisk).

The human SARA of Tables 1 and 2, identified as described in Example 2, regulates the subcellular localization of Smad2 and Smad3 and recruits these
5 Smads into distinct subcellular domains. This SARA also interacts with TGF β receptors and TGF β signaling induces dissociation of Smad2 or Smad3 from the SARA protein with concomitant formation of Smad2/Smad4 complexes and nuclear translocation.

Table 10 shows alignment of the amino acid sequences of the FYVE
10 domains from hSARA1, XSARA1, KIAA0305, FGD1, Hrs-1, Hrs-2 and EEA1. Identical residues (dark grey) and conservative changes (light grey) are marked. A consensus sequence (bottom) was derived from positions in which at least 6 out of 7 residues were conserved or when proteins contained one of only two alternate residues.

15 The regulation of the subcellular localization of components of signaling pathways can be key determinants in the effective initiation and maintenance of signaling cascades. Targeting of signal transduction proteins to specific subcellular regions is highly regulated, often through specific interactions with scaffolding or anchoring proteins (Faux and Scott, 1996; Pawson and Scott,
20 1997). Scaffolding proteins have been defined as proteins that bind to multiple kinases to coordinate the assembly of a cascade, while anchoring proteins are tethered to specific subcellular regions in the cell and can act to bring together components of a pathway. Regulating location of signaling components can thus coordinate the activity of a signaling network, maintain signaling specificity
25 or facilitate activation of a pathway by localizing kinases together with their downstream substrates.

As described herein, a recombinantly produced human SARA protein bound directly and specifically to unphosphorylated Smad2 and Smad3. In addition, receptor-dependent phosphorylation induced Smad2 to dissociate from
30 SARA, bind to Smad4 and translocate to the nucleus. Thus, the hSARA1 protein functions in TGF β signaling upstream of Smad activation to recruit Smad2 to the

TGF β receptor by mediating the specific subcellular localization of Smad and by associating with the TGF β receptor complex. Furthermore, inducing mislocalization of Smad2 by expressing a mutant of the hSARA1 protein blocks TGF β -dependent transcriptional responses, indicating an essential role for SARA-mediated localization of Smads in signaling. Together, these results identify the cloned hSARA1 protein as a novel component of the TGF β pathway that functions to anchor Smad2 to specific subcellular sites for activation by the TGF β receptor kinase.

In vitro, receptor-regulated Smads are recognized by the receptor kinases and are phosphorylated on the C-terminal SSXS motif (Abdollah et al., 1997; Kretschmar et al., 1997; Macias-Silva et al., 1996; Souchelnytskyi et al., 1997). This phosphorylation is similar to receptor-dependent phosphorylation in mammalian cells, suggesting that SARA is not absolutely required for recognition of Smads by the receptor complex. In intact cells, however, receptor-regulated Smads are cytosolic proteins that require activation by transmembrane serine/threonine kinase receptors. Consequently, Smads may require recruitment by SARA to interact with TGF β superfamily receptors. Domains in which SARA is found correspond to regions where TGF β receptors are also localised. TGF β receptors display regionalized localization and hSARA1 recruits Smad2 to these domains. The identity of these intracellular domains is unclear. However, they contain receptors and recent evidence has shown that FYVE finger domains interact with membranes, so it is reasonable to suggest that these domains represent membrane vesicles. Thus, clustering of the TGF β receptor, as previously described by Henis et al. (1994), may function to direct the receptor to hSARA1 and the Smad2 substrate. This activity may be most critical *in vivo*, where ser/thr kinase receptors are often found in low numbers and only a small proportion need to be activated for biological responses (Dyson and Gurdon, 1998). This activity is likely to be most critical *in vivo*, where ser/thr kinase receptors are often found in low numbers and only a small proportion need to be activated for biological responses (Dyson and Gurdon, 1998). This may impose

on the pathway a stringent requirement for SARA to anchor Smads in these sites for receptor interaction.

The colocalization and association of hSARA1 with the TGF β receptor defines a role for hSARA1 in recruiting Smad2 to the receptor kinase.

- 5 Furthermore, deletion of the FYVE domain interferes with receptor binding, prevents the correct localization of hSARA1/Smad2 and blocks TGF β signaling (see Example 8 below), suggesting that this is an important function in the pathway. Interestingly, the binding of the hSARA1 protein identified in Example 2 to the receptor was enhanced upon Smad2 expression and, on its own, SARA
10 may interact inefficiently with the receptor. However, within the hSARA1/Smad complex, Smad2 might help drive association with the receptor through its recognition of the catalytic region of the kinase domain. Consistent with this, cooperation requires a kinase deficient type I receptor which also traps the Smad2 substrate (Macías-Silva et al., 1996). Thus, Smad2 may bind to the
15 catalytic pocket of the type I kinase domain while hSARA1, which is not a substrate of the kinase, may interact with regions outside of the domain.

- The human SARA protein identified in Example 2 did not interact with any of the other Smads tested, indicating that it functions specifically in Smad2 and Smad3 pathways (see Example 3). However, Smad5 localization in 293
20 cells displayed a remarkably similar pattern to that of this SARA protein (Nishimura et al., 1998) and similar patterns were observed for endogenous Smad1 or 5 in the kidney epithelial cell line, IMCD-3. Thus, localization of BMP-regulated Smads (for example, Smad1, Smad5 and Smad8) may also be regulated by a specific SARA family member.

- 25 The genes for two other SARA family member proteins were also identified and cloned. One of these, identified in *Xenopus* and designated XSARA2 (Tables 7 and 8), is related to XSARA1, while the other one, hSARA2 (Tables 3 and 4), is a human clone, related to the hSARA1 of Tables 1 and 2. This second human clone has been identified in EST clone KIAA0305. A
30 comparison of the SBD from hSARA1 with a similar region from the KIAA0305 sequence indicated that the amino terminal half of the region of the SBD was

highly divergent from the amino acid sequence encoded by KIAA0305. This suggests that the protein encoded by KIAA0305 may mediate binding with other as yet unidentified proteins, eg. other Smads. In contrast to the SBD, the FYVE domain of the KIAA0305 protein is more closely related to the hSARA1 FYVE domain (70% identity), suggesting that this protein may be an anchor for other Smad proteins that function either in the TGF β pathway or in other signaling cascades, such as the BMP signal transduction pathway.

SARA is not limiting in Smad activation and TGF β superfamily signaling

It was observed that elevating Smad2 levels can saturate hSARA1 and yield a diffuse distribution for Smad2. Thus, the level of the hSARA1 protein is a key determinant in controlling Smad2 localization. As a consequence, endogenous Smad2 may or may not display a hSARA1-like distribution, depending on the relative expression of the two proteins. Indeed, in Mv1Lu cells, endogenous Smad2 displays a punctate pattern with some diffuse staining in the cytosol. While not meaning to limit the invention to a particular mechanism, the data are consistent with the view that once signaling has commenced, Smad2 dissociates from hSARA1, binds to Smad4 and translocates to the nucleus, freeing hSARA1 to recruit additional Smad2 from the cytosolic reservoir. This would provide a mechanism to allow quantitative activation of Smads in the presence of high levels of TGF β signaling.

By functioning to recruit Smad2 to the TGF β receptor, hSARA1 is located in an important regulatory position in the pathway. Thus, control of hSARA1 localization or protein levels, or its interaction with Smad2, could modulate TGF β signaling. Further, disruption of normal hSARA1 function could potentially be involved in loss of TGF β responsiveness that is a common feature during tumour progression.

Modular Domains in SARA

The function of hSARA1 in TGF β signaling is mediated by three independent domains, the Smad binding domain (SBD) that mediates specific

interaction with Smad2 and Smad3, the FYVE domain that targets hSARA1/Smad2 to specific subcellular sites and the carboxy terminus which mediates association with the TGF β receptor. The *Xenopus* and mouse forkhead-containing DNA binding proteins, FAST1 and FAST2, bind specifically to Smad2 and Smad3 and like hSARA1, interact with the MH2 domains (Chen et al., 1996; Chen et al., 1997a; Labbé et al., 1998; Liu et al., 1997a). Comparison of the SBD from this SARA with the Smad Interaction Domain (SID) from these FAST proteins revealed no regions of obvious similarity. However, since hSARA1 acts upstream and FAST downstream of Smad activation, these proteins may employ structurally unrelated domains to distinguish unactivated versus activated forms of Smad2. Thus, the SBD of this SARA protein preferentially binds unphosphorylated monomeric Smad2 while the SID from FAST must bind phosphorylated Smad2 in heteromeric complexes with Smad4. By analogy, the SBD of other SARA family members may bind the unphosphorylated monomeric species of other Smads that mediate signal transduction in other pathways (eg. Smads 1, 5 or 8 in the BMP signal transduction pathway).

In hSARA1, the FYVE domain functions independently of the SBD, to mediate the subcellular targetting of the protein. The FYVE-finger motif has now been identified in at least 30 proteins from diverse species, such as FGD1, Hrs-1 and 2, and EEA1 (Gaullier et al., 1998; Wiedemann and Cockcroft, 1998). Recent advances have demonstrated that FYVE finger motifs from a variety of divergent proteins have a conserved function and bind phosphatidyl inositol-3-phosphate (PtdIns(3)P) with high specificity (Burd et al., (1998); Patki (1998); Gaullier (1998)). Through this interaction, the FYVE finger can mediate protein interactions with phospholipid bilayers. However, PtdIns(3)P is present ubiquitously on cell membranes and in the case of EEA1, further protein-protein interactions with Rab5-GTP are required in addition to the FYVE domain to target the protein to the correct membranes (Simonsen et al., 1998). Given that PtdIns(3)P binding by FYVE fingers is conserved in yeast and mammals, it is likely that the FYVE finger of hSARA1 similarly mediates interaction with the

membrane. Furthermore, it is possible that additional protein-protein interactions may be required to direct hSARA1 to regions that contain the TGF β receptors. The carboxy terminus of hSARA1, which is required for efficient interaction with the TGF β receptor, may function in this capacity.

- 5 Together, these data define discrete domains in SARA that fulfill specific aspects of SARA function in TGF β superfamily signaling. Without being limited to any particular mechanism, a possible model of the interaction of SARA with a receptor regulated Smad in TGF β superfamily signaling, as exemplified by hSARA1 and its interactions with Smad2 in TGF β signaling, is shown
- 10 diagrammatically in Figure 18. The FYVE domain likely functions to direct SARA to the membrane, perhaps through interactions with PtlIns(3)P. It thus fulfills an important role in recruiting hSARA1 to specific subcellular domains that have been shown also to contain the TGF β receptor. The SBD in turn functions to bind unactivated Smad2, thus recruiting the receptor substrate to this subcellular
- 15 region. Once localized to this region, the C-terminal domain of hSARA1 functions with Smad2 bound to the SBD to promote interaction with the receptor complex. These three domains thus function cooperatively to recruit Smad2 to the TGF β receptor.

20 **Additional Roles for SARA**

- Controlling the localization of kinases and their substrates may allow not only for efficient recognition and phosphorylation but may also function to maintain specificity and suppress crosstalk between signaling pathways. Thus, by controlling Smad localization, a SARA family member protein could
- 25 additionally function to maintain the highly specific regulation of Smad phosphorylation by ser/thr kinase receptors that is observed *in vivo* and could prevent promiscuous phosphorylation by other kinases in the cell. Furthermore, through its interactions with a particular receptor, a SARA protein might function to control the activity or turnover of the receptor complex. Alternatively, SARA
- 30 may also fulfill scaffolding functions to coordinate the receptor-dependent

activation of Smads with other as yet unidentified components of a signaling pathway.

Nucleic Acids

- 5 In accordance with one series of embodiments, the present invention provides isolated nucleic acids corresponding to, or related to, the human and *Xenopus* SARA nucleic acid sequences disclosed herein. In addition to the SARA nucleotide sequences disclosed herein, one of ordinary skill in the art is now enabled to identify and isolate homologues of the SARA genes described
- 10 herein. One of ordinary skill in the art may screen preparations of genomic or cDNA from other species using probes or PCR primers derived from nucleotide sequences disclosed herein. In accordance with a further embodiment, the invention provides isolated nucleic acids of at least 10 consecutive nucleotides, preferably 15 consecutive nucleotides, more preferably 20 consecutive
- 15 nucleotides of Sequences ID NO:1, Sequence ID NO:3, Sequence ID NO:5 and Sequence ID NO:7, up to the complete sequences. Short stretches of nucleotide sequence are useful as probes or primers useful for identification or amplification of the nucleic acids of the invention or for encoding fragments, functional domains or antigenic determinants of SARA proteins.
- 20 The invention also includes polynucleotides which are complementary to the disclosed sequences, polynucleotides which hybridise to these sequences at high stringency and degeneracy equivalents of these sequences.

Proteins

- 25 SARA proteins may be produced by culturing a host cell transformed with a DNA sequence encoding a selected SARA protein. The DNA sequence is operatively linked to an expression control sequence in a recombinant vector so that the protein may be expressed.
- Host cells which may be transfected with the vectors of the invention
- 30 may be selected from the group consisting of *E. coli*, *Pseudomonas*, *Bacillus*

subtilis, or other bacilli, yeasts, fungi, insect cells or mammalian cells including human cells.

For transformation of a mammalian cell for expression of a SARA protein, the vector may be delivered to the cells by a suitable vehicle. Such vehicles
5 including vaccinia virus, adenovirus, retrovirus, Herpes simplex virus and other vector systems known to those of skill in the art.

A SARA protein may also be recombinantly expressed as a fusion protein. For example, the SARA cDNA sequence is inserted into a vector which contains a nucleotide sequence encoding another peptide (e.g. GST-glutathione succinyl
10 transferase). The fusion protein is expressed and recovered from prokaryotic (e.g. bacterial or baculovirus) or eukaryotic cells. The fusion protein can then be purified by affinity chromatography based upon the fusion vector sequence and the SARA protein obtained by enzymatic cleavage of the fusion protein.

The protein may also be produced by conventional chemical synthetic
15 methods, as understood by those skilled in the art.

SARA proteins may also be isolated from cells or tissues, including mammalian cells or tissues, in which the protein is normally expressed.

The protein may be purified by conventional purification methods known to those in the art, such as chromatography methods, high performance liquid
20 chromatography methods or precipitation.

For example, anti-SARA antibodies may be used to isolate SARA protein which is then purified by standard methods.

Antibodies

25 The provision of the polynucleotide and amino acid sequences of SARA proteins provides for the production of antibodies which bind selectively to a SARA protein or to fragments thereof. The term "antibodies" includes polyclonal antibodies, monoclonal antibodies, single chain antibodies and fragments thereof such as Fab fragments.

30 In order to prepare polyclonal antibodies, fusion proteins containing defined portions or all of a SARA protein can be synthesized in bacteria by

expression of the corresponding DNA sequences, as described above. Fusion proteins are commonly used as a source of antigen for producing antibodies. Alternatively, the protein may be isolated and purified from the recombinant expression culture and used as source of antigen. Either the entire protein or
5 fragments thereof can be used as a source of antigen to produce antibodies.

The purified protein is mixed with Freund's adjuvant and injected into rabbits or other appropriate laboratory animals. Following booster injections at weekly intervals, the animals are then bled and the serum isolated. The serum may be used directly or purified by various methods including affinity
10 chromatography to give polyclonal antibodies.

Alternatively, synthetic peptides can be made corresponding to antigenic portions of a SARA protein and these may be used to inoculate the animals.

In a further embodiment, monoclonal anti-SARA antibodies may be produced by methods well known in the art. Briefly, the purified protein or
15 fragment thereof is injected in Freund's adjuvant into mice over a suitable period of time, spleen cells are harvested and these are fused with a permanently growing myeloma partner and the resultant hybridomas are screened to identify cells producing the desired antibody. Suitable methods for antibody preparation may be found in standard texts such as Antibody Engineering, 2d. edition,
20 Barreback, ED., Oxford University Press, (1995).

Transgenic animals

In accordance with a further embodiment, the invention provides for the production of transgenic non-human animals which afford models for further
25 study of the SARA family of proteins and also provide tools for the screening of the candidate compounds as therapeutics.

Animal species which are suitable for use include rats, mice, hamsters, guinea pigs, rabbits, dogs, cats, goats, sheep, pigs and non-human primates.

In accordance with one embodiment, a transgenic animal may be
30 prepared carrying a heterologous SARA gene by inserting the gene into a germ line or stem cell using standard technique of oocyte microinjection, or

transfection or microinjection into embryonic stem cells. The techniques of generating transgenic animals are now well known and fully described in the literature. For example, a laboratory manual in the manipulation of the mouse embryo describes standard laboratory techniques for the production of transgenic mice (Hogan et al. (1986), Manipulating the Mouse Embryo, Cold Spring Harbour Laboratory Press, Cold Spring Harbour, New York).

In accordance with a further embodiment, the invention enables the inactivation or replacement of an endogenous SARA gene in an animal by homologous recombination. Such techniques are also fully described in the literature. Such techniques produce "knock-out" animals, with an inactivated gene, or "knock-in" animals, with a replaced gene.

EXAMPLES

The examples are described for the purposes of illustration and are not intended to limit in any way the scope of the invention.

Methods of molecular genetics, protein and peptide biochemistry and immunology referred to but not explicitly described in this disclosure and examples are reported in the scientific literature and are well known to those skilled in the art.

Example 1: Methods

Isolation of *Xenopus* and human SARA

To prepare a probe for library screening, the MH2 domain of Smad2 (amino acids 241-467) was subcloned into a modified pGEX4T-1 vector containing the protein kinase A recognition site derived from pGEX2TK (Pharmacia). This bacterial fusion protein was purified, labelled with [³²P]γATP and used as probe to screen a λZAP II *Xenopus* dorsal lip library as described (Chen and Sudol, 1995). A screen of 1 x 10⁶ plaques yielded four phage which represented repeated isolates of the same clone. This partial cDNA contained a 2.1 kb open reading frame and 1 kb of 3' untranslated region (UTR). A full length clone was obtained by a combination of rescreening of the same dorsal

28

lip library using a 670 base pair EcoRI/HpaI fragment at the 5' end of this clone and by 5' RACE (Gibco/BRL) using stage 10 *Xenopus* RNA.

To obtain a human homolog of *Xenopus* SARA, cDNA was synthesized from randomly primed total RNA isolated from HepG2 cells. This cDNA was subjected to polymerase chain reaction (PCR) using degenerate primers as described previously (Attisano et al., 1992). The 5' and 3' primers, designed to encode the zinc-finger motif, correspond to

GC(A/C/G/T)CC(A/C/G/T)AA(C/T)TG(C/TATGAA(A/C/G/T)TG(C/T) and (A/G)CA(A/G)TA(C/T)TC(A/C/G/T)GC(A/C/G/T)GG(A/G)TT(A/G)TT, respectively.

- 10 A 150 base pair PCR product was sequenced and then used as probe for screening a λ ZAP human fetal brain cDNA library (Stratagene). Eight positive plaques were obtained, two of which contained an overlap of approximately 1kb and covered the entire open reading frame. The sequence of the 5' UTR was confirmed by sequencing of an expressed sequence tag database clone (clone ID 15 260739).

Construction of Plasmids

- For mammalian expression constructs of SARA, the open reading frame of hSARA was amplified by PCR and was subcloned into pCMV5 in frame with an amino-terminal Flag or Myc tag (Hoodless et al., 1996). The deletion mutants of 20 pCMV5-Flag-hSara Δ 893-1323, Δ 346-132, Δ 893-1323, and Δ 346-1323 were constructed by deletion of EcoRV-HindIII, XbaI-HindIII, Sall-EcoRV, and Sall-XbaI fragments, respectively. pCMV5-Flag-hSara Δ 1-594 and Δ 1-686 were obtained by partial digestion with Asp718/Sall and for pCMV5-Flag-hSARA Δ 665-1323 a 25 Asp718/HindIII partial digest was used. pCMV5-Flag-hSARA Δ 596-704 was constructed by deleting Asp718 fragment. The other hSARA mutants were constructed by PCR using appropriate primers. pCMV5B-Myc-Smad3 and Myc-Smad6, pGEX4T-1-Smad2/MH1 (amino acids 1-181), pGEX4T-1-Smad2/linker (amino acids 186-273), pGEX4T-1-Smad2/MH2 (amino acids 241-467) and 30 pGEX4T-1-h SARA (amino acids 665-750) were constructed by PCR.

***In Vitro* Protein Interactions**

In vitro transcription/translation reactions were performed using the TNT coupled reticulocyte lysate system (Promega) following the manufacturer's instructions using T3 RNA polymerase. Translation was carried out in the presence of [³⁵S]-methionine and labelled proteins were incubated with purified GST fusion proteins in TNTE buffer with 10% glycerol for 2 hours at 4°C and then washed five times with the same buffer. Bound protein was separated by SDS-PAGE and visualized by autoradiography.

Immunoprecipitation and Immunoblotting

COS-1 cells transfected with LipofectAMINE (GIBCO BRL) were lysed with lysis buffer (Wrana et al., 1994) and subjected to immunoprecipitation with either anti-Flag M2 (IBI, Eastern Kodak) or anti-Myc (9E10) monoclonal antibody followed by adsorption to protein-G sepharose. Precipitates were separated by SDS-PAGE, transferred to nitrocellulose membranes and immunoblotted as described previously (Hoodless et al., 1996).

Affinity-Labeling

LipofectAMINE transfected COS-1 cells were incubated with 200 pM [¹²⁵I]TGFβ in media containing 0.2% bovine fetal serum at 37°C for 30 minutes and receptors were cross-linked to ligand with DSS as described previously (Macias-Silva et al., 1996). Cell lysates were immunoprecipitated with anti-Flag antibody and receptors visualized by SDS-PAGE and autoradiography. In some cases, cross-linked [¹²⁵I]TGFβ was determined by gamma counting.

Subcellular Localization by Immunofluorescent Confocal Microscopy

Mv1Lu cells, plated on gelatin-coated Permanox chamber slides (Nunc), were transfected by the calcium phosphate-DNA precipitation method. Fixation, permeabilisation and reaction with the primary and secondary antibodies were described previously (Hoodless et al., 1996). Monoclonal anti-Flag antibodies were visualized by FITC-conjugated goat anti-mouse IgG (Jackson Laboratories)

and polyclonal Myc antibody (A14, Santa Cruz) was visualized with Texas-Red-conjugated goat anti-rabbit IgG (Jackson Laboratories). Immunofluorescence was analyzed on a Leica confocal microscope.

5 **Transcriptional Response Assay**

Mv1Lu cells were transiently transfected with the reporter plasmid, p3TP-lux (Wrana et al., 1992), CMV- β gal and selected constructs using calcium phosphate transfection. Twenty-four hours after transfection, cells were incubated overnight with or without 50 pM TGF β . Luciferase activity was
10 measured using the luciferase assay system (Promega) in a Berthold Lumat LB 9501 luminometer and was normalized to β -galactosidase activity.

Example 2 - Identification of SARA family members

The MH2 domain of Smad2 was fused to glutathione-S-transferase (GST)
15 that included a kinase recognition site for protein kinase A (PKA). The bacterially-expressed fusion protein was labelled to high specific activity using PKA (Chen and Sudol, 1995), and then used to screen a λ ZAPII expression library prepared from the dorsal blastopore lip of *Xenopus*. From this screen, four clones were identified, all of which presented a repeated isolate of a partial
20 cDNA clone with no similarity to sequences in the GenBank database. To confirm that the product encoded by this clone interacted with Smad2, an *in vitro* transcription/translation system was used to produce [35 S]methionine-labelled protein. Translation of the cDNA yielded a protein product of approximately 80 kDa which corresponded in size to the longest open reading
25 frame (ORF) identified in the sequence. Incubation of this product with bacterially-produced GST-Smad2(MH2) resulted in efficient binding of the translated product to the fusion protein (data not shown). Interaction with full length Smad2 was also observed, whereas binding to bacterially-expressed Smad1 or Smad4 was not.

30 To isolate a full length cDNA, the partial clone identified in the interaction screen was used as a probe to rescreen the same blastopore lip

library. Since the resulting clones lacked the 5' end, 5' RACE was conducted to obtain the entire coding sequence. Analysis of the complete cDNA sequence (Table 5) revealed a long open reading frame that was contiguous with that of the partial clone. The predicted protein, XSARA1, is 1235 amino acids long with an estimated molecular mass of 135 kDa (Table 6). Analysis of the full length cDNA sequence (Table 9) revealed a region in the middle portion of the predicted protein that had similarity to a double zinc finger domain (recently renamed the FYVE domain; Mu et al., 1995). The FYVE domain has been identified in a number of unrelated signaling molecules that include FGD1, a putative guanine exchange factor for Rho/Rac that is mutated in faciogenital dysplasia (Pasteris et al., 1994), the HGF receptor substrate Hrs-1 and its homolog Hrs-2 (Bean et al., 1997; Komada and Kitamura, 1995), EEA1, a protein involved in formation of the early endosome (Mu et al., 1995) and the yeast proteins FAB1, VPS27 and VAC1 (Piper et al., 1995; Weisman and Wickner, 1992; Yamamoto et al., 1995). Comparison of the FYVE domains from the vertebrate proteins with that from SARA revealed extensive conservation of residues throughout the domain (Table 10). Thus, SARA contains a FYVE domain that may fulfill important functions in diverse proteins.

To investigate the role of SARA in TGF β superfamily signaling in mammalian cells, a human homologue was identified. Using a carboxy-terminal portion of XSARA1, a human library was screened and a protein was identified that was distantly related to *Xenopus* SARA (34% identity) and which was also sequenced as an EST (KIAA0305). However, no homologs closer to XSARA were identified. Thus, degenerate oligonucleotide primers were designed encoding amino acids in XSARA1 (Table 9) and HepG2 RNA was used as template for degenerate PCR. A related sequence was identified and this partial cDNA was used to screen a human brain cDNA library. Four overlapping clones, encoding a long open reading frame were identified and a search of the EST database with this sequence led to the identification of additional overlapping cDNA clones from libraries derived from T cells, uterus, endothelial cells and melanocytes. Analysis of the contiguous sequence revealed a long

open reading frame that had a consensus start codon preceded by stop codons in all three reading frames (Table 1). Comparison of the predicted protein hSARA1 (Table 2), from this cDNA with XSARA1 (Table 9) revealed an overall identity of 62%, with a divergent 558 residue amino terminal domain (35% identity)

5 followed by a closely related carboxy terminus (85% identity).

Example 3 - hSARA interacts specifically with Smad2 and Smad3

To characterize the interaction of hSARA with Smads, the full length protein was translated *in vitro* and tested for binding to bacterially-expressed
10 Smad fusion proteins. Similar to the *Xenopus* clone, hSARA1 bound specifically to full length Smad2, but not Smad1 or Smad4 (Figure 1). In addition, full length Smad3, which is highly related to Smad2, also interacted with hSARA1. To define the domains of Smad2 that bound hSARA, in bacteria various fragments of Smad2 corresponding to the MH1 domain, linker region and MH2 domain were
15 expressed in bacteria. Similar to the *Xenopus* clone, hSARA interacted efficiently with fusion proteins that comprised the MH2 domain, while no association was detected between hSARA and either the MH1 or non-conserved linker domains (Figure 1). Thus, hSARA1 specifically interacts with Smad2 through the MH2 domain.

20 To confirm that hSARA also bound to Smads in mammalian cells, a Flag epitope tag was introduced at the amino terminus of the protein to create Flag-SARA. Transient expression of Flag-SARA in COS cells yielded a protein of the predicted molecular weight for SARA (Figure 2) that was not present in untransfected cells (data not shown). To investigate the interaction of SARA with
25 Smads, Flag-SARA was expressed in COS cells together with Myc-tagged versions of Smads 1, 2, 3, 4, 6 and 7. Cell lysates were subjected to anti-Flag immunoprecipitation followed by immunoblotting with anti-Myc antibodies. In other immunoprecipitates of cells expressing either Smad2 or Smad3, efficient coprecipitation of either Smad with Flag-hSARA1 was observed (Figure 2). In
30 contrast, none of the other Smads coprecipitated with hSARA1. Specific binding of this SARA family member to both Smad2 and Smad3 is consistent with the

observation that these two proteins possess very closely related MH2 domains (97% identity) and are both activated by TGF β or activin type I receptors (Liu et al., 1997b; Macias-Silva et al., 1996; Nakao et al., 1997a). Together, these results demonstrate that this SARA family member is a specific partner for
5 receptor-regulated Smads of the TGF β /activin signaling pathway.

Example 4- Phosphorylation of Smad2 induces dissociation from SARA

Previous findings have shown that activation of TGF β signaling results in phosphorylation of Smad2 or Smad3 by type I receptors on C-terminal serine
10 residues (Liu et al., 1997b; Macias-Silva et al., 1996). A constitutively active TGF β type I receptor was prepared by substituting a threonine in the GS domain with an aspartate residue (Wieser et al., 1995). This activated type I receptor induces TGF β signaling in the absence of type II receptors and ligand and regulates the phosphorylation and activation of Smad proteins in a manner
15 similar to ligand (Macias-Silva et al., 1996; Wieser et al., 1995). COS cells were transfected with combinations of Smad2, hSARA1 or both in the presence or absence of activated T β RI. Cells were then metabolically labelled with [32 P]phosphate and phosphorylation of either hSARA1 or Smad2 was assessed in immunoprecipitates. Analysis of SARA phosphorylation revealed that the protein
20 was basally phosphorylated and the coexpression of the activated type I receptor did not appreciably affect the overall phosphorylation (Figure 3). In contrast, analysis of Smad2 immunoprecipitated from total cell lysates showed that the activated type I receptor induced strong phosphorylation of the protein as described previously (Macias-Silva et al., 1996). These results suggest that SARA
25 is not phosphorylated in response to TGF β signaling.

The phosphorylation state of Smad2 that coprecipitated with hSARA1 was examined. Interestingly, unlike the strong induction of Smad2 phosphorylation in the total cellular pool, phosphorylation of Smad2 associated with hSARA1 was not enhanced, but rather appeared to decrease in the presence of TGF β signaling
30 (Figure 3). This suggested that receptor-dependent phosphorylation of Smad2 might induce dissociation from hSARA1. To examine this directly, the

interaction of hSARA1 with wild type Smad 2 or a mutant version lacking the C-terminal phosphorylation sites (Smad2(2SA)) was analysed. In the absence of TGF β signaling, association of hSARA1 with either Smad2 or Smad2(2SA) was comparable (Figure 4). In contrast, in cells coexpressing the activated receptor, a significant decrease in the interaction of wild type Smad2 with hSARA1 was observed. However, hSARA1/Smad2(2SA) complexes were not reduced by the activated receptor. Together, these results suggest that hSARA1 is not phosphorylated in response to TGF β signaling and that it preferentially interacts with the unphosphorylated form of Smad2.

Example 5 - SARA and Smad4 form mutually exclusive complexes with Smad2

Phosphorylation of Smad2 induces its interaction with Smad4 (Lagna et al., 1996; Zhang et al., 1997). hSARA1/Smad2 complexes in COS cells coexpressing Smad4 were assessed. In unstimulated cells, the level of hSARA1/Smad2 complex formation was comparable either in the presence or absence of Smad4 (Figure 5, lanes 3 and 6). However, upon activation of TGF β signaling, dissociation of Smad2 from hSARA1 was significantly enhanced by coexpression of Smad4 (Figure 5, lanes 4 and 7). These results indicated that phosphorylated Smad2 might preferentially interact with Smad4 rather than hSARA1 and suggested that Smad2 might form mutually exclusive complexes with either Smad4 or hSARA1. The formation of Smad2/Smad4 and Smad2/hSARA4 complexes in the same transfectants was then examined. Cell lysates were subjected to immunoprecipitation with anti-Flag antibodies directed towards tagged Smad2 and then immunoblotted for the presence of Smad4 and hSARA1. Consistent with previous findings (Lagna et al., 1996; Zhang et al., 1997), interaction of Smad4 with Smad2 was strongly stimulated by the activated type I receptor (Figure 6, lane 3 and 4). Concomitant with the formation of Smad2/Smad4 complexes, the interaction of Smad2 with hSARA1 was disrupted by activation of signaling (Figure 6, lanes 6 and 7). Thus, complexes of Smad2/hSARA1 and Smad2/Smad4 are mutually exclusive, supporting the notion that Smad4 may compete for Smad2 to enhance dissociation of hSARA1/Smad2

complexes. Together these results demonstrate that during TGF β signaling, hSARA1/Smad2 complexes are transient and phosphorylation of Smad2 induces dissociation and formation of heteromeric complexes with Smad4.

5 **Example 6- hSARA1 regulates the subcellular localization of Smad2**

The studies described above suggest that SARA functions upstream in the pathway and might control the subcellular localization of Smad2. To test this, an investigation was done to determine whether coexpression of hSARA1 might alter the localization of Smad2 in the TGF β -responsive epithelial cell line, Mv1Lu, using confocal microscopy. Mv1Lu cells were used rather than COS since the Myc antibodies crossreacted with endogenous proteins in the COS and obscured nuclear staining of tagged proteins. In cells expressing hSARA1 alone, the protein displayed a punctate staining pattern that was present throughout the cytosolic compartment and was excluded from the nucleus (Figure 7A). This localization of hSARA1 was in contrast to the diffuse staining typically observed for Smad2 in cells overexpressing the protein (Figure 7B). Cells transiently transfected with both hSARA1 and Smad2 were examined. In these cells, the distribution of hSARA1 was indistinguishable from cells transfected with hSARA1 alone (Figure 7D, left photo). In contrast, the localization of Smad2 in the presence of hSARA1 displayed a dramatic shift to a punctate pattern (compare Figure 7B to 7D, centre photos). Moreover, analysis of these immunofluorescent staining patterns by confocal microscopy revealed that hSARA1 and Smad2 precisely colocalized in the cytosol (yellow stain, Figure 7D, right photo). Interestingly, expression of Smad2 at much higher levels than hSARA1 reverted the distribution of Smad2 to that observed in cells transfected with Smad2 alone (data not shown). This supports the notion that elevating the amount of Smad2 can saturate hSARA1 and yield a diffuse distribution of Smad2 throughout the cell.

Studies were conducted to determine whether activation of TGF β signaling induces nuclear translocation of Smad2 in the presence of hSARA1. As shown in Figure 7, the localization of hSARA1 in the cytosolic compartment

looked similar in the presence or absence of the constitutively active TGF β type I receptor (compare Figure 7D and E, left photos). However, TGF β signaling caused a significant proportion of Smad2 to translocate to the nucleus (Figure 7E, centre photo) and this correlated with a shift to an orangy-red colour in the cytosolic colocalization stain (Figure 7E, right photo). Thus activation of TGF β signaling induces Smad2 to dissociate from hSARA1 and translocate to the nucleus.

To confirm that the punctate localization of overexpressed SARA reflected that of the endogenous protein, the localization of endogenous SARA and Smad2 was examined in Mv1Lu cells. Analysis of the distribution of endogenous hSARA1 using affinity-purified rabbit anti-hSARA1 antibodies revealed a punctate distribution that was similar to the pattern observed for transiently transfected, epitope-tagged hSARA1 (Figure 7F, left photo). This staining was specific, since cells stained with preimmune antisera, or purified antibody blocked with the hSARA1 antigen, revealed no detectable staining in the cytosol, although some weak background staining was observed in the nucleus (data not shown). Examination of endogenous Smad2 distribution in the same cell using goat anti-Smad2 antibodies revealed a punctate distribution for Smad2 (Figure 7F, centre photo) as published previously (Janknecht et al., 1998). Furthermore, analysis of hSARA1 and Smad2 together revealed extensive colocalization of the two proteins (Figure 7F, right photo). Colocalization was not complete and may reflect differences in the stoichiometry of hSARA1 versus Smad2 protein levels as suggested above, or the presence of additional regulatory mechanisms in the cell that control interaction of the endogenous proteins.

Taken together with the biochemical analysis, these results indicate that hSARA1 functions to anchor or recruit Smad2 to specific subcellular regions prior to activation by TGF β signaling.

Example 7 - hSARA1 co-localises with T β RII

The positioning of hSARA1 upstream of Smad2 activation suggested to us that hSARA1 might recruit Smad2 to specific subcellular domains for

phosphorylation and activation by the receptor. Interestingly, previous studies on the TGF β receptor demonstrated clustering of the receptor complex into punctate domains that resembled those displayed by hSARA1 (Henis et al., 1994). To test whether hSARA1 might colocalize with TGF β receptors, the subcellular localization of hSARA1 and TGF β Mv1Lu receptors was investigated in Mv1Lu cells. Endogenous TGF β receptors could not be detected, likely due to the low numbers of TGF β receptors present on these cells and the even fewer number that are activated in the presence of ligand. The localization of hSARA1 in Mv1Lu cells cotransfected with T β RII and treated with TGF β was therefore examined. In the absence of hSARA1, T β RII displayed a punctate staining pattern similar to the hSARA1 pattern (Figure 8A, panels i and ii, respectively), as observed previously in COS cells. Furthermore, in cells coexpressing hSARA1 and TGF β receptors, extensive colocalization of hSARA1 and T β RII was observed (Figure 8A, panel iii). This colocalization was not complete. This may be due to a restricted distribution of hSARA1 in only a subset of the intracellular compartments normally occupied by transmembrane receptors, which include the endoplasmic reticulum, Golgi and endocytic pathways. Thus, hSARA1 and the TGF β receptors colocalize to common subcellular domains.

The colocalization of hSARA1 and the TGF β receptors suggested the possibility that hSARA1 may interact with the TGF β receptor. To test this, a strategy was utilised similar to that employed to characterize the interaction of Smad2 with the TGF β receptor (Macías-Silva et al., 1996). Briefly, COS cells were cotransfected with TGF β receptors in the presence of hSARA1 and were affinity-labelled using [125 I]TGF β . hSARA1 was then immunoprecipitated from the cell lysates and coprecipitating receptor complexes were resolved by SDS-PAGE and visualized by autoradiography or were quantitated using a gamma counter. Analysis of cells expressing wild type receptors type II and type I, revealed that receptor complexes coprecipitated with hSARA1 (Figure 8B, lane 3). Furthermore, in the presence of kinase deficient type I receptor, there was a small increase in binding of hSARA1 to the receptor (Figure 8B, lane 2). This is in contrast to Smad2, which only interacts with TGF β receptor complexes that

contain kinase deficient type I receptors (Macías-Silva et al., 1996). These data suggest that hSARA1 associates with the TGF β receptor.

Next examined was whether coexpression of Smad2 might enhance the interaction of hSARA1 with TGF β receptors. In cells expressing wild type
5 receptor I, no difference in the amount of receptor complexes that coprecipitated with hSARA1, either in the presence or absence of Smad2, was observed (Figure 8B, compare lanes 3 and 5). In contrast, the association of hSARA1 with receptor complexes containing kinase-deficient type I receptors was enhanced by Smad2 (Figure 8B, lane 4). This finding was consistent with the previous
10 demonstration that kinase-deficient type I receptors stabilize interactions of Smad2 with the receptors. To investigate further the requirement for Smad2 in the interaction of hSARA1 with the receptor, a mutant of hSARA1, SARA(Δ SBDB), that removes the Smad binding domain, was tested. Analysis of wild type
15 hSARA1 interaction with receptor complexes containing kinase-deficient T β RI showed that wild type hSARA1 interacted with the receptor and this was enhanced approximately two-fold by Smad2 (Figure 9A). The Δ SBDB mutant of hSARA1 retained the capacity to associate with the receptor, although the efficiency of interaction was slightly reduced relative to wild type hSARA1. Importantly, unlike wild type hSARA1, binding of mutant hSARA1 to the
20 receptor was not enhanced by coexpression of Smad2. Together, these data suggest that hSARA1 interacts with the TGF β receptor independently of Smad2 binding and that Smad2 cooperates to enhance the association.

To further characterize the domains in SARA that mediate binding to the TGF β receptor, the interaction of a panel of SARA mutants with the TGF β
25 receptor was tested. Interestingly, interaction with the TGF β receptor was strongly suppressed in three mutants in which the FYVE domain was disrupted (Figure 9B; Δ 594, Δ 664 and the internal deletion Δ 597-665). Since the FYVE domain is required for the correct subcellular localization of SARA, it was postulated that, once bound to the membrane, other regions in SARA might
30 contribute to the interaction with the receptor. To examine this possibility, several carboxy-terminal truncation mutants of hSARA1 were tested.

Interestingly, deletion of the C-terminus downstream of position 750 suppressed receptor interaction, despite efficient expression of the truncated protein. This suggests that regions in the carboxy-terminus of SARA contribute to receptor interaction. In these analyses, the question of whether overexpression of Smad2 could rescue some interaction of SARA mutants with the receptor was also explored. For both the FYVE domain mutants and the C-terminal truncation, Smad2 expression was able to restore some interaction with the TGF β receptor. It is likely that the high levels of protein and receptor expression that are achieved in COS cells can drive some receptor interaction, even in the absence of appropriate localization signals.

Example 8 - A modular domain in SARA mediates association with Smads

To investigate the functional importance of SARA in TGF β signaling, the domains in the protein that mediate both its localization to specific subcellular regions and its interaction with Smad2 were defined. To this end, a series of deletion mutants of hSARA1 were constructed and tested for their ability to interact with Smad2 in COS cells by immunoprecipitation followed by immunoblotting. As summarized in Figure 10, loss of the first 665 amino acids of hSARA1, which included the double zinc finger/FYVE domain, did not interfere with hSARA1 binding to Smad2. However, further deletions (Δ 1-704) completely abolished the interaction of Smad2 with hSARA1. To map the carboxy-terminal boundary of the Smad binding domain, a number of C-terminal truncations were also analyzed. Deletion of all residues downstream of position 750 did not affect Smad2 interaction with hSARA1, while an additional loss of 85 amino acids (Δ 665-1323) completely abrogated binding to Smad2. To determine whether the region defined by this deletional analysis was sufficient to bind Smad2, the 85 amino acids referred to as the Smad Binding Domain (SBD) were linked to GST and the fusion protein was expressed in bacteria (GST-h SARA(665-750)). Incubation of lysates prepared from cells expressing Smad2 or Smad3 with GST-SBD resulted in efficient binding of both Smads to the fusion protein (Figure 11A). This interaction is likely direct, since bacterially expressed

SBD associates efficiently with bacterially-produced Smad2 (data not shown). These studies thus define a novel domain in SARA that mediates interaction with Smad2 and Smad3 and which is located downstream of the FYVE domain.

The above-described analysis in COS cells showed that phosphorylation of Smad2 by the TGF β receptor induced dissociation from SARA. To determine whether this reflects an alteration in the ability of the SBD to bind phosphorylated Smad2, the interaction of GST-SBD with Smad2 in lysates obtained from cells expressing Smad2 alone, or Smad2 together with either wild type or activated TGF β type I receptor, was tested. As described previously, coexpression of activated type I receptors with the appropriate receptor-regulated Smad yields efficient phosphorylation of Smad protein. In lysates from cells expressing Smad2 alone or Smad2 with wild type receptors, efficient binding of Smad2 to GST-SBD was observed. In contrast, in the presence of activated T β RI, the interaction of Smad2 with GST-SBD was strongly reduced (Figure 11B). This reduction correlated with receptor-dependent phosphorylation, since the phosphorylation site mutant, Smad2(2SA), interacted efficiently with GST-SBD, even in the presence of activated T β RI (data not shown). These data strongly support a mechanism whereby SARA interacts with unphosphorylated Smad2 and receptor-dependent phosphorylation induces dissociation by altering the affinity of Smad2 for the SBD.

Example 9 - The FYVE domain controls the subcellular localization of SARA

The subcellular localization of a selection of the SARA mutants was analysed by immunofluorescence and confocal microscopy. Analysis of truncation mutants that removed the amino terminus upstream of the FYVE domain (Δ 1-531) yielded wild type patterns of staining (Figure 12, compare panels i and ii). However, a further deletion (Δ 1-664) that disrupted the FYVE domain but did not interfere with the Smad binding domain, abolished the wild type staining pattern (Figure 12, panel iii). Similar studies of the C-terminal domains showed that residues downstream of the FYVE domain (Δ 665-1323) did not alter the localization of the mutant protein (Figure 12, panel iv), while

truncations within the FYVE domain ($\Delta 596-1323$) led to diffuse localization throughout the cell (Figure 12, panel v). Of note, the $\Delta 665-1323$ mutant lacked the Smad binding domain, thereby indicating that interaction with Smad2 is not required for proper SARA localization. To confirm that FYVE domain function was required for localization of SARA, a mutant with a small internal deletion that removes the FYVE domain ($\Delta 597-664$) was tested. Consistent with the other mutants, localization of this protein was clearly disrupted (Figure 12, panel vi). Since none of these mutants interfered with Smad binding, the FYVE domain appears to be required to maintain the normal localization of SARA but is not involved in mediating interactions with Smads.

Example 10 - SARA-mediated localization of Smad2 is necessary for TGF β signaling

The availability of mutants of hSARA1 that interact with Smad2 but fail to target to the appropriate subcellular sites allowed the question of whether hSARA1-mediated localization of Smad2 was important to TGF β signaling to be addressed. Whether SARA($\Delta 1-594$) and SARA($\Delta 1-664$), which bind Smad but fail to distribute to the correct subcellular domains, would mislocalize Smad2 was examined. Coexpression of either mutant with Smad2 showed that they were unable to recruit Smad2 to the normal SARA domains (Figure 13A, panels i and ii). As expected, SARA($\Delta 1-704$), which lacks a Smad binding domain, was unable to control Smad2 localization (Figure 13A, panel iii). Whether these mutants could cause mislocalization of Smad2 was also examined. For this, cells were cotransfected with wild type hSARA1 and Smad2 either in the absence or presence of SARA($\Delta 1-594$), SARA($\Delta 1-664$) or SARA($\Delta 1-704$). In control transfectants, performed in the absence of mutant hSARA1, hSARA1 and Smad2 were colocalized in punctate domains as described above (Figure 13B, panel i). However, in the presence of either SARA($\Delta 1-594$) or SARA($\Delta 1-664$), the localization of wild type hSARA1 was normal, but the distribution of Smad2 was clearly disrupted and displayed a diffuse pattern (Figure 13B, panels ii and iii, respectively). Moreover, coexpression of SARA($\Delta 1-704$), which does not

bind Smad2, resulted in Smad2 distribution that was indistinguishable from that of the wild type pattern (Figure 13B, panel iv). Thus, SARA(Δ 1-594) and SARA(Δ 1-664) induce the mislocalization of Smad2.

Since SARA(Δ 1-664) mislocalizes Smads and interferes with receptor association, we investigated whether this mutant would disrupt TGF β signaling. To test this, we transiently transfected the TGF β -responsive reporter gene 3TP-lux into Mv1Lu cells in the presence and absence of wild type or mutant versions of hSARA1. Expression of wild type hSARA1 had no effect on TGF β signaling (Figure 14). In contrast, transfection of SARA(Δ 1-664) significantly inhibited TGF β -dependent signaling at the lowest concentration of DNA tested, while transfection of higher doses completely abolished responsiveness of the cells. We also tested SARA(Δ 1-704) which lacks a functional Smad binding domain and does not alter Smad2 localization. Transfection of this mutant had no effect on TGF β signaling (Figure 14). In addition to analysis of the 3TP promoter, we examined induction of the activin response element (ARE) from the Xenopus Mix.2 gene in HepG2 cells.

This ARE is stimulated by either TGF β or activin signaling, which induces assembly of a DNA binding complex that is composed of Smad2, Smad4 and a member of the FAST family of forkhead DNA binding proteins. Since HepG2 cells do not possess endogenous FAST activity, wild type or mutants of hSARA1 were cotransfected with FAST2 and the ARE-lux reporter plasmid as described previously (Labbé et al., 1998). Expression of either SARA(1- Δ 594) or SARA(1- Δ 664), which interfere with or delete the FYVE domain, respectively, resulted in a strong suppression of TGF β -dependent induction of the ARE (Figure 15). However, none of the other mutants tested suppressed activation of this promoter. Since none of these latter mutants disturb the localization of hSARA1-Smad2 complexes, these data strongly suggest that recruitment of Smad2 to the receptor-containing subcellular domains is important for TGF β signaling.

30 Example 11 - Tissue distribution of hSARA expression

The 3'UTR of hSARA1 and a Smad2 cDNA fragment were used to probe a human multiple tissue Northern blot (Clontech). The results are shown in Figure 16 - hSARA1: upper panel and Smad2: lower panel. hSARA1 and Smad2 were ubiquitously expressed in the tissues examined; relatively low levels of hSARA1 were selected in liver. hSARA1 and Smad2 showed a similar expression pattern except in placenta, where proportionally more Smad2 message was observed. A single transcript of 5.0 kb is seen, corresponding to the full length hSARA1 cDNA.

SARA expression was examined in a variety of cell lines using RT-PCR analysis and the gene was found to be expressed in every cell line tested. These included HepG2 hepatoma cells, NBFL neuroblastoma cells, SW480 colorectal cancer cells, N1H 3T3 fibroblasts, P19 embryonic carcinoma cells, MC3T3 calvarial cells and Mv1Lu lung epithelial cells (data not shown). hSARA1 appears to be a ubiquitously expressed partner for Smad2 and Smad3.

15

Example 12 - Interaction of endogenous hSARA1 and Smad2 in mammalian cells

Lysates from HepG2 cells, either untreated or treated with InM TGF β , were immunoprecipitated with an affinity-purified, anti-hSARA1 rabbit polyclonal antibody and the immunoprecipitates were immunoblotted with a polyclonal, anti-Smad2 antibody (Macias-Silva et al., 1998). Controls were immunoprecipitated with pre-immune sera or N19 anti-Smad2/3 antibody. The results are shown in Figure 17. In immunoprecipitates prepared with preimmune antisera, no Smad2 was detectable. Anti-hSARA1 immunoprecipitates clearly showed Smad2 co-precipitating with hSARA1. TGF β treatment prior to lysis gave decreased association of Smad2 and SARA.

25

These results demonstrate that SARA is a specific partner of receptor-regulated Smads in the TGF β /activin signaling pathway and further suggest that TGF β signaling induces dissociation of SARA/Smad complexes.

WO 00/05360

PCT/CA99/00656

44

The present invention is not limited to the features of the embodiments described herein, but includes all variations and modifications within the scope of the claims.

REFERENCES

- Abdollah, S., Macías-Silva, M., Tsukazaki, T., Hayashi, H., Attisano, L.,
and Wrana, J.L. (1997). T β R1 phosphorylation of Smad2 on Ser 465 and 467 is
5 required for Smad2/Smad4 complex formation and signaling. *J. Biol. Chem.* 272,
27678-27685.
- Attisano, L. and Wrana, J.L. (1998). Mads and Smads in TGF β signaling.
10 *Curr. Op. Cell Biol.* 10, 188-194.
- Attisano, L., Wrana, J.L., Cheifetz, S., and Massagué, J. (1992). Novel
activin receptors: Distinct genes and alternative mRNA splicing generate a
repertoire of serine/threonine kinase receptors. *Cell* 68, 97-108.
- 15 Bean, A.J., Siefert, R., Chen, Y.A., Sacks, R., and Scheller, R.H. (1997).
Hrs-2 is an ATPase implicated in calcium-regulated secretion. *Nature* 385, 826-
829.
- Burd et al., (1998), *Mol. Cell.*, 2, 157-162.
- 20 Chen, H.I. and Sudol, M. (1995). The WW domain of Yes-associated
protein binds a proline-rich ligand that differs from the consensus established for
Src homology 3-binding modules. *Proc Natl Acad Sci USA* 82, 7819-7823.
- 25 Chen, X., Rubock, M.J., and Whitman, M. (1996). A transcriptional
partner for MAD proteins in TGF- β signaling. *Nature* 383, 691-696.
- Chen, X., Weisberg, E., Fridmacher, V., Watanabe, M., Naco, G., and
Whitman, M. (1997a). Smad4 and FAST-1 in the assembly of activin-responsive
30 factor. *Nature* 389, 85-89.
- Chen, Y., Bhushan, A., and Vale, W. (1997b). Smad8 mediates the
signaling of the receptor serine kinase. *Proc. Natl. Acad. Sci. USA* 94, 12938-
12943.
- 35 Chen, Y., Lebrun, J.-J., and Vale, W. (1996). Regulation of transforming
growth factor β - and activin-induced transcription by mammalian Mad proteins.
Proc. Natl. Acad. Sci. USA 93, 12992-12997.
- 40 Dennler, S., Itoh, S., Vivien, D., ten Dijke, P., Huet, S., and Gauthier, J.-
M. (1998). Direct binding of Smad3 and Smad4 to critical TGF β -inducible
elements in the promoter of human plasminogen activator inhibitor-type 1 gene.
EMBO J. 17, 3091-3100.
- 45 Dyson, S. and Gurdon, J.B. (1998). The Interpretation of Position in a
Morphogen Gradient as Revealed by Occupancy of Activin Receptors. *Cell* 93,
557-568.

- Faux, M. and Scott, J.D. (1996). Molecular glue: kinase anchoring and scaffold proteins. *Cell* 85, 9-12.
- 5 Gaullier et al., (1998), *Nature*, 394, 433-434.
- Heldin, C.-H., Miyazono, K., and ten Dijke, P. (1997). TGF- β signaling from cell membrane to nucleus through SMAD proteins. *Nature*. 390, 465-471.
- 10 Henis, Y.I., Moustakas, A., Lin, H.Y., and Lodish, H.F. (1994). The type II and III transforming growth factor- β receptors form homo-oligomers. *J. Cell Biol.* 126, 139-154.
- 15 Hoodless, P.A., Haerry, T., Abdollah, S., Stapleton, M., O'Connor, M.B., Attisano, L., and Wrana, J.L. (1996). MADR1, a MAD-related protein that functions in BMP2 signaling pathways. *Cell* 85, 489-500.
- Janknecht et al., (1998), *Genes & Development*, 12, 2114-2119.
- 20 Kim, J., Johnson, K., Chen, H.J., Carroll, S., and Laughon, A. (1997). *Drosophila* Mad binds to DNA and directly mediates activation of *vestigial* by decapentaplegic. *Nature* 388, 304-308.
- 25 Komada, M. and Kitamura, N. (1995). Growth factor-induced tyrosine phosphorylation of Hrs, a novel 115-kilodalton protein with a structurally conserved putative zinc finger domain. *Mol Cell Biol* 15, 6213-6221.
- 30 Kretzschmar, M., Liu, F., Hata, A., Doody, J., and Massagué, J. (1997). The TGF- β family mediator Smad1 is phosphorylated directly and activated functionally by the BMP receptor kinase. *Genes Dev.* 11, 984-995.
- 35 Kretzschmar, M. and Massagué, J. (1998). SMADs: mediators and regulators of TGF- β signaling. *Current Opinion in Genetics & Development* 8, 103-111.
- 40 Labbé, E., Silvestri, C., Hoodless, P.A., Wrana, J.L., and Attisano, L. (1998). Smad2 and Smad3 positively and negatively regulate TGF β -dependent transcription through the forkhead DNA binding protein, FAST2. *Molecular Cell* in press.
- Lagna, G., Hata, A., Hemmati-Brivanlou, A., and Massagué, J. (1996). Partnership between DPC4 and SMAD proteins in TGF- β signaling pathways. *Nature* 383, 832-836.
- 45 Liu, F., Pouponnot, C., and Massagué, J. (1997a). Dual role of the Smad4/DPC4 tumor suppressor in TGF β -inducible transcriptional complexes. *Genes & Development* 11, 3157-3167.

- Liu, X., Sun, Y., Constantinescu, S.N., Karam, E., Weinberg, R.A., and Lodish, H.F. (1997b). Transforming growth factor β -induced phosphorylation of Smad3 is required for growth inhibition and transcriptional induction in epithelial cells. *Proc. Natl. Acad. Sci. USA* 94, 10669-10764.
- Macías-Silva, M., Abdollah, S., Hoodless, P.A., Pirone, R., Attisano, L., and Wrana, J.L. (1996). MADR2 is a substrate of the TGF β receptor and its phosphorylation is required for nuclear accumulation and signaling. *Cell* 87, 1215-1224.
- Mu, F.T., Callaghan, J.M., Steele-Mortimer, O., Stenmark, H., Parton, R.G., Campbell, P.L., McCluskey, J., Yeo, J.P., Tock, E.P., and Toh, B.H. (1995). EEA1, an early endosome-associated protein. EEA1 is a conserved alpha-helical peripheral membrane protein flanked by cysteine "fingers" and contains a calmodulin-binding IQ motif. *J Biol Chem* 270, 13503-13511.
- Nakao, A., Imamura, T., Souchelnytskyi, S., Kawabata, M., Ishisaki, A., Oeda, E., Tamaki, K., Hanai, J.-i., Heldin, C.-H., Miyazono, K., and ten Dijke, P. (1997a). TGF- β receptor-mediated signaling through Smad2, Smad3 and Smad4. *EMBO J.* 16, 5353-5362.
- Nakao, A., Röijer, E., Imamura, T., Souchelnytskyi, S., Stenman, G., Heldin, C.-H., and ten Dijke, P. (1997b). Identification of Smad2, a human Mad-related protein in the transforming growth factor β signaling pathway. *J. Biol. Chem.* 272, 2896-2900.
- Nakayama, T., Snyder, M.A., Grewal, S.S., Tsuneizumi, K., Tabata, T., and Christian, J.L. (1998). *Xenopus* Smad8 acts downstream of BMP-4 to modulate its activity during vertebrate embryonic patterning. *Development* 125, 857-867.
- Nishimura, R., Kato, Y., Chen, D., Harris, S.E., Mundy, G.R., and Yoneda, T. (1998). Smad5 and DPC4 are key molecules in mediating BMP-2-induced osteoblastic differentiation of the pluripotent mesenchymal precursor cell line C2C12. *J. Biol. Chem.* 273, 1872-1879.
- Pasteris, N.G., Cadle, A., Logie, L.J., Porteous, M.E., Schwartz, C.E., Stevenson, R.E., Glover, T.W., Wilroy, R.S., and Gorski, J.L. (1994). Isolation and characterization of the faciogenital dysplasia (Aarskog-Scott syndrome) gene: a putative Rho/Rac guanine nucleotide exchange factor. *Cell* 79, 669-678.
- Patki et al., (1998), *Nature*, 394, 433-4.
- Patterson, G., Kowek, A., Wong, A., Liu, Y., and Ruvkun, G. (1997). The DAF-3 Smad protein antagonizes TGF- β -related receptor signaling in the *C. elegans* dauer pathway. *Genes and Dev.*

- Pawson, T. and Scott, J.D. (1997). Signaling through scaffold, anchoring and adaptor proteins. *Science* 278, 2075-2080.
- 5 Piper, R.C., Cooper, A.A., Yang, H., and Stevens, T.H. (1995). VPS27 controls vacuolar and endocytic traffic through a prevacuolar compartment in *Saccharomyces cerevisiae*. *J Cell Biol* 131, 603-617.
- 10 Savage, C., Das, P., Finelli, A., Townsend, S., Sun, C., Baird, S., and Padgett, R. (1996). The *C. elegans sma-2, sma-3* and *sma-4* genes define a novel conserved family of TGF- β pathway components. *Proc. Natl. Acad. Sci. USA* 93, 790-794.
- 15 Sekelsky, J.J., Newfeld, S.J., Raftery, L.A., Chartoff, E.H., and Gelbart, W.M. (1995). Genetic characterization and cloning of Mothers against dpp, a gene required for decapentaplegic function in *Drosophila melanogaster*. *Genetics* 139, 1347-1358.
- 20 Simonsen et al., (1998), *Nature*, 394, 494-495.
- Souchelnytskyi, S., Tamaki, K., Engström, U., Wernstedt, C., ten Dijke, P., and Heldin, C.-H. (1997). Phosphorylation of Ser⁴⁶⁵ and Ser⁴⁶⁷ in the C Terminus of Smad2 Mediates Interaction with Smad4 and Is Required for Transforming Growth Factor- β Signaling. *J. Biol. Chem.* 272, 28107-28115.
- 25 Topper, J.N., Cai, J., Qiu, Y., Anderson, K.R., Xu, Y.-Y., Deeds, J.D., Feeley, R., Gimeno, C.J., Woolf, E.A., Tayber, O., Mays, G.G., Sampson, B.A., Schoen, F.J., Gimbrone, M.A.J., and Falb, D. (1997). Vascular MADs: two novel MAD-related genes selectively inducible by flow in human vascular endothelium. *Proc. Natl. Acad. Sci. USA* 94, 9314-9319.
- 30 Weisman, L.S. and Wickner, W. (1992). Molecular characterization of VAC1, a gene required for vacuole inheritance and vacuole protein sorting. *J Biol Chem* 267, 618-623.
- 35 Wiedemann et al., (1998), *Nature*, 394, 426-427.
- 40 Wieser, R., Wrana, J.L., and Massague, J. (1995). GS domain mutations that constitutively activate T β R-I, the downstream signaling component in the TGF- β receptor complex. *EMBO J.* 14, 2199-2208.
- 45 Wrana, J.L., Attisano, L., Carcamo, J., Zentella, A., Doody, J., Laiho, M., Wang, X.-F., and Massagué, J. (1992). TGF- β signals through a heteromeric protein kinase receptor complex. *Cell* 71, 1003-1014.
- Wrana, J.L., Attisano, L., Wieser, R., Ventura, F., and Massague, J. (1994). Mechanism of activation of the TGF- β receptor. *Nature* 370, 341-347.

Yamamoto, A., DeWald, D.B., Boronenkov, I.V., Anderson, R.A., Emr, S.D., and Koshland, D. (1995). Novel PI(4)P 5-kinase homologue, Fab1p, essential for normal vacuole function and morphology in yeast. *Mol Biol Cell* 6, 525-539.

Yingling, J.M., Datto, M.B., Wong, C., Frederick, J.P., Liberati, N.T., and Wang, X.-F. (1997). Tumour Suppressor Smad4 is a Transforming Growth Factor β -Inducible DNA Binding Protein. *Mol. Cell. Biol.* 17, 7019-7028.

Zawel, L., Dai, J.L., Buckhaults, P., Zhou, S., Kinzler, K.W., Vogelstein, B., and Kern, S.E. (1998). Human Smad3 and Smad4 are sequence-specific transcription activators. *Mol. Cell* 1, 611-617.

Zhang, Y., Musci, T., and Derynck, R. (1997). The tumor suppressor Smad4/DPC4 as a central mediator of Smad function. *Curr. Biol.* 7, 270-276.

TABLE 1 - hSARA1 - Sequence ID NO:1

GCATACTGAATCAGCAGGACTGGCTGGTGGTGCAGCAGACATCATGAGTAAGCACCGA
 GAAGTCTGTTTCCTTATCACGTGTGTAAGGGGAAAAAGGTTTAAACAAGTCTCTTAAGT
 GGTGTTTCCTCACCGATGGAGAATTACTTCCAAGCAGAAGCTTACAACCTGGGACAAG
 GTGTTAGATGAATTTGAACAAAACGAAGATGAAACAGTTTCTTCTACTTTATTGGATA
 CAAAGTGGAATAAGATTCTAGATCCCCCTTCTCACC GGCTGTCATTTAACCTACTTT
 GGCCAGTGTGAATGAATCTGCAGTTTCTAATGAGTCACAACCACAACCTGAAAGTCTTC
 TCCCTGGCTCATTGAGCTCCCTGACCACAGAGGAAGAGGATCACTGTGCTAATGGAC
 AGGACTGTAATCTAAATCCAGAGATTGCCACAATGTGGATTGATGAAAATGCTGTTGC
 AGAAGACCAGTTAATTAAGAGAACTATAGTTGGGATGATCAATGCAGTGCTGTTGAA
 GTGGGAGAGAAGAAATGTGGAACCTGGCTTGTCTGCCAGATGAGAAGATGTTCTTG
 TTGTAGCCGTCATGCATAACTGTGATAAAAGGACATTACAAAACGATTACAGGATTG
 TAATAATTATAATAGTCAATCCCTTATGGATGCTTTTAGCTGTTCACTGGATAATGAA
 AACAGACAACTGATCAATTTAGTTTTAGTATAAATGAGTCCACTGAAAAAGATATGA
 ATTCAGAGAAACAAATGGATCCATTGAATAGACCGAAAACAGAGGGGAGATCTGTTAA
 CCATCTGTGTCCTACTTCATCTGATAGTCTAGCCAGTGTCTGTTCCCTTTCACAATTA
 AAGGATGACGGAAGTATAGGTAGAGACCCCTCCATGTCTGCGATTACAAGTTTAAACGG
 TTGATTCAGTAATCTCATCCAGGGAACAGATGGATGTCCTGCTGTTAAAAAGCAAGA
 GAACTATATACCAGATGAGGACCTCACTGGCAAAATCAGCTCTCCTAGGACAGATCTA
 GGGAGTCCAAATTCCTTTTCCCATGAGTGAGGGGATTTTGATGAAAAAGAGCCAG
 CAGAGGAGAGCACCACCTGAAGAATCCCTCGGTCTGGTTTACCTTTGCTTCTCAAACC
 AGACATGCCTAATGGGTCTGGAAGGAATAATGACTGTGAACGGTGTTCAGATTGCCTT
 GTGCCTAATGAAGTTAGGGCTGATGAAAATGAAGGTATGAACATGAAGAACTCTTG
 GCACTACAGAATTCCTTAATATGACAGAGCATTCTCTGAATCTCAGGACATGACTAA
 TTGGAAGTTGACTAACTAAATGAGATGAATGATAGCCAAGTAAACGAAGAAAAGGAA
 AAGTTTCTACAGATTAGTCAGCCTGAGGACACTAATGGTGATAGTGAGGAGCAGTGTG
 TTGGATTGGCAGATGCAGGTCTAGATTTAAAGGAACTTGCATTAGTGAAAGTGAAGA
 ATGTGATTTCTCCACTGTTATAGACACACCAGCAGCAAATTATCTATCTAATGGTTGT
 GATTCCTATGGAATGCAAGACCCAGGTGTTTCTTTTGTTCCAAAGACTTTACCTTCCA
 AAGAAGATTTCAGTAACAGAAGAAAAAGAAATAGAGGAAAGCAAGTCAGAATGCTACTC
 AAATATTTATGAACAGAGAGGAAATGAGGCCACAGAAGGGAGTGGACTACTTTTAAAC
 AGCACTGGTGACCTAATGAAGAAAAATTATTTACATAATTTCTGTAGTCAAGTTCCAT
 CAGTGCTTGGGCAATCTTCCCCAAGGTAGTAGCAAGCCTGCCATCTATCAGTGTTCC
 TTTTGGTGGTGCAAGACCCAAGCAACCTTCTAATCTTAAACTTCAAATTCCAAAGCCA
 TTATCAGACCATTACAAAATGACTTTCCTGCAACAGTGGAAATAATACTAAAAATA
 AAAATGATATTTCTTGGGAAAGCAAAATTAGGGGAAACTCAGCAACCAATGTATGTCAG
 TCCATCTTTGGGAAACATCTCTAATGTGATACAAAATGGGGAACATTTAGAAAGTTAT
 GAGGCTGAGATCTCCACTAGACCATGCCTTGCAATTAGCTCCAGATAGCCAGATAATG
 ATCTCAGAGCTGGTCAGTTTGAATTTCTGCCAGAAAGCCATTACCACGCTGGGTGA
 GGTGGCTCCAGTATGGGTACCGGATTCTCAGGCTCCAAATTGCATGAAATGTGAAGCC
 AGGTTTACATTACCAAAGGAGGCATCACTGCAGAGCATGTGGGAAGGTTTTCTGTG
 CTTCTGCTGTAGCCTGAAATGTAACTGTTATACATGGACAGAAAGGAAGCTAGAGT
 GTGTGTAATCTGCCATTGAGTGCTAATGAATGCTCAAGCCTGGGAGAACATGATGAGT
 GCCTCAAGCCAGAGCCCTAACCTAACAATCTGCTGAATACTGTTCTACTATCCCTC
 CCTTGCAGCAAGCTCAGGCCCTCAGGAGCTCTGAGCTCTCCACCTCCCACTGTGATGGT
 ACCTGTGGGAGTTTTAAAGCACCCCTGGAGCAGAAGTGGCTCAGCCCAGAGAGCAGAGG
 CGAGTTTGGTTTGTGATGGGATCTTGCCCAATGGAGAAGTTGCTGATGCAGCCAAAT
 TAACAATGAATGGAACCTTCTCTGCAGGAACCTGGCTGTGTACACGACCCAGTCAA
 GCCAGTAATACCAGTCTCTACCAGCAGAGACGGATATTTGTCTATTCTCTGGGAGT
 ATAATCAGGTTGGAAGTCTGTTGGAAGTGAATGAATCTTATTCCTGAAGATGGCC
 TTCTCTCCATTCTCATCTCCACTGGTGTAAAAGGAGACTATGCTGTGGAAGAGAAACC
 ATCACAGATTTTCAGTAATGCAGCAGTTGGAGGATGGTGGCCCTGACCCACTTGTATTT
 GTTTTAAATGCAAAATTTGTTGTCAATGGTTAAATTTGTAATTTATGTGAACAGGAAGT
 GCTGGTGTTCACAACCAAGGGAATGCATGCAGTGGGTGAGTCTGAGATAGTCATTCT
 TCTACAGTGTTTACCGGATGAAAAGTGTGTTGCCAAAGGATATCTTTAATCACTTTGTG
 CAGCTTTTATCGGGATGCTCTGGCAGGGAATGTGGTGAGCAACTTGGGACATTTCCTTCT
 TCAGTCAAAGTTTTCTTGGCAGTAAAGAACATGTTGGATTCTTATATGTGACATCTAC

TABLE 1 - hSARA1 Continued

CTACCAGTCACTGCAAGACCTAGTACTCCCAACCCACCTTACTTGTTTGGGATTCTT
ATCCAGAAATGGGAACTCCTTGGGCTAAAGTATTTCTATCCGTCTGATGTTGAGAC
TTGGAGCTGAATATCGACTTTATCCATGCCCACTATTCAGTGTGAGATTTCGGAAGCC
ATTGTTTGGAGAGACGGGGCATACCATCATGAATCTTCTTGCAGACTTCAGAAATTAC
CAGTATACCTTGCCAGTAGTTCAAGGTTTGGTGGTTGATATGGAAGTTTCGGAATACTA
GCATCAAAATTCAGCAACAGATACAATGAGATGATGAAAGCCATGAACAAGTCCAA
TGAGCATGTCCTGGCAGGAGGTGCCTGCTTCAATGAAAAGGCAGACTCTCATCTTGTTG
TGTGTACAGAATGATGATGGAACTATCAGACCCAGGCTATCAGTATTCACAATCAGC
CCAGAAAAGTGAAGTGGTGGCAGTTTCTTTGTGTTTCAAGTGGCGCTCTGAAATCCTCTTC
TGGATACCTTGGCAAGTCCAGTATTGTGGAAGATGGTGTATGGTCCAGATTACTGCA
GAGAATCATGGATTCTTGGAGCAGGCACTGCGAGAGATGAAGGACTTCACCATCACCT
GTGGGAAGGCGGACGCGGAGGAACCCAGGAGCACATCCACATCCAGTGGGTGGATGA
TGACAAGAACGTTAGCAAGGGTGTGCGTAAGTCTTATAGATGGGAAGTCCATGGAGACT
ATAACAAATGTGAAGATATTCATGGATCAGAATATAAAGCAAATGGAAAAGTAATCA
GATGGACAGAGGTGTTTTTCTAGAAAACGATGACCAGCACAATTGCCTCAGTGATCC
TGCAGATCACAGTAGATTGACTGAGCATGTTGCCAAAGCTTTTTGCCTTGCTCTCTGT
CCTCACCTGAACTTCTGAAGGAAGATGGAATGACCAAACTGGGACTACGTGTGACAC
TTGACTCAGATCAGGTGGCTATCAAGCAGGGAGCAATGGCCAGCCCCCTTCCCTCGCA
GTACATGAATGATCTGGATAGCGCCTTGGTGGCGGTGATCCATGGAGGGGCTGCCAG
CTTAGTGAGGGCCCCGTTGTATGGAATCATCTTTTATATTCTGGAAAACATCGTAT
AAACAGAGAAGACTTCATTTTTTTCTGTTTCAAGCTTGTGCAACAGCAGTCATACCCA
AATCATTTGCACTTTAAACTGGAAGATTAAGCTTTTGTTAACACTATTAATGGGGTG
GGGAATAGGGTGGGAGTGGGGGTTTGGGAGACGGGTGGGAAAGGGTGGTTGGGGGGAC
CGATGTTCCATAATTCTAAGTCTTCTATGCATTGTCCACCAAGAAGATCTGGGCAGCT
TCTGTTCTGCACAACAGTTATGCTATCCTTGACGCTAATCCCCTTCTGTTACTGTTT
AGACAAGAATTCGCTCCTCTCTCAAGATTTACTTATGGTCATGTGCTCAGAAATGCT
CAAATGGGTACAACCATCACCAAGGGTGGGATGGGAGGGCAGAGGGGAAATAAAATAT
AAAGCATCAAAAAAAAAAAAAAAAAA

TABLE 2 - hSARA1 - Sequence ID NO:2

MWIDENAVAEDQLIKRNYSWDDQCSAVEVGEKKCGNLACLPEKKNVLVVAVMHNC DKR
TLQNDLQDCNNYNSQSLMDAFSCSLDNENRQTDQFSFSINESTEKDMNSEKQMDPLNR
PKTEGRSVNHLCP TSSDSLAVCSPSQLKDDGSIGRDPMSAITS LTVD SVISSQGT
GCPAVKKQENYIPDEDLTGKISSPR TDLGSPNSFSH MSEGILMKKEPAEESTTEESLR
SGLP LLLKPDMPNGSGRNND CERCSDCLVPNEVRADENEGYEHEETLG TTEFLNMTEH
FSESQDMTNWKLTKLNEMNDSQVNEEKEKFLQISQPEDTINGDSSGGQCVGLADAGLDL K
GTCISESEECDFSTVIDTPAANYLSNGCDSYGMQDPGVSFVPKTLPSKEDSVTEEKEI
EESKSECYSNIYEQRGNEATEGSGLLLNSTGDLMKKNYLHNFC SQVPSVLGQSSPKVV
ASLPSISVPFGGARPKQPSNLKLQIPKPLSDHLQNDFPANSGNNTKNKNDILGKAKLG
ENSATNVCSPSLGNISNVD TNGEHLESYEA EISTRPC LALAPDSPDN DLRA GQFGISA
RKPFTTLGEVAPVWVPDSQAPNCMKCEARFTFTKRRHHC RACGKVFCASCCSLKCKLL
YMDRKEARVCVICHSVLMNAQAWENMMSASSQSPNPNNAEYCSTIPPLQQAQASGAL
SSPPPTVMVPVGV LKHPGA EVAQPREQRRVWFADGILPNGEVADA AKLTMNGTSSAGT
LAVSHDPVKPV TTSPLPAETD ICLFSGSITQVGS P VGSAMNLIPEDGLPPILISTGVK
GDYAVEEKPSQISVMQOLEDGGPDPLVFVLNANLLSMVKIVNYVNRKCWCFTTKGMHA
VGQSEIVILLOCLPDEKCLPKDIFNH FVQLYRDALAGNVVSNLGHSFFS QSFLGSKEH
GGFLYVTSTYQSLQDLVLP TPYPYLF GILIQK WETPWAKVFP IRLMLRLGA EYRLYPCP
LFSVRFRKPLFGETGHTIMNLLADFRNYQYTLPVVQGLVVDMEVRKTSIKIPSNRYNE
MMKAMNKSNEHVLAGGACFNEKADSHLV CVQND DGNYQTQAISIHNQPRKVTGASFFV
FSGALKSSSGYLAKSSIVEDGVMVQITAENMDSL RQALREMKDFTITCGKADAE EPQE
HIHIQWVDDDKNVSKGVVSPIDGKSMETITNVKIFHGSEYKANGKVIRWTEVFFLEND
DQHNCLSDPADHSRLTEHVAKAFCLALCTQLKLLKGDGMTKLGLRVTLDS DQVGYQAG
SNGQHLPSQYMND FDSDLVKMIHGGACQLSEGPVVMELIFYILENIV

TABLE 3 - human SARA2 - Sequence ID NO:3

ACTCCCGGGCCGGGGTAGCTCTTCACTCCTCAGCGCGACGTCGTGTCGAGTTCCCCAAA
AGCTCCGCAGGGGCTGTAGGGAGGTGATCTCATCCATTAAACAGCTGTGTGTTGCCAGT
TCCCAAATCTTTATCTATCTCAGACTTCTCTCCTGCATTCCAGATTCTTATATTCAGC
TGCCTTTTTGGATATCTCTCCAGGATGTTCTCAAGGCATACAAGAATTAAATTCTGAA
TAAGTCTGCAGGTAGGATGGACAGTTATTTTAAAGCAGCTGTCAGTGACTTGGACAAA
CTCCTTGATGATTTTGAACAGAACCAGATGAACAAGATTATCTCGCAGATGTACAAA
ATGCATATGATTCTAACCCTGCTCAGTTTCTTCAGAGTTGGCTTCTCACAGCGAAC
TTCATTGCTCCCAAAGACCAAGAGTGCCTTAATAGTTGTGCCTCATCAGAAACAAGC
TATGGAACAAATGAGAGTTCCCTGAATGAAAAAACACTCAAGGGACTTACTTCTATAC
AAAATGAAAAAATGTAAACAGGACTTGATCTTCTTTCTTCTGTGGATGGTGGTACTTC
AGATGAAATCCAGCCGTTATATATGGGACGATGTAGTAAACCTATCTGTGATCTGATA
AGTGACATGGGTAAGTTAGTTCATGCAACCAATAGTGAAGAAGATATTAAAAAATTAT
TGCCAGATGATTTTAAGTCTAATGCAGATTCCCTTGATTGGATTGGATTTATCTTCAGT
GTCAGATACTCCCTGTGTTTCTTCAACAGACCATGATAGTGATACTGTCTAGAGAACA
CAGATGATATCAGTTCTGAATTACAAAATAGAGAAATCGGAGGAATCAAAGAATTGG
GTATAAAAGTAGATACAACACTTTCAGATTCTTATAATTACAGTGGAACAGAAAATTT
AAAAGATAAAAAGATCTTTAATCAGTTAGAAATCAATTGTTGATTTTAAACATGTCTCT
GCTTTGACTCGACAAAGTTTCCAAAATGTTTCATGCCAAAGACAAGCTACAACACAAGA
GCCAGCCATGTGGATTACTAAAAGATGTTGGCTTAGTAAAAGAGGAAGTAGATGTGGC
AGTCATAACTGCCGCAGAATGTTTAAAAGAAGAGGGCAAGACAAGTGCTTTGACCTGC
AGCCTTCCGAAAAATGAAGATTTATGCTTAAATGATTCAAATTCAGAGATGAAAATT
TCAAATTACCTGACTTTTTCTTTTCAGGAAGATAAGACTGTTATAAAACAATCTGCACA
AGAAGACTCAAAAAGTTTAGACCTTAAGGATAATGATGTAATCCAAGATTCCTCTTCA
GCTTTACATGTTTCCAGTAAAGATGTGCCGTCCTCATTGTCTGTCTTCTGCGTCTG
GGTCTATGTGTGGATCATTAAATTGAAAGTAAAGCACGGGGTGATTTTTTACCTCAGCA
TGAACATAAAGATAATATACAAGATGCAGTGACTATACATGAAGAAATACAGAACAGT
GTTGTTCTAGGTGGGGAACCATTCAAAGAGAATGATCTTTTGAAACAGGAAAAATGTA
AAAGCATACTCCTTCAGTCATTAATTGAAGGGATGGAAGACAGAAAGATAGATCCTGA
CCAGACAGTAATCAGAGCTGAGTCTTTGGATGGTGGTGACACCAGTTCTACAGTTGTA
GAATCTCAAGAGGGGCTTTCTGGCACTCATGTCCCAGAGTCTTCTGATTGTTGTGAAG
GTTTTATTAATACTTTTTCAAGCAATGATATGGATGGGCAAGACTTAGATTACTTTAA
TATTGATGAAGGCGCAAAAAGTGGCCCACTAATTAGTGATGCTGAACCTTGATGCCTTT
CTGACAGAACAGTATCTTCAGACCACTAACATAAAGTCTTTTGAAAGAAAATGTAAATG
ACTCTAAATCGCAATGAATCAGATAGATGAAAGGCTTAGATGATGGAAACATCAA
TAATATATATTTCAATGCAGAAGCAGGAGCTATTGGGGAAAGTCATGGTATTAATATA
ATTTGTGAAACAGTTGATAAACAAAATACAATAGAAAATGGCCTTTCTTTAGGAGAAA
AAAGCACTATTCCAGTTCAACAAGGGTTACCTACCAGTAAGTCTGAGATTACAAATCA
ATTATCAGTCTCTGATATTAACAGTCAATCTGTTGGAGGGGCCAGACCTAAGCAATTG
TTTAGCCTTCCATCAAGAACAAGGAGTTCAAAGGACCTGAATAAGCCAGATGTTCCAG
ATACAATAGAAAGTGAACCCAGCACAGCAGATACCGTTGTTCCAATCACTTGTCAT
AGATTCTACAGCTGATCCACAGGTTAGCTTCAACTCTAATTACATTGATATAGAAAGT
AATTCTGAAGGTGGATCTAGTTTCGTAAGTCAATGAAGATTCTGTACCTGAAAACA
CTTGCAAGAAGGCTTGGTTTTGGGCCAGAAACAGCCTACTTGGGTTTCTGATTGAGA
AGCTCCAAACTGTATGAACTGCCAAGTCAAATTTACTTTTACCAAACGGCGACACCAT
TGCCGAGCATGTGGGAAAGTATTTTGTGGTGTCTGTTGTAATAGGAAGTGTAAGTGC
AATATCTAGAAAAGGAAGCAAGAGTATGTGTAGTCTGCTATGAACTATTAGTAAAGC
TCAGGCATTTGAAAGGATGATGAGTCCAAGTGGTTCTAATCTTAAGTCTAATCATTCT
GATGAATGTACTACTGTCCAGCCTCCTCAGGAGAACCAAACATCCAGTATACCTTCAC
CAGCAACTTTGCCAGTCTCAGCACTTAAACAACAGGTGTTGAAGGACTATGTTCCAA
AGAACAAGAGAGATGATGTTTTGCAGATGTTATATTGCCCAATGGTGAAGTTGCAGAT
ACAACAAAATTATCATCTGGAAGTAAAGATGTTCTGAAGACTTTAGTCTCTCTCAC
CTGATGTGCCTATGACAGTAAACACAGTGGATCATTCCCATTCTACTACAGTGGAAAA
GCCAAACAATGAGACAGGAGATATTACAAGAAATGAGATAATTGAGAGTCTTATTTCT
CAGGTTCCATCAGTGGAAAAATGTTCTATGAACACAGGAAATGAGGGGTTACCTACTT
CTGGTTCAATTTACACTAGATGATGATGTTTTTGCAGAACTGAAGAACCATCTAGTCC

TABLE 3 - human SARA2 - Continued

TACTGGTGTCTTAGTTAACAGCAATTTACCTATTGCTAGTATTTTTCAGATTATAGGTTA
CTGTGTGATATTAACAAGTATGTCTGCAATAAGATTAGTCTTCTACCTAATGATGAGG
ACAGTTTGCCCCCACTTCTGGTTGCATCTGGAGAAAAGGGATCAGTGCCTGTAGTAGA
AGAACATCCATCTCATGAGCAGATCATTGCTTCTTGAAGGTGAAGGCTTTCATCCT
GTTACATTTGTCTAAATGCTAATCTACTCGTGAATGTCAAATTCATATTTTATTCCT
CAGACAAATATTGGTACTTTTCAACCAATGGATTGCATGGCTTGGGACAGGCAGAAAT
TATTATTCTATTGTTATGTTTGCCAAATGAAGATACTATTCCCTAAGGACATCTTCAGA
CTATTTATCACCATATATAAGGATGCTCTAAAAGGAAAATACATAGAAAACCTGGACA
ATATTACCTTTACTGAGAGTTTCTCAGTAGCAAGGATCACGGAGGATTCCCTGTTTAT
TACACCTACTTTTTCAGAACTTGATGATCTCTCATTACCAAGTAATCCTTTTCTTGT
GGAATTCCTATCCAGAAGCTTGAGATTCCCTGGGCAAAGGTTTTTCTATGCGTTTAA
TGTTGAGATTGGGTGCAGAAATATAAGCATATCCTGCTCCTCTAACAAGCATCAGAGG
CCGAAAACCTCTTTTGGAGAAATAGGACACACTATTATGAACCTTACTTGTGACCTT
CGAAATTACCAGTATACCTTGCATAATATAGATCAACTGTTGATTTCATATGGAAATGG
GAAAAAGCTGCATAAAAAATACCACGGAAAAAGTACAGTGATGTAATGAAAGTACTAAA
TTCTTCCAATGAGCATGTCTATTAGCATTGGAGCAAGTTTTCAGTACAGAAGCAGATTCT
CATCTAGTCTGTATACAGAATGATGGAATTTATGAAACACAGGCCAACAGTGCCACTG
GCCATCCTAGAAAAGTGACAGGTGCAAGTTTTGTGGTATTCAATGGAGCTCTAAAAAC
ATCTTCAGGATTTCTTGCTAAGTCCAGCATAGTTGAAGATGGCTTAATGGTACAAATA
ACTCCAGAGACCATGAATGGCTTGCGGCTAGCTTTACGAGAACAGAAAGACTTTAAAA
TTACATGTGGGAAAGTTGATGCAGTAGACCTGAGAGAATACGTGGATATCTGCTGGGT
AGATGCTGAAGAAAAAGGAAACAAAGGAGTTATCAGTTTCAGTGGATGGAATATCATT
CAAGGATTTCCAAGTGAAAAAATAAACTGGAAGCAGATTTTGAAACCGATGAGAAGA
TTGTAAAATGTACCGAGGTGTTCTACTTTCTAAAGGACCAGGATTTATCTATTTTATC
AACTTCTTATCAGTTTGCAAAAGAAATAGCCATGGCTTGTTAGTGCTGCGCTGTGCCCT
CACCTGAAAACCTCTAAAAAGTAATGGGATGAATAAAATTGGACTCAGAGTTTCCATTG
ACACTGATATGTTTGAATTTCAAGGCAGGATCTGAAGGCCAACTTCTGCCTCAGCATTA
TCTAAATGATCTTGATAGTGCTCTGATACCTGTGATCCATGGTGGGACCTCCAACCTCT
AGTTTACCATTAGAAATAGAATTAGTGTCTTTTTCATTATAGAACATCTTTTGTAGTAA
AGAATGTGCCATATTACATATTGCAACCTAATTTGTTAAAACTAACTCCAGCACTAAA
GCTGAAATGCCACAAACACTAAAAGTATAAATATGTCTGATTTTTGAAACACATAAGC
TTTGCTCTTTAGGCAGGAATGATCTTTTCAAATCATTAGCACAAATATTTAAATATCTA
AAAATTTAAGAGATCCATACTTTCTGTAGCTTTACAATTAATTTAAGTACTAAAAAGA
CAAGGATTTCTTTTAAGAAATTTATAGCATTACTGTGTTATTTAAATGCTAAGCCAA
AGTATCTGCACCTTAGGTATACCTCTTTATGCCAATAATGATTTTAAATGAAGGCTCTTT
TCAGATGTAACCTTATGAAGGAAATATCTGCTTTGTGTATATGCCAGTTAGAATACTG
GTTTCTAAAGTCTGTCAAATTGTATTTTCAGTGGCACAACCAAGTTTGGAGGCTTTA
GACTTATAATTTCTTGAATAAACTGATACTTATTTGTATAATTGGAGTGGAGACCT
ACCTCCATAATTAGATAAACTCTTTTGGATTATAATCAGAATTTTGCCTTTTTTCTT
CTCAAATTATTACATATGTATGTATTATATATCCACATATATAGTTTTCCCTGATTAA
ATGGATATTAAATAAATTGCGGGTGCTTCAGGACTTTTGTCTTCTATATTTAAGTATA
TTGTTTTTATAGCAAGACATATTCTGAATGTTTTATAAATCTTTAATAATTTATATG
TAGGTAATATTTTTGTATCACAATGCATTATTTTTTCTCTCTTCTCCTCCAAACTA
TACCACTGTATTTACCACTTCTAAGAGTGACTGACGACGGGCCAGATGACCCTTGAAG
TAGTCAATTATGTAGCAATAAATGAAGCCTGAAACAGGTTTTTTTACTTCCACTTAAT
CCTTAGAAATTTCTTGGCAACTTCGCATATTTTTCATTGACACTGGTGTATAAGTATAA
ATTTAAATGAACATAATTACTTTTGCATATTTTAAATCTTTTATATGGTAGTTATTTT
TATAACAGGATATTTAACATAAGTTAAATCCTATGTATTTGAAATTGTTACAGAGCTTT
CCTCTTTACTTCAAACAGCAAAAAAGTGGGGGGCATATTGTAGTCTGTCAATTTAAGT
TATGTAAAAAATTTAATCATTATTTTGATGCTTTAAACATTCTCATGTGTAATATATG
TTTTTGTATCAAAAACACTCATATATTTCAAGAAAAAGAAATTATGTTAAATAGCCCT
GTTTTAAGAAAAATATTTATGAAGCATCTCAACTGAAGATCAAGTCAAAGTTATAAC
TCAGGATCTGAGGTCTCAAGCTAGGAGAGACTGAGAATTTTAAATCAGTTTGGGCATAT
AGTTTGGACTCAATCACATCTGTAGTACTTTAGCCAAAGACAATTTGGAGGAGAAATC
AGCCTTCTGGAAGTAGCTACTTCTGAACAATGTAAAGTGTGCGCAGATATTCAATAAA

WO 00/05360

PCT/CA99/00656

55

TABLE 3 - human SARA2 Continued

ATGGCAACCTGTTATAATTTGTGAAATTTATTGAAATGGTGTAAGATGAAAACAATTG
CATATCAAACCCAATTTATGTTTTCTAAATATAGTGTATGTATTCTGCCATGTAAGTA
ATTGAACAGTCTTAAATAACCAAATGGTAGAGGGCTGTTCCATGATGGGACAGCTTT
GGATTTGTTTTCATAAAATCTCTACATTCAATAAAAATTGGAATTATGTGCCTGAAGT
TTGGAGGCACATTTTGAAGT

TABLE 4 - human SARA2 - Sequence ID NO:4

MDSYFKA AVSDLDKLLDDFEQNPDEQDYLDVQNAYDSNHCSVSSELASSQRTSLLPK
DQECVNSCASSSETS YGTNESSLNEKTLKGLTSIQNEKNVTGLDLLSSVDGGTSDEIQP
LYMGRCSK PICDLISDMGNLVHATNSEEDIKKLLPDDFKSNADSLIGLDLSSVS DTPC
VSSTDHDSDTVREQQNDTSSELQNREIGGIKELGIKVDTTLSDSYNYSGTENLKDKKI
FNQLESIVDFNMSSALTRQSSKMFHAKDKLOHKSQPCGLLKDVGLVKEEVDVAVITAA
ECLKEEGKTSALTCSLPKNEDLCLNDSNSRDENFKLPDFS FQEDKTVIKQSAQEDSKS
LDLKDNDVIQDSSSALHVSSKDVPSLSCLPASGSMCGSLIESKARGDFLPQHEHKDN
IQDAVTIHEEIQNSVVLGGEPFKENDLLKQEKCKSILLQSLIEGMEDRKIDPDQTVIR
AESLDGGDTSSSTVVESEQEGLSGTHVPESDCCCEGFINTFSSNDMDGQDLDFYNIDEGA
KSGPLISDAELDAFLTEQYLQTTNIKSFEENVNDSKSO MNQIDMKGLDDGNINNIYFN
AEAGAIGESHGINIICETVDKQNTIENGLSLGEKSTIPVQQGLPTS KSEITNQLSVSD
INSQSVGGARPKQLFSLPSRTRSSKDLNKPDPVDTIESEPSTADTVVPITCAIDSTAD
POVSFN SNYIDIESNSEGGSSFVTANEDSV PENTCKEGLVLGQKQPTWVPDSEAPNCM
NCQVKFTFTKRRHHCRACGKVF CGVCCNRKCKLQYLEKEARVCVVCYETISKAAQAFER
MMSPTGSNLKSNHSDECTTVQPPQENOTSSIPSPATLPVSALKQPGVEGLCSKEQKRV
WFADGILPNGEVADTTKLSSGSKRCSEDFSP LSPDVPMTVNTVDHSHSTTVEKPNNET
GDITRNEIIQSPISQVPSVEKLSMNTGNEGLPTSGSFTLDDDVFAETE EPSSPTGVLV
NSNLP IASISDYRLLCDINKYVCNKISLLPNDEDSL PPLLVASGEKGSVPVVEEHPSH
EQIILLLEGE GFHPVTFVLNANLLVNVKFI FYSSDKYWFSTNGLHGLGQAEI IILL
CLPNEDTIPKDI FRLFITIIYKDALKGKYIENLDNITFTESFLSSKD HGGFLFITPTFQ
KLDDLSLPSNPFLCGILIQKLEIPWAKVFP MRLMLRLGA EYKAYPAPLTSIRGRKPLF
GEIGHTIMNLLV DLRNYQYTLHNIDQLLIHMEMGKSCIKIPRKYS DVMKVLNSSNEH
VISIGASFSTEADSHLVCIQNDGIYETQANSATGHPRKVTGASFVVFNGALKTSSGFL
AKSSIVEDGLMVQITPETMNGRLRLALREQDFKITCGKVDAVDLREYVDICWVDAEEK
GNKGVISSVDGISLQGF PSEKIKLEADFETDEKIVKCTEVFYFLKDQDLSILSTSYQF
AKEIAMACSAALCPHLKTLKSNGMNKIGLRVSI DTMVEFQAGSEGQLLPQHYLNDLD
SALIPVIHGGTSNSSLPLEIELVFFIIEHLF

TABLE 5 - XSARA1 - Sequence ID NO:5

CTGTAAGTTTGACTATGTAGGAAAGCATTCTGTTATCTATGAAGTATGTTTTAGAGT
CAGACCAATAACTAAACGGTTTTCTTTTTTTTTGTTTATTTCCCTCAGATGAGACTGT
CTCTCCAAAGCTATTAGATGCTAAGTGGAATCAAATCTTAGAACCGCATTACACATAAA
GTCGCTGATAACTCCGCCCTTGACAATGTCTGTAAATCAATCATTGCTATTGAAGCTC
ATCTCAAAGTCAGGTCACCCGGCTTGTCAGCCCTTGAGGTCACATATGTGAATGG
AGAAGTAGGTATTGTGGCACCTGAAATGCCCAAATGGTGATAGGAGACACCATTATG
GCAGAGGATTCACTTTTAAACAACACTGGTCCCTCTGAAATTGTATGCAACCCATCTA
CTGTGGAGAGTCAAAGTTTACAAGCTTTAGATGATCAATCAGTGAATATTCACAATGA
AAAAAGTGTCTGCTCGCTGATGGCTTTTACCATGCAGTAGCCCCAAAAGTATTATA
AACTTTGACTGCTTGACCATGGATAACGAAATGCCCTTGCACAGTCAAATGAGTGTG
ATGACAATGACAAAGAACTGTAACAATTTAGTCCTTCCAACAATCATAACAGGATAC
TAGTAACGTAAGCACAGACCCAGCTATCAATAAACCTGGCACTAAAGAACCCCATAGA
GCATTAAAGGAAACCACATCAGTTATTCTGCCTGAAATAAAGCCTTACTCCACATGTG
CTGCCCTTTGTTTTGAAAATAACAATAAGGTTCCAGTTATCAATTAATAATACAGA
TCTACTCAGCGTTTCACCAAGTGGTTGAAGCATGTAGTGAGCAGCAGCAAAAACATACA
TCTTCCTTGCATGAAGAAAACTTTTGAAGGTGTTTCTGCAACGGAGTCTTTTGCAG
CCACTGCTGCGGAAACTGTACTGGATAATGAGGCTCTCCGTAGTGCTGAATTCCTTTGA
CATTGTTGTAAAGAACTTTTCTGACTCTTGTGTGATTAATGGCGACTTGACTAAAAGT
TGTGGCCTCTCTCAAGAAAGCAATGAAAAGTTTTGTGCAAGTAAAGAGTTTGAAGGAG
GGGTAGATGCTAATGTCTTGTGGAAAATGCATGTGTAGCTTATAAAGAAGCAATAGA
TTTGCTGGAAGAAAATGGAACATAATGCACCAATGTCTCTGTACAATGGGTGTGATTCC
TATGGAATGAAAAACCCAGCCGTAGCTCAAAACCCAAAGAATTTACCTTCAAAGAAG
ATTCTGTGACAGAAGAAAAGAAATGAAGAAAGCAAGTCAGAATACTATACTGGTGT
TTATGAACAACAAAGAGAAGATGATGTTACAGAGAGAGGTGGACTTCTGTTAAATGCT
AAGGCTGACCAATGAAGAACAATTTGCATAGTCTTTGTAATCAGGTTCCATCCATGC
ATGGGCAAAACATCACCAAAAAGGGCAAGATTGTGCAATCTCTCAGTGTTCCATACGG
TGGAGCACGCACTAAGCAGCCAACTCATCTCAAACCTCCATATTCCAAAGCCATTGTCT
GAAATGTTGCAGAGCGATCTCATTCTCCAAATGCTGGCTGCAGCTCTAAATACAAAA
ATGACATGTTAAACAAATCAAATCAGGGGGATAACCTGATTTTCAAGATCACTGCGTGA
GGATTCTGCAGTGCGCAGCCCTGTTACTGATGCTAATGGTGATTTCCCTGGAGAATAC
AGGGGACCTGGCAGCTTGTGCCTTGCAAGTGTCTCCAGACAGCCAGACAACGATCTGC
TTGCCGGGCAAGTTTGGGGTACCCATCTCTAAGCCATTTACTACTCTAGGGGAAGTGGC
TCCAGTCTGGGTGCCAGATTCCCAAGCACCAAACTGCATGAAGTGCGAGGCGAGATT
ACATTTACCAAAAGGAGGCATCACTGCCGAGCTTGTGGAAAGGTGTTCTGTGCTGCTT
GTTGCAGTCTAAATGCAAACTACAGTACATGGATAAAAAGGAGGCTCGTGTGTGTGT
TATTTGTCAATCTGTGCTTATGAATGCTCAAGCATGGGAGAACATGTTAAGTGCATCG
GTCCAAAGCCCAAATCCAAATAATCCTGCTGAATACTGCTCAACTATCCCTCCGATGC
AGCAGGCACAAGCTTCAGGAGCACTGAGTTCCCCACCTCCCACTGTCATGGTGCCAGT
GGGTGTGTTAAACATCCAGGAAGTGAAGGGTCACAGTCAAAGGAACAGCGCCGTGTT
TGGTTTGCTGATGGAATATTACCCAACGGAGAGACTGCTGACTCAGATAATGCAAACG
TAACATACAGTGGCTGGGACACTTACTGTGTGCATACCAACAATTCACATCTTCAGA
GTCTGAGAACACCTCTGGATTCTGTGGAAGTATAACTCAGGTTGGCAGTGCAATGAAC
CTTATTCAGAAGATGGGCTTCTCCTATACTAATCTCTACTGGAGTAAAAGGAGATT
ACGCAGTTGAGGAACGCCCTTCCAGATGTCTGTGATGCAGCAACTAGAGGAAGGAGG
ACCAGATCCTTTGGTTTTTGTCTAAATGCAAATCTTTTGGCCATGGTTAAGATCGTG
AACTATGTTAACAGGAATGCTGGTGCTTTACTACAAAGGGAATGCATGCAGTGGGCC
AGGCTGAGATCGTAATCCTGTTGCAGTGCCTGCCTGATGAGAAGTGCCTGCCGAGGGA
CCTGTTTAGCCATTTTGTGTGAGCTGTACAGGAGGCAATTGCAGGTAATGTATGGGG
AACCTGGGGCATTCCTTCTCAGCCAGAGTTCCTGSGGTAGTAAGGATCATGGTGGAT
TTCTTTATGTTTGACCAACCTACCAGTCCCTCCAGGACCTGGTTCTTCTGTCAGAGCC
GTACTTGTGTTGGAATCCTTATTCAAAGTGGGAGACTCCATGGGCCAAAGTGTTCCTCC
ATTCGGCTTATGCTGCGTTTAGGTGCAGAATACAGATTGTACCCATGTCCACTCTTCA
GTGTTTCGATACAGAAAACCTCTGTTTGGGGAAACCGGACACACCATCATTAAATGTTCT
AGCCGATTTTCAAGAACTATCAGTATACTCTGCCAGTGGTSCAGGGCTTGGTGGTGGAT
ATGGAAGTCAGAAAACTAGCATTAAATCCCCAGCAATAGATACAATGAGATGATGA
AAGCAATGAACAAATCCAATGAGCATGTGTTGGCCATAGGAGCATGCTTCAACCAGAT

TABLE 5 - XSARA1 Continued

GGCAGACTCTCACCTTGTGTGTGTGCAAAACGATGATGGCAATTACCAGACCCAGGCA
ATTAGTATCCACAAACAACCACGTAAAGTGACCGGGGCCAGCTTCTTTGTCTTCAGTG
GTGCACTAAAGTCTTCTTCCGGATACCTGGCCAAATCCAGCATAGTAGAAGATGGGGT
AATGGTTCAGATCACCGCAGAGAGCATGGATGCCCTCAGACAGTCCCTTCGGGAGATG
AAGGATTTTACCATTACATGTGGAAAAGCTGATGCAGAGGAGTCACAGGAACATGTCT
ATGTCCAGTGGGTGGAGGATGACAAGAACTTTAACAAAGGAGTTTTTAGTCCAATCGA
TGGCAAATCAATGGAGTCTGTGACCAGCGTCAAGATTTTTTCATGGCTCAGAATACAA
GCTAGTGGAAAAATAATTGCTGGATAGAGGTCTTCTTTCTGGACAATGAGGAGCAAC
AGAGTGGCCTGAGTGACCCTGCTGATCACAGCCGACTCACTGAAAATGTGGCCAAAGC
ATTCTGTTTTAGCGCTTTGCCCACACCTCAAGCTACTGAAGGAAGATGGAATGACCAGG
TTAGGTCTGCGGGTGTCACTGGACTCAGACCAGGTGGATACCAAGCTGGGAGCAATG
GGCAACTCCTGCCTGCCCCGATACACCAATGATTTGGATGGTGCTTTGGTACCAGTGAT
ACACGGGGGCACATGCCAGTTAAGTGAAGGGCCTGTCAGTATGGAGCTGATATTTTAT
ATCCTTGAGAACATCTCCTAGGAAAGACACATGTGTCTCCTCACAAACTGCCATCGCC
CAAACCATTTGCACTTTAACCGCAAAAGATTCATTTTTCTTTTCTTTTGCTAACACTA
GTATTAGGTGAGGGTGGGAGAGGCAGACACCTGAACTCTTAAACCTTCTATGCATTTT
CACAGTAAGGATCAAGCTGCAGCTGGGAATTTCTGTTACTAATCCAATGTGGGACGT
TAGAAGTGATCGGTGGCACTGACTATCTAGCTGTTCAACCTTCTCTGGCTCCTCTAAG
GACTCTAGTGCCAGGGGGTGAGACATTCAAGTTTAAACGAAACTCTAAATACAATC
AGGAATCTCACTCTGACCTCATTTAAATCATCACTGCGACTTTTTTCTCTGCTCGCAT
TCTTTATTTTGCATCTTACTCAAGTTTACATTGTCAAGACCAGCCTAAGCCTTCAGTC
CTTTCTCAATTAACTACTCGTGATGGCAAGGAGACTTTTCGTTGCACAGCCTGAAAT
ATACCAATCACTTCCCAAACCACAAGCATGAATCCAACGTTTTTCTGACTGGTTGGCT
CTGCTGTGAAAGGGACAGCAATATTATTTTTCTACAGTTGACAAAACCTTTTGTCTATG
TCTGTGTCTCTCATGGGGGATTTGTTGCCCTGATGGGCAGCCTCCGGAGAGAAGAATTC
CACCCGTGTGTAATATACAGTCTAAGTGTATGGTCTGCTATGTAAACACCTGTTGCGCA
GTGCAAATGCACTGACTCTCTGGAAGGCTATAGAGTTTTTAAAAACGGTTAGTCTTTTA
AAAAAAAA

TABLE 6 - XSARA1 - Sequence ID NO:6

MPKMVIGDTIMAEDSLFNNTGPPSEIVCNPSTVESQSLOALDDQSVNIHNEKSVLLADG
FSPCSSPKSIINFDCLTMDNEMPLHSQMSVDDNDKETVTISVLPTIIQDTSNVSTDPA
INKPGTKEPHRALKETTSSVILPEIKPYSTCAALSFENNNKVPSYQLNNTDLLSVSPVV
EACSEQQQKHTSSSLHEEKLFEVGSATESFAATAAETVLDNEALRSAEFFDIVVKNFSD
SCVINGDLTKSCGLSQESNEKFCASKEFEGGV DANVLL ENACVAYKEAIDLPEENG TN
APMSLYNGCDSYGMKNPAVAQNPKNLPSKEDSVTEEKEIEESKSEYYTGVYEQQREDD
VTERGGLLLNAKADQMKNLHSLCNQVPSMHGQTSPKKGKIVQSLSVPYGGARTKQPT
HLKLHIPKPLSEMLQSDLIIPPNAGCSSKYKNDMLNKSNOGDNLISESLREDSAVRSPV
TDANGDFPGEYRGPGSLCLAVSPDSPDNLLAGQFGVPI SKPFTTLGEVAPVWVPDSQ
APNCMKCEARFTFTKRRHHCACGKVFCAACCSLKCKLOYMDKKEARVCVICHSVLMN
AQAWENMLSASVQSPNPNPAEYCSTIPPMQQAQASGALSSPPPTVMVPVGV LKHPGT
EGSQSKEQRRVWFADGILPNGETADSDNANVTTVAGTLTVSHTNNTSSESENTSGFC
GSITQVGSAMNLIPEGLPPILISTGVKGDYAVEERPSQMSVMQQL EEGGPDPLVFVL
NANLLAMVKIVNYVNRKCWCFTTKGMHVGQAEIVILLQCLPDEKCLPRDLFSHFVEL
YQEAIAGNVVGNLGHSFLSQSFLGSKDHGGFLYVAPTYQSLQDLVLP AEPLYLFGILIQ
KWETPWAKVFFIRLMLRLGAEYRLYPCPLFSVRYRKPLFGETGHTI INVLADFRNYQY
TLPVVQGLLVDM EVRKT SIKIPSNRYNEMMKAMNKSNEHVLAIGACFNQ MADSHLVCV
QNDDGNYQTQAISIHQPRKVTGASFFVFSGALKSSSGYLAKSSIVEDGVMVQITAES
MDALRQSLREMKDFTITCGKADAEESQEHVYVQWVEDDKNFNKGVFSPIDGKSMESVT
SVKIFHGSEYKASGKIIRWIEVFFLDNEEQQSGLSDPADHSRLTENVAKAFCLALCPH
LKLLKEDGMTRLGLRVSLDSDQVGYQAGSNGQLLPARYTNDLDGALVPVIHG GTCQLS
EGPVSMELIFYILENIS*

TABLE 7 - XSARA2 - Sequence ID NO:7

AGTTTTATTTTCAGAAGACGTTGCATCTTTATTTTAAACATTAAGTTTCACTATGTAG
TAAACATTACTGTTGTATATACAGTATGTTGTAGACATATAACGTAAGTTTGGCTT
TGTGCTTTCTTTCCCTCCTCAGATGAAACTGTCTTTCCAAAGCTGTTAGATGCTAAGTG
GAATCAATTCTTAGAACACATTTCGCATAAAGTCACTGATAAACAGCTCTTGACAA
GTCTGTAAATCAATCATTGCTATTGAAGCTCATCTCAAAGTCAGGTCACCCAGCTTGA
CAGCCCTTGCAAGGTCCACATATGTGAATGGAGAAGTAGGTATTGTGACTCCTGAAAT
GCCTAAAATGGTGATAGGAGACACCGATATGGCAGAGGATTCACTTTTTAACACTGGT
CCCTCTGAAATTGTATGCAACTCTATTGTGGAGAGTCAAAGTTTAGAAGTTTAGATG
ATGTACCAGTGAGTATTAACAATGAAAAAAGTGTCTTCTTGATGATGGATTTTCTCC
GTACAGTAGCCCCAAAAGTGTCTAAACTCTGCTTGCTTGACCATGAATAACGGAAAG
CCCTCACACGGTCAAAAATTTGTTAATGACCAAGATAAAGAAGCTGTAACAATTTTCA
TCCTTCCAATGATCATACAGGATACTACTAACGTAAGCACAGACCCAGCTTTCAATAA
ATCTGGCACTGAAGAAGCTTATAGTGCATTAACAAACACATCAGTTATTCTGCCT
GAAATAAAGCCTTATTCCATACAGGCTGCCCTTTTCATGTGAAAATATCAACAAGATC
CCAGATGTCAATTAAATAATACAGATCTACTCAGCATTTTACCAGTGCGTTGAAGCATG
TAGTGAGAAGCAGCAAAATCATACAACTTCTTGCATGAAAAAAACTTGCAGCTGTG
TCTGCAACTGCGTTCTTTCCAGTCACTGCTGCTGAAACTGTACTAGGTAATGAAGCTC
TCCATAGTGCTGATTTTTTTGACATTGTTGTAAAGAACGTTTCTGACTCGTGTGTGTT
TAATGGTGACCTAAGTAACTAATGGACTCTCACAAGAAAAACAATGAAATGTTTTAT
GCAAGTAAAGAGTTGGAAGGAGGGGTAGATGCTAATATCTTATTGGAAGATGCATGCA
TAGCTTATAAAGAAAGATAGATTGTCTGAAGAAAATGGAAGTAAATGCACCAATGTA
TCTGTACAATGGGTGTGATTCTTATGGAATGAAAAACCCTGCTGTACGTCAAAACCCA
AAGAATTTACCATCAAAAGAAGATTCTGTGACAGAAGAAAAAGAAATTGAAGAAAGCA
AGTCAGAATACTATTCTGGTGTATTGAACAACAGAAGGAAGATGACATAACTGAGAG
AGGTGGAGTCTTGTAAATGCCAAGGTTGACCAAATGAAGAACAGTTTGCATAGTCTT
TATAATCCGGTTCATCCATGCATGGGCAACCTCACCAGGGAAGGCAAGATTGTGC
AATCCCTCAGTGTTCCATATGGTGGAGCTCGCCCCAAGCAGCCCACTCATCTCAA
CAATATTCCACAGCCATTGTCTGAAATGTTACAGTGTGATCTCATTCCGCCAAATGCT
GGATGCAGCTCTAAAAACAAAAATGACATGTTAAACAAATCAAATCGGGGGGATAACC
TGATTTTCAGAACTACTACGTGAGGAAGTGACAGCCCTGTTACTGATACAAATGGTGA
AGTCCCTCGAGAAAAACAGGGGACCTGGCAGCCTGTGCCTTGCAGTGTCTCCAGACAGC
CCTGACAATGATCTGCTTGCTGGACAGTTTGGGGTACCCATCTCTAAGCCATTTACTA
CTCTAGGGGATGTGGCTCCAGTCTGGGTGCCAGATTCCCAAGCACCAGTGCATGAA
GTGCGAGGCCAGATTTACATTACCAAAAGGAGGCATCACTGCCGAGCTTGTGGAAAG
GTATGTAAAGAAATGTGGTGTTCATCAGGGCAACAGTAATCACGGCAAATTATTAT
AACAAAATGTGTTTACGAGATTTCAGTTAAAGTAGACTTATAAGTTACACAGTAACAAT
TCATCTGCTCAGCCTCATTGTTGAAGTAGATAAAATATATTTTATTAGGAACTCTGGG
GAGATATAAGGGAAAGCTTGCCTAAAGTAGATGTTCTGTATATTATTGTTAGTCAA
AGATGATTTTCATGAAAAAAGGTTATTTGTAAAAAGTACAAAATGGGTAGAGACTAGAC
AATAAAAAGTAAGGAGTAAAAAACTAGGTATGTAAAGTATATTAAATAATTTTATGA
TTTTAATATTTACTGCACATTTTCTACAGTGCAGTGATTGTATAACCATGCAATTAT
CAAATGCTTAGTGCCTTCACACAAAGTGCCTTTAATAAAAATTATTTTATAAATTATC
ATATTTTCTTTATATGTAGTCATCATCTTTTTTGTCTCATTTCTTGGAAATCGTTCTAC
TTATGTTCTACTGATATGTTTTTACCCGAGACCTATCTTGCTCCTCTAAAGTAATTGG
CTTGTCAACTGGCTGTAGGGGATTTTCAGAGTTATAGCTTAGTACTGTTAATGAGCC
ATAGGTTGAAATAGTGCTCTAGATTTACATGTTGTACAACAGTTATTGCAATATGTGT
AGGGGGGGGG

TABLE 8 - XSARA2 - Sequence ID NO:8

MPKMVIGD TDMAEDSLFNTGPSEIVCNSIVESQSLEVLDDVPVSINNEKSVLLDDGFS
PYSSPKSVLNSACLTMMNGKPSHGQKIVNDQDKEAVTISVLPMI IQDTTNVSTDPAFN
KSGTEEAYSALKQTTSVILPEIKPYSIQAAALSCENINKIPRCQLNNTDLLSISPVEA
CSEKQQNHTTSLHEKKLA AVSATAFFPVTA AETVLGNEALHSADFFDIVVKNVSDSCV
FNGDLTRTNGLSQENNEMFYASKELEGGVDANILLEDACIAYKERIDLSEENG TNAPM
YLYNGCDSYGMKNPAVRQNPKNLPSKEDSVTEEKEIEESKSEYYSGVYEQQKEDDITE
RGGVLLNAKV DQMKNSLHSLYNPVPSMHGQTS PKKGKIVQSLSVPYGGARPKQPTHLK
LNIPQPLSEMLQCDLIPP NAGCSSKNKNDMLNKS NRGDNLISESLREEVHSPVTD TNG
EVPRENRGPGSLCLAVSPDSPDNDLLAGQFGVPISKPF TTLGDVAPVWVPDSQAPNCM
KCEARFTFTKRRHHC RACGKVCKEMWCFIRATVITANYS

TABLE 9

nsSARA	MAIDENVAEDCQIKRNYSWDDQCSAVENGKKCGNACLPDEKNVLLVAVMMNICDKRTLONDLODNNYNSGELMC	7
XSARA	MPKMYIGDTIMAEISLFFNMITGPSEIENPSTVESLQALDDOSVNIMNIEKSVLLADGFSPPSSKSIIN	70
nsSARA	AFSCSLDMENROTDQFSFSINESTEKDMNBEKOMPLNRPKTEORSVNMCPSTSSLASVICSFSLKDDGSIPROPSMS	157
XSARA	FDCLTMDNEMPLHBMQSVDDNDKSTVTISVLPITIDTISNVSTIDPAINKIPCTKEPHR	127
nsSARA	AITSLIVDSVSSDGTGCPAVKKDENYTPDEDLTGKISSPRTDGGPNSFEMHSEIGILMKKEPAEESITTEESLRSGLP	236
XSARA	ALKETITSVILPEIKPYSICALEFIENNMKNVPSYOLNNTDLEVSPVVEIACSEIQOQKNTSILWEEKLFEQVS	198
nsSARA	LLLKPDPNGSGRNDQCERCSDCLPVNEVRADENEGYEHEETLTTEFLNATEHFSESODMTNWKLTKLNEINOSOVNEE	316
XSARA	ATESFAATAAETVLONEALRSAEFFDIVVMNFSOSCVINGDLTKSCGLS	250
nsSARA	KEKFLQISCPEDTNGDSQOCVGLADAGLDEKGTCTSESSEECDFSTVIDTPAANYLSNGCDSYGMODPGVSVFKLPSK	396
XSARA	NEKFCASKEFEQGDANVULENACVAYKEAIDOLPEENGTHAPMSLYNGCDSYGMKNPIAIAONPKNLPK	319
nsSARA	EDSVTEEKEIEESKSEYSNIVEQFONEATEGSDLLNSITGLMKKNYLHNFEISQVPSVILGSSPKVVASLPISVYFQ	475
XSARA	EDSVTEEKEIEESKSEYTYGVYEQOREDONTERGGLLNAKADOMKNNLHSLCNOVPSMHGQTSPPKGIYDLSVYQ	398
nsSARA	GARPKOPSNLKLQIPKPLSDHLQNDFIANSONNTNKNNDILGKAKLGENSATHVCSPILGNI SNVDINGEHLSEAE	553
XSARA	GARTKOPTHLKLNIKPLSEMLQSDLIPPAACISIKYKNOMLUNKSNQDDMLISESLREDAVRSPTYDANGDFFGEVGRP	478
nsSARA	STRPCLALAPDSDPNDLQAGQFGISAKKPFETTLGEVAPVWVPSQAPNCKMCEARFTFTKRRHHCRCAGKVFCAACCSL	633
XSARA	GECLAVSPDSDPNDLQAGQGVPSKPFETTLGEVAPVWVPSQAPNCKMCEARFTFTKRRHHCRCAGKVFCAACCSL	556
nsSARA	KCKLLYMDRKEARVCVICHSVLMNAQAWENHMSASSPNNPNNAEYCSITPPLQQAQAGALSSPPPVTMVVQVQKHP	713
XSARA	KCKLLYMDRKEARVCVICHSVLMNAQAWENHMSASSPNNPNNAEYCSITPPLQQAQAGALSSPPPVTMVVQVQKHP	636
nsSARA	GAENADPREORRVWFADGILLPNGEMADAAKLTNNGTSSAGTLAYBOPVKPVITP LP AETDIELFSGSITQVQSPVGEA	793
XSARA	QTEGSSKEORRVWFADGILLPNGEMADSIDNANVTITVAGTLVSTNNTSSESSENTSGFCGSTQVQSPVGEA	705
nsSARA	MNLIPEDGLPPIILISTGVKQDYAVEEKPSQISVMQOLEDQGPDPVLFVLLNANLLSMVKLVNYVNRKWCFTTKQMHAVGQ	873
XSARA	MNLIPEDGLPPIILISTGVKQDYAVEERPSQMSVMQOLEDQGPDPVLFVLLNANLLSMVKLVNYVNRKWCFTTKQMHAVGQ	785
nsSARA	SEIVILLQCLPDEKCLPKDIFNMFVOLYDALAGNVVSNLGHSHFSSQSFLOSKEHGGFLVYTS TYQS LQDLVLP TPYLF	953
XSARA	AEIVI LQCLPDEKCLPKDIFSHFVELYOEIAGNVVGNLGHSHFSSQSFLOSKEHGGFLVYAPTYQS LQDLVLP AEYLF	845
nsSARA	DILLOKWE TPWAKVFPILRLMLRLGAERYLYPCPLFSVRFKPLFGETGHTLHNLADFRNYOYTLPPVVOGLVVDMEVRKT	1033
XSARA	DILLOKWE TPWAKVFPILRLMLRLGAERYLYPCPLFSVRYRKPLFGETGHTLHNLADFRNYOYTLPPVVOGLVVDMEVRKT	945
nsSARA	SIKIPENRYNEMMKAMNKSNEHVLADGACFNKADSHLVCVQNDGNYOTOAISIMOPRKVTGASFFVFSGALKSSSGY	1113
XSARA	SIKIPENRYNEMMKAMNKSNEHVLADGACFNKADSHLVCVQNDGNYOTOAISIMOPRKVTGASFFVFSGALKSSSGY	1025
nsSARA	LAKSEIYEDQVMVOITAEINMDSLRQALREMKDFTITCGKADAEEDENHIDWVODDKMYSKGVVSPIDGKSMETITNMK	1193
XSARA	LAKSEIYEDQVMVOITAEINMDSLRQALREMKDFTITCGKADAEEDENHIDWVEDDKMYSKGVVSPIDGKSMETITNMK	1105
nsSARA	IFHQSEYKANKYVIRWIEVFFLENDODHNCSDPADHSRLTEHVAKAFCLALCPHLKLLKEDGMTRLGLRVSLDSDOVG	1273
XSARA	IFHQSEYKANKYVIRWIEVFFLENDODHNCSDPADHSRLTEHVAKAFCLALCPHLKLLKEDGMTRLGLRVSLDSDOVG	1185
nsSARA	DAGENGQPLPSGYMOLDLSALVPKIHQGAQQLSEGPVIMELIFVILENIN	1323
XSARA	DAGENGQPLPARYTNDGALVPIHQGTQQLSEGPVIMELIFVILENIS	1235

TABLE 10

nsSARA	587	CGEVAPVWVPSQAPNCKMCEARFTFTKRRHHCRCAGKVFCAACCSILKCKLDMORH	655
XSARA	510	LGEVAPVWVPSQAPNCKMCEARFTFTKRRHHCRCAGKVFCAACCSILKCKLDMORH	578
KIAA0305	737	LGOKDPTWVPSQAPNCKMCEARFTFTKRRHHCRCAGKVFCAACCSILKCKLDMORH	800
FGD1	720	LGKRAPIPIREKENITCMACOLEPNSITKRRHHCRCAGKVFCAACCSILKCKLDMORH	485
Hrs	153	XERAPDWD	219
Hrs-2	153	AAERAPDWD	219
EEA-1	1341	TOALNARKADENETONCMAKCKVLEVTYVRRHHCRCAGKVFCAACCSILKCKLDMORH	1408

CONSENSUS.....P-W.....C-C-F.....RKHORAG-YFG-CG.....RVC-C-L

WE CLAIM:

1. An isolated polynucleotide comprising a nucleotide sequence encoding a SARA protein or a splice variant thereof.
5
2. The isolated polynucleotide of claim 1, wherein the SARA protein is a mammalian SARA protein.
3. The isolated polynucleotide of claim 1, wherein the SARA protein is a
10 non-mammalian SARA protein.
4. The isolated polynucleotide of claim 2, wherein the SARA protein is a human SARA protein.
- 15 5. The isolated polynucleotide of claim 3, wherein the SARA protein is a Xenopus SARA protein.
6. The isolated polynucleotide of claim 1, wherein the nucleotide sequence is selected from the group consisting of
20 (a) a nucleotide sequence encoding the amino acid sequence of Sequence ID NO:2;
(b) a nucleotide sequence encoding the amino acid sequence of Sequence ID NO:4;
(c) a nucleotide sequence encoding the amino acid sequence of
25 Sequence ID NO:6;
(d) a nucleotide sequence encoding the amino acid sequence of Sequence ID NO:8; and
(e) a nucleotide sequence encoding a SARA protein and capable of hybridising to a sequence complementary to the nucleotide sequence of
30 any of (a) to (d) under stringent hybridisation conditions.

7. The isolated polynucleotide of claim 4 comprising the nucleotide sequence of Sequence ID NO:1 or a degeneracy equivalent thereof.
8. The isolated polynucleotide of claim 4 comprising the nucleotide sequence of Sequence ID NO:3 or a degeneracy equivalent thereof.
9. The isolated polynucleotide of claim 3 comprising the nucleotide sequence of Sequence ID NO:5 or a degeneracy equivalent thereof.
10. The isolated polynucleotide of claim 3 comprising the nucleotide sequence of Sequence ID NO:7 or a degeneracy equivalent thereof.
11. An isolated polynucleotide comprising a nucleotide sequence of at least 10 up to the total number of consecutive nucleotides of a sequence selected from the group consisting of Sequence ID NO:1, Sequence ID NO:3, Sequence ID NO:5 and Sequence ID NO:7 or a nucleotide sequence complementary to any one of said sequences.
12. An isolated polynucleotide comprising a nucleotide sequence encoding at least one functional domain of a SARA protein.
13. The isolated polynucleotide of any one of the preceding claims wherein the polynucleotide is a polydeoxyribonucleotide.
14. The isolated polynucleotide of any one of claims 1 to 11 wherein the polynucleotide is a polyribonucleotide.
15. An isolated polynucleotide encoding a SARA protein FYVE domain.
16. A recombinant vector comprising the isolated polynucleotide of any one of claims 1 to 15.

17. A host cell comprising the recombinant vector of claim 16.
18. A process for recombinantly producing a SARA protein or a fragment
5 thereof comprising culturing the host cell of claim 17 under conditions whereby
the SARA protein or fragment thereof is expressed and isolating the expressed
SARA protein or fragment thereof.
19. A substantially pure SARA protein.
- 10 20. The protein of claim 19 which is a mammalian SARA protein.
21. The protein of claim 19 which is a non-mammalian SARA protein.
- 15 22. The protein of claim 20 which is a human SARA protein.
23. The protein of claim 22 comprising the amino acid sequence of Sequence
ID NO:2 or Sequence ID NO:4.
- 20 24. The protein of claim 21 comprising the amino acid sequence of Sequence
ID NO:6 or Sequence ID NO:8.
25. A SARA protein that is at least 50 percent identical in amino acid
sequence to the sequence of Sequence ID NO:2 or Sequence ID NO:4.
- 25 26. The protein of claim 25 wherein the SARA protein has a FYVE domain
having at least 65 percent identity in amino acid sequence to the FYVE domain
of hSARA1 (Sequence ID NO:2) and a C-terminal sequence of 550 consecutive
amino acids which have at least 50 percent identity to the C-terminal 550 amino
30 acid residues of hSARA1.

27. The protein of claim 25 wherein the SARA protein has an FYVE domain having at least 65 percent identity in amino acid sequence to the FYVE domain of hSARA1 (Sequence ID NO:2) and wherein the portion of the SBD corresponding to amino acid residues 721 to 740 of hSARA1 has at least 80 percent identity with that portion of hSARA1.
28. A substantially pure polypeptide comprising an amino acid sequence of at least 4 up to the total number of consecutive amino acids of a sequence selected from the group consisting of Sequence ID NO:2, Sequence ID NO:4, Sequence ID NO:6 and Sequence ID NO:8.
29. A substantially pure polypeptide comprising at least one functional domain of a SARA protein.
30. A substantially pure polypeptide selected from the group consisting of
- (a) SASSQSPNPNPAEYCSTIPPLQQAQASGALSSPPPTVMVPV GVLKHPGAEVAQPREQRRVWFADGILPNGEVADA AKLTMNGTSS; and
 - (b) amino acids 589 to 672 of the XSARA1 sequence of Table 9.
31. A substantially pure polypeptide comprising a SARA protein FYVE domain.
32. The polypeptide of claim 31 comprising a polypeptide selected from the group consisting of
- (a) amino acids 587 to 655 of the hSARA1 sequence of Table 9;
 - (b) amino acids 510 to 578 of the XSARA1 sequence of Table 9;
 - (c) the consensus amino acid sequence of Table 10; and
 - (d) a functional fragment of a polypeptide of any of (a) to (c).
33. A substantially pure polypeptide comprising a SARA protein TGF β receptor interacting domain.

34. The polypeptide of claim 33 selected from the group consisting of
- (a) amino acids 751 to 1323 of the hSARA1 sequence of Table 9; and
 - (b) a functional fragment of polypeptide of (a).
- 5
35. A substantially pure antibody which selectively binds to an antigenic determinant of a SARA protein.
36. A cell line producing the antibody of claim 35.
- 10
37. A method for identifying an allelic variant or homologue of a human SARA gene comprising
- choosing a nucleic acid probe or primer capable of hybridising to a human SARA gene sequence under stringent hybridisation conditions;
 - 15 mixing the probe or primer with a sample of nucleic acids which may contain a nucleic acid corresponding to the homologue variant or homologue; and
 - detecting hybridisation of the probe or primer to the nucleic acid corresponding to the variant or homologue.
- 20
38. A method for modulating signal transduction by a TGF β superfamily member through a SARA protein-dependent pathway, the method comprising modulating the binding of the SARA protein with its binding partner.
- 25
39. The method of claim 38 comprising a method selected from the group consisting of
- (a) modulating the binding of the SARA protein to a Smad binding partner;
 - (b) modulating the binding of the SARA protein FYVE domain to its
 - 30 binding partner; and
 - (c) modulating the binding of the SARA protein to the TGF β receptor.

40. A method for preventing or treating a disorder characterised by an abnormality in a TGF β superfamily member signaling pathway which involves a SARA protein, the method comprising modulating the binding of the SARA protein involved in the pathway with its binding partner.
41. A method for screening a candidate compound for its potential as a modulator of SARA protein-dependent signaling by a TGF β superfamily member comprising
- (a) determining the ability of the compound to bind to a SARA protein; and
- (b) determining the ability of the compound to alter the phosphorylation state of a SARA protein.
42. A non-human transgenic animal comprising a polynucleotide encoding a heterologous SARA protein or a portion thereof.
43. The transgenic animal of claim L01 wherein the polynucleotide encodes a human SARA protein or a portion thereof.
44. A non-human animal having a genome from which the SARA gene has been deleted.

PCT


WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁷ : C12N 15/12, C07K 14/47, C12Q 1/68, G01N 33/50, A01K 67/027		A1	(11) International Publication Number: WO 00/05360
			(43) International Publication Date: 3 February 2000 (03.02.00)
(21) International Application Number: PCT/CA99/00656 (22) International Filing Date: 20 July 1999 (20.07.99) (30) Priority Data: 2,237,701 20 July 1998 (20.07.98) CA 2,253,647 10 December 1998 (10.12.98) CA (71) Applicant (for all designated States except US): HSC RESEARCH AND DEVELOPMENT LIMITED PART- NERSHIP [CA/CA]; Suite 5270, 555 University Avenue, Toronto, Ontario M5G 1X8 (CA). (72) Inventor; and (75) Inventor/Applicant (for US only): WRANA, Jeffrey, L. [CA/CA]; HSC Research and Development Limited Partnership, Suite 5270, 555 University Avenue, Toronto, Ontario M5G 1X8 (CA). (74) Agent: RAE, Patricia, A.; Sim & McBurney, 6th floor, 330 University Avenue, Toronto, Ontario M5G 1R7 (CA).		(81) Designated States: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.	

(54) Title: SARA PROTEINS



(57) Abstract

A new family of proteins, the SARA proteins, has been identified. These proteins bind to receptor-regulated Smad proteins and modulate signal transduction by TGF β , activin and bone morphogenetic protein.




FIGURE 1




FIGURE 2

A

Myc-Smad2: + - + + + +
Flag-hSARA: - + - - + +
T β RI: - - WT A WT A




FIGURE 3




FIGURE 4




FIGURE 5




FIGURE 6




FIGURE 7




FIGURE 8A

WO 00/05360

PCT/CA99/00656




FIGURE 8B




FIGURE 9A




FIGURE 9B




FIGURE 10




FIGURE 11A




FIGURE 11B




FIGURE 12




FIGURE 13




FIGURE 14




FIGURE 15




FIGURE 16





FIGURE 17



DECLARATION AND POWER OF ATTORNEY FOR PATENT APPLICATION

Attorney Docket No. 3477-91

As a below named inventor, I hereby declare that:

My residence, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled **SARA PROTEINS**,

the specification of which

☐ is attached hereto

OR

☒ was filed on 20 July 1999 as United States Application No. _____ or PCT

International Application Number PCT/CA99/00656 and was amended on _____ (if applicable).

I hereby state that I have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to patentability as defined in Title 37 Code of Federal Regulations, §1.56.

I hereby claim foreign priority benefits under Title 35, United States Code, § 119(a)-(d) or § 365(b) of any foreign application(s) for patent or inventor's certificate, or § 365(a) of any PCT International application which designated at least one country other than the United States of America, listed below and have also identified below any foreign application for patent or inventor's certificate, or of any PCT International application having a filing date before that of the application on which priority is claimed.

2,237,701	CA	07/20/1998	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
Number	Country	MM/DD/YYYY Filed	Priority Claimed

2,253,647	CA	12/10/1998	<input checked="" type="checkbox"/> Yes <input type="checkbox"/> No
Number	Country	MM/DD/YYYY Filed	Priority Claimed

			<input type="checkbox"/> Yes <input type="checkbox"/> No
Number	Country	MM/DD/YYYY Filed	Priority Claimed

I hereby claim the benefit under Title 35, United States Code, § 119(e) of any United States provisional application(s) listed below.

Application Number(s)	Filing Date (MM/DD/YYYY)

Application Number(s)	Filing Date (MM/DD/YYYY)

I hereby claim the benefit under Title 35, United States Code, § 120 of any United States application(s) or § 365(c) of any PCT international application designating the United States of America, listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States or PCT International application(s) in the manner provided by the first paragraph of Title 35, United States Code, § 112, I acknowledge the duty to disclose information which is material to patentability as defined in Title 37, Code of Federal Regulations, § 1.56 which became available between the filing date of the prior application and the national or PCT international filing date of this application (37 C.F.R. § 1.63(d)).

Appln. Serial No.	Filing Date	Status Patented/Pending/Abandoned

Appln. Serial No.	Filing Date	Status Patented/Pending/Abandoned

Appln. Serial No.	Filing Date	Status Patented/Pending/Abandoned

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

CONFIDENTIAL

POWER OF ATTORNEY: As a named inventor, I hereby appoint the following registered attorney(s) to prosecute this application and transact all business in the Patent and Trademark Office connected therewith.

Customer Number 20792

Send correspondence to: Karen A. Magri
Myers Bigel Sibley & Sajovec
Post Office Box 37428
Raleigh, NC 27627

Direct telephone calls to: Karen A. Magri
(919)854-1400

Facsimile: (919) 854-1401

Full name of (first/sole) inventor: Jeffrey L. WRANA

Inventor's Signature: [Signature] Date: March 28/01

Residence: Canada

Citizenship: Canada
Post Office Address: c/o HSC Research and Development Limited Partnership
555 University Avenue, Suite 5270
Toronto, Ontario M5G 1X8, Canada CAX

SEQUENCE LISTING

<110> HSC Research and Development Limited Partnership

<120> SARA PROTEINS

<130> 3206-172/PAR

<140> PCT/CA99/00656

<141> 1999-07-20

<150> 2,237,701

<151> 1998-07-20

<160> 8

<170> PatentIn Ver. 2.1

<210> 1

<211> 4839

<212> DNA

<213> Homo sapiens

<400> 1

```
gcatactgaa tcagcaggac tggctgggtg tgcagcagac atcatgagta agcaccgaga 60
agtctgttcc ttatcacgtg tgtaagggga aaaagggtta aacaagtctc ttaagtgggtg 120
tttcctcacc gatggagaat tacttccaag cagaagctta caacctggga caaggtgtta 180
gatgaatttg aacaaaacga agatgaaaca gtttcttcta ctttattgga tacaaagtgg 240
aataagattc tagatcccc ttctcaccgg ctgtcattta accctacttt ggccagtggtg 300
aatgaatctg cagtttctaa tgagtcacaa ccacaactga aagtcttctc cctgggtcat 360
tcagctcccc tgaccacaga ggaagaggat cactgtgcta atggacagga ctgtaatcta 420
aatccagaga ttgccacaat gtggattgat gaaaatgctg ttgcagaaga ccagttaatt 480
aagagaaaact atagttggga tgatcaatgc agtgctgttg aagtgggaga gaagaaatgt 540
ggaaacctgg cttgtctgcc agatgagaag aatgttcttg ttgtagccgt catgcataac 600
tgtgataaaa ggacattaca aaacgattta caggattgta ataattataa tagtcaatcc 660
cttatggatg cttttagctg ttctactggat aatgaaaaca gacaaaactga tcaatttagt 720
tttagtataa atgagtcacc tgaaaaagat atgaattcag agaaacaaat ggatccattg 780
aatagaccga aaacagaggg gagatctggt aaccatctgt gtctacttc atctgatagt 840
ctagccagtg tctgttcccc ttcacaaata aaggatgacg gaagtatagg tagagacccc 900
tccatgtctg cgattacaag tttaacggtt gattcagtaa tctcatccca gggaacagat 960
ggatgtcctg ctgttaaaaa gcaagagaac tatataccag atgaggacct cactggcaaa 1020
atcagctctc ctaggacaga tctagggagt ccaaattcct tttcccatat gactgagggg 1080
atcttgatga aaaaagagcc agcagaggag agcaccactg aagaatccct ccggtctggt 1140
ttacctttgc ttctcaaaac agacatgcct aatgggtctg gaaggaataa tgactgtgaa 1200
cgggtgttcag attgccttgt gcctaatagaa gttagggtctg atgaaaatga aggttatgaa 1260
catgaagaaa ctcttggtcac tacagaattc cttaatatga cagagcattt ctctgaatct 1320
caggacatga ctaattggaa gttgactaaa cttaatgaga tgaatgatag ccaagtaaac 1380
gaagaaaagg aaaagtttct acagattagt cagcctgagg acactaatgg tgatagtggg 1440
ggacagtggt ttggattggc agatgcaggc ctgattttaa aaggaacttg cattagttaa 1500
agtgaagaat gtgatttctc cactgttata gacacaccag cagcaaatta tctatctaata 1560
ggtgtgtgatt cctatggaat gcaagaccga ggtgttctt ttgttccaaa gactttaccc 1620
tccaaagaag attcagtaac agaagaaaaa gaaatagagg aaagcaagtc agaatgctac 1680
tcaaatatatt atgaacagag aggaaatgag gccacagaag ggagtggact acttttaaac 1740
agcactgggt acctaatagaa gaaaaattat ttacataatt tctgtagtca agttccatca 1800
gtgcttgggc aatcttcccc caaggtagta gcaagcctgc catctatcag tgttcctttt 1860
ggtggtgcaa gacccaagca accttctaata cttaaaacttc aaattccaaa gccattatca 1920
gaccatttac aaaatgactt tcttgcaaac agtggaataa atactaaaaa taaaaatgat 1980
attcttggga aagcaaaatt aggggaaaaac tcagcaacca atgtatgcag tccatctttg 2040
ggaaacatct ctaatgtcga tacaaatggg gaacatttag aaagttatga ggctgagatc 2100
tccactagac catgccttgc attagctcca gatagcccag ataatgatct cagagctggt 2160
cagtttgga tttctgccag aaagccattc accacgctgg gtgaggtggc tccagtatgg 2220
```

gtaccggatt	ctcaggetcc	aaattgcatg	aaatgtgaag	ccagggtttac	attcaccaaa	2280
agggaacatc	actgcagagc	atgtgggaag	gttttctgtg	cttctctgctg	tagcctgaaa	2340
tgtaaacgtg	tatacatgga	cagaaaggaa	gctagagtgt	gtgtaatctg	ccattcagtg	2400
ctaataaatg	ctcaagcctg	ggagaacatg	atgagtgcct	caagccagag	ccctaaccct	2460
aacaatcctg	ctgaatactg	ttctactatc	cctcccttgc	agcaagctca	ggcctcagga	2520
gctctgagct	ctccacctcc	cactgtgatg	gtacctgtgg	gagttttaaa	gcaccctgga	2580
gcagaagtgg	ctcagcccag	agagcagag	cgagtttggg	tgtctgatgg	gatcttgccc	2640
aatggagaag	ctctgatgc	agccaaatta	acaatgaatg	gaacttctct	tgagggaacc	2700
ctggctgtgt	tgcagacccc	agtc aaagca	gtaactacca	gtcctctacc	agcagagacg	2760
gatatattgtc	tattctctgg	gagtataact	cagggttgaa	gtcctgttgg	aagtgcaatg	2820
aatcttatct	ctgaagatgg	ccttctctcc	attctcatct	ccactgggtg	aaaaggagac	2880
tatgctgtgg	aagagaaacc	atcacagatt	tcagtaatgc	agcagttgga	ggatgggtgg	2940
cctgacccac	ttgtatttgt	tttaaatgca	aatgtgttgt	caatggttaa	aattgtaaaa	3000
tatgtgaaca	ggaagtgtcg	gtgtttcaca	accaagggaa	tgcactcagt	gggtcagctc	3060
gagatagtca	ttcttctaca	gtgtttaccg	gatgaaaagt	gtttgccaaa	ggatatcttt	3120
aatcacctttg	tgcagcttta	tcgggatctg	ctggcaggga	atgtgggtgag	caacttgggg	3180
cattccttct	tcagtcaaag	tttccctggc	agtaaagaac	atgggtggatt	cttatatgtg	3240
acatctacct	accagtcact	gcaagaccta	gtactcccaa	ccccacctta	cttgtttggg	3300
attcttatcc	agaaatggga	aactccttgg	gctaaagtat	ttcctatccg	tctgatgttg	3360
agacttggag	ctgaatatcg	actttatcca	tgccacctat	tcagtgctcg	atttcggga	3420
ccattgtttg	gagagacggg	gcataccatc	atgaatcttc	ttgcagactt	cagaaattac	3480
cagtaatact	tgccagtagt	tcaaggttgg	gtgggtgata	tggaagttcg	gaaaactagc	3540
atcaaaaattc	cgcagcaacg	atacaatttg	atgatgaaag	ccatgaacaa	gtccaatgag	3600
catgtcctgg	caggaggtgc	ctgcttcaat	gaaaaggcag	actctcatct	tgtgtgtgta	3660
cagaatgatg	atggaaacta	tcagacccag	gctatcagta	ttcacaaatc	gccagaaaaa	3720
gtgactgggtg	ccagtttctt	tgtgttcagt	ggcgtctctg	aatcctcttc	tggataacct	3780
gccaaagtcca	gtattgtgga	agatgggtgt	atgggtccaga	ttactgcaga	gaacctggat	3840
tccttggagg	aggcactcgg	agagatgaag	gacttcacca	tcacctgtgg	gaaggcggac	3900
cgggaggaac	cccaggagca	catccacatc	cagtggtgtg	atgatgacaa	gaacgttagc	3960
aagggtgtcg	taagtctcat	agatgggaag	tccatggaga	ctataacaaa	tgtgaagata	4020
ttccatggat	cagaatataa	agcaaagtga	aaagtaatca	gatggacaga	gggtgttttc	4080
ctagaaaacg	atgaccagca	caattgcctc	agtgatcctg	cagatcacag	tagattgact	4140
gagcatgttg	ccaaagcttt	ttgccttgct	ctctgtcctc	acctgaaact	tctgaaggaa	4200
gatggaatga	ccaaactggg	actacgtgtg	acacttgact	cagatcaggt	tggctatcaa	4260
gcagggagca	atggccagcc	ccttccctcg	cagtacatga	atgatctgga	tagcgccttg	4320
gtgccggtga	tccatggagg	ggcctgcag	cttagtgagg	gccccgttgt	catggaactc	4380
atcttttata	ttctggaaaa	catcgtataa	acagagaaga	cttcattttt	ttctgttcag	4440
acttgttgca	acagcagtca	tacccaaatc	atttgcactt	taaaactgga	agattaagct	4500
tttgtaataa	ctattaatgg	gggtggggaat	aggggtgggag	tgggggtttg	ggagacgggt	4560
gggaaagggt	ggttgggggg	accgatgttc	cataattcta	agtcttctat	gcattgtcca	4620
ccaagaagat	ctgggcagct	tctgttccctg	cacaacagtt	atgctatcct	tgcagctaata	4680
ccccttctgt	tactgtttag	acaagaattc	cgctcctctc	tcaagattta	cttatggtca	4740
tgtgctcaga	aatgctcaaa	tgggtacaac	catcaccaag	ggtggggatgg	gagggcagag	4800
gggaataaaa	atataaagca	tcaaaaaaaaa	aaaaaaaaaa			4839

```
<210> 2
<211> 1323
<212> PRT
<213> Homo sapiens
```

```

<400> 2
Met Trp Ile Asp Glu Asn Ala Val Ala Glu Asp Gln Leu Ile Lys Arg
  1                      5                      10                     15

Asn Tyr Ser Trp Asp Asp Gln Cys Ser Ala Val Glu Val Gly Glu Lys
          20                      25                     30

Lys Cys Gly Asn Leu Ala Cys Leu Pro Asp Glu Lys Asn Val Leu Val
      35                      40                     45

```

[illegible]

Val 50	Ala	Val	Met	His	Asn	Cys 55	Asp	Lys	Arg	Thr	Leu 60	Gln	Asn	Asp	Leu
Gln 65	Asp	Cys	Asn	Asn	Tyr 70	Asn	Ser	Gln	Ser	Leu 75	Met	Asp	Ala	Phe	Ser 80
Cys	Ser	Leu	Asp	Asn 85	Glu	Asn	Arg	Gln	Thr 90	Asp	Gln	Phe	Ser	Phe 95	Ser
Ile	Asn	Glu	Ser 100	Thr	Glu	Lys	Asp	Met 105	Asn	Ser	Glu	Lys	Gln 110	Met	Asp
Pro	Leu 115	Asn	Arg	Pro	Lys	Thr	Glu 120	Gly	Arg	Ser	Val	Asn 125	His	Leu	Cys
Pro	Thr 130	Ser	Ser	Asp	Ser	Leu 135	Ala	Ser	Val	Cys	Ser 140	Pro	Ser	Gln	Leu
Lys 145	Asp	Asp	Gly	Ser 150	Ile	Gly	Arg	Asp	Pro	Ser 155	Met	Ser	Ala	Ile	Thr 160
Ser	Leu	Thr	Val 165	Asp	Ser	Val	Ile	Ser	Ser 170	Gln	Gly	Thr	Asp	Gly 175	Cys
Pro	Ala	Val 180	Lys	Lys	Gln	Glu	Asn 185	Tyr	Ile	Pro	Asp	Glu	Asp 190	Leu	Thr
Gly	Lys 195	Ile	Ser	Ser	Pro	Arg	Thr 200	Asp	Leu	Gly	Ser 205	Pro	Asn	Ser	Phe
Ser 210	His	Met	Ser	Glu	Gly	Ile 215	Leu	Met	Lys	Lys	Glu 220	Pro	Ala	Glu	Glu
Ser 225	Thr	Thr	Glu	Glu	Ser 230	Leu	Arg	Ser	Gly	Leu 235	Pro	Leu	Leu	Leu	Lys 240
Pro	Asp	Met	Pro	Asn 245	Gly	Ser	Gly	Arg	Asn 250	Asn	Asp	Cys	Glu	Arg 255	Cys
Ser	Asp	Cys	Leu 260	Val	Pro	Asn	Glu	Val 265	Arg	Ala	Asp	Glu	Asn 270	Glu	Gly
Tyr	Glu	His 275	Glu	Glu	Thr	Leu	Gly 280	Thr	Thr	Glu	Phe 285	Leu	Asn	Met	Thr
Glu 290	His	Phe	Ser	Glu	Ser	Gln 295	Asp	Met	Thr	Asn	Trp 300	Lys	Leu	Thr	Lys
Leu 305	Asn	Glu	Met	Asn	Asp 310	Ser	Gln	Val	Asn	Glu 315	Glu	Lys	Glu	Lys	Phe 320
Leu	Gln	Ile	Ser	Gln 325	Pro	Glu	Asp	Thr	Asn 330	Gly	Asp	Ser	Gly	Gly 335	Gln
Cys	Val	Gly	Leu 340	Ala	Asp	Ala	Gly	Leu 345	Asp	Leu	Lys	Gly	Thr 350	Cys	Ile
Ser	Glu 355	Ser	Glu	Glu	Cys	Asp	Phe 360	Ser	Thr	Val	Ile 365	Asp	Thr	Pro	Ala
Ala	Asn	Tyr	Leu	Ser	Asn	Gly	Cys	Asp	Ser	Tyr	Gly	Met	Gln	Asp	Pro

[illegible]

Val	Pro	Val	Gly	Val	Leu	Lys	His	Pro	Gly	Ala	Glu	Val	Ala	Gln	Pro	705	710	715	720
Arg	Glu	Gln	Arg	Arg	Val	Trp	Phe	Ala	Asp	Gly	Ile	Leu	Pro	Asn	Gly	725	730	735	
Glu	Val	Ala	Asp	Ala	Ala	Lys	Leu	Thr	Met	Asn	Gly	Thr	Ser	Ser	Ala	740	745	750	
Gly	Thr	Leu	Ala	Val	Ser	His	Asp	Pro	Val	Lys	Pro	Val	Thr	Thr	Ser	755	760	765	
Pro	Leu	Pro	Ala	Glu	Thr	Asp	Ile	Cys	Leu	Phe	Ser	Gly	Ser	Ile	Thr	770	775	780	
Gln	Val	Gly	Ser	Pro	Val	Gly	Ser	Ala	Met	Asn	Leu	Ile	Pro	Glu	Asp	785	790	795	800
Gly	Leu	Pro	Pro	Ile	Leu	Ile	Ser	Thr	Gly	Val	Lys	Gly	Asp	Tyr	Ala	805	810	815	
Val	Glu	Glu	Lys	Pro	Ser	Gln	Ile	Ser	Val	Met	Gln	Gln	Leu	Glu	Asp	820	825	830	
Gly	Gly	Pro	Asp	Pro	Leu	Val	Phe	Val	Leu	Asn	Ala	Asn	Leu	Leu	Ser	835	840	845	
Met	Val	Lys	Ile	Val	Asn	Tyr	Val	Asn	Arg	Lys	Cys	Trp	Cys	Phe	Thr	850	855	860	
Thr	Lys	Gly	Met	His	Ala	Val	Gly	Gln	Ser	Glu	Ile	Val	Ile	Leu	Leu	865	870	875	880
Gln	Cys	Leu	Pro	Asp	Glu	Lys	Cys	Leu	Pro	Lys	Asp	Ile	Phe	Asn	His	885	890	895	
Phe	Val	Gln	Leu	Tyr	Arg	Asp	Ala	Leu	Ala	Gly	Asn	Val	Val	Ser	Asn	900	905	910	
Leu	Gly	His	Ser	Phe	Phe	Ser	Gln	Ser	Phe	Leu	Gly	Ser	Lys	Glu	His	915	920	925	
Gly	Gly	Phe	Leu	Tyr	Val	Thr	Ser	Thr	Tyr	Gln	Ser	Leu	Gln	Asp	Leu	930	935	940	
Val	Leu	Pro	Thr	Pro	Pro	Tyr	Leu	Phe	Gly	Ile	Leu	Ile	Gln	Lys	Trp	945	950	955	960
Glu	Thr	Pro	Trp	Ala	Lys	Val	Phe	Pro	Ile	Arg	Leu	Met	Leu	Arg	Leu	965	970	975	
Gly	Ala	Glu	Tyr	Arg	Leu	Tyr	Pro	Cys	Pro	Leu	Phe	Ser	Val	Arg	Phe	980	985	990	
Arg	Lys	Pro	Leu	Phe	Gly	Glu	Thr	Gly	His	Thr	Ile	Met	Asn	Leu	Leu	995	1000	1005	
Ala	Asp	Phe	Arg	Asn	Tyr	Gln	Tyr	Thr	Leu	Pro	Val	Val	Gln	Gly	Leu	1010	1015	1020	

Val Val Asp Met Glu Val Arg Lys Thr Ser Ile Lys Ile Pro Ser Asn
1025 1030 1035 1040

Arg Tyr Asn Glu Met Met Lys Ala Met Asn Lys Ser Asn Glu His Val
1045 1050 1055

Leu Ala Gly Gly Ala Cys Phe Asn Glu Lys Ala Asp Ser His Leu Val
1060 1065 1070

Cys Val Gln Asn Asp Asp Gly Asn Tyr Gln Thr Gln Ala Ile Ser Ile
1075 1080 1085

His Asn Gln Pro Arg Lys Val Thr Gly Ala Ser Phe Phe Val Phe Ser
1090 1095 1100

Gly Ala Leu Lys Ser Ser Ser Gly Tyr Leu Ala Lys Ser Ser Ile Val
1105 1110 1115 1120

Glu Asp Gly Val Met Val Gln Ile Thr Ala Glu Asn Met Asp Ser Leu
1125 1130 1135

Arg Gln Ala Leu Arg Glu Met Lys Asp Phe Thr Ile Thr Cys Gly Lys
1140 1145 1150

Ala Asp Ala Glu Glu Pro Gln Glu His Ile His Ile Gln Trp Val Asp
1155 1160 1165

Asp Asp Lys Asn Val Ser Lys Gly Val Val Ser Pro Ile Asp Gly Lys
1170 1175 1180

Ser Met Glu Thr Ile Thr Asn Val Lys Ile Phe His Gly Ser Glu Tyr
1185 1190 1195 1200

Lys Ala Asn Gly Lys Val Ile Arg Trp Thr Glu Val Phe Phe Leu Glu
1205 1210 1215

Asn Asp Asp Gln His Asn Cys Leu Ser Asp Pro Ala Asp His Ser Arg
1220 1225 1230

Leu Thr Glu His Val Ala Lys Ala Phe Cys Leu Ala Leu Cys Thr Gln
1235 1240 1245

Leu Lys Leu Leu Lys Gly Asp Gly Met Thr Lys Leu Gly Leu Arg Val
1250 1255 1260

Thr Leu Asp Ser Asp Gln Val Gly Tyr Gln Ala Gly Ser Asn Gly Gln
1265 1270 1275 1280

His Leu Pro Ser Gln Tyr Met Asn Asp Phe Asp Ser Asp Leu Val Lys
1285 1290 1295

Met Ile His Gly Gly Ala Cys Gln Leu Ser Glu Gly Pro Val Val Met
1300 1305 1310

Glu Leu Ile Phe Tyr Ile Leu Glu Asn Ile Val
1315 1320

<210> 3
<211> 6632
<212> DNA

<213> Homo sapiens

<400> 3

```

actcccgccc ggggtagctc ttcactcctc agcgcgcacgt cgtgtcgagt tccccaaaaag 60
ctccgcaggg gctgtaggga ggtgatctca tccattaaca gctgtgtgtt gccagttccc 120
aaatcttftat ctatctcaga cttctctcct gcattccaga ttcttatatt cagctgcctt 180
ttggatatct ctcccaggat gttctcaagg catacaagaa ttaaatctctg aataagtctg 240
caggtaggat ggacagttat tttaaagcag ctgtcagtgat cttggacaaa ctcccttgatg 300
atthttgaaca gaaccagat gaacaagatt atctcgaga tgtacaaaat gcatatgatt 360
ctaaccactg ctacagtttct tcagagttgg cttcctcaca gcgaacttca ttgctcccaa 420
aagaccaaga gtgcgttaat agttgtgcct catcagaaac aagctatgga acaaatgaga 480
gttccctgaa tgaaaaaaca ctcaaggagc ttacttctat acaaaatgaa aaaaatgtaa 540
caggacttga tcttcttctt tctgtggatg gtggtacttc agatgaaatc cagccgttat 600
atatgggacg atgtagtata cctatctgtg atctgataag tgacatgggt aacttagttc 660
atgcaaccaa tagtgaagaa gatattaaaa aattattgcc agatgatttt aagtctaattg 720
cagatttcctt gattggattg gatttatctt cagtgtcaga tactccctgt gtttcttcaa 780
cagaccatga tagtgatact gtcagagaac aacagaatga tatcagttct gaattacaaa 840
atagagaaat cggaggaatc aaagaattgg gtataaaaag agatacaaca ctttcagatt 900
cctataatta cagtggaaaca gaaaatttaa aagataaaaa gatctttaat cagttagaat 960
caattgttga ttttaacatg tcatctgctt tgactcgaca aagttccaaa atgtttcatg 1020
ccaaagacaa gctacaacac aagagccagc catgtggatt actaaaagat gttggccttag 1080
taaaagagga agtagatgtg gcagtcataa ctgccgcaga atgtttaaaa gaagaggggca 1140
agacaagtgc tttgacctgc agccttccga aaaatgaaga tttatgctta aatgattcaa 1200
attcaagaga tgaaaatttc aaattacctg acttttctt tcaggaagat aagactgtta 1260
taaaacaatc tgcacaagaa gactcaaaaa gtttagacct taaggataat gatgtaatcc 1320
aagattcctc ttcagcttta catgtttcca gtaaagatgt gccgtcctca ttgtcctgtc 1380
ttcctgcgtc tgggtctatg tgtggatcat taattgaaag taaagcacgg ggtgattttt 1440
tacctcagca tgaacataaa gataatatac aagatgcagt gactatacat gaagaaatc 1500
agaacagtg tttctaggt ggggaaccat tcaaagagaa tgatcttttg aaacaggaaa 1560
aatgtaaaag catactcctt cagtcattaa ttgaagggat ggaagacaga aagatagatc 1620
ctgaccagac agtaatcaga gctgagttct tggatggtgg tgacaccagt tctacagttg 1680
tagaatctca agaggggctt tctggcactc atgtcccaga gtcttctgat tgttgtgaag 1740
gttttattaa tactttttca agcaatgata tggatgggca agacttagat tactttaata 1800
ttgatgaagg cgcaaaaagt gggccactaa ttagtgatgc tgaacttgat gcctttctga 1860
cagaacagta tcttcagacc actaacataa agtcttttga agaaaatgta aatgactcta 1920
aatcgcaaat gaatcagata gatatgaaag gcttagatga tggaaacatc aataatatat 1980
atthtcaatgc agaagcagga gctattgggg aaagtcattg tattaatata atthtgaaga 2040
cagttgataa acaaaataca atagaaaatg gcctttcttt aggagaaaaa agcactattc 2100
cagttcaaca aggttacct accagtaagt ctgagattac aaatcaatta tcagtctctg 2160
atattaacag tcaatctgtt ggaggggcca gacctaagca attgtttagc cttccatcaa 2220
gaacaaggag ttcaaaggac ctgaataagc cagatgttcc agatacaata gaaagtgaac 2280
ccagcacagc agataccgtt gttccaatca cttgtgctat agattctaca gctgatccac 2340
aggttagctt caactctaata tacattgata tagaaaagta ttctgaagggt ggtatctagt 2400
tcgtaactgc aaatgaagat tctgtacctg aaaacacttg caaagaaggc ttggtttttg 2460
gccagaaaaca gcctacttgg gttcctgatt cagaagctcc aaactgtatg aactgccaag 2520
tcaaatttac ttttaccaaa cggcgacacc attgccgagc atgtgggaaa gtattttgtg 2580
gtgtctgttg taataggaag tgtaaacctg aatatctaga aaaggaagca agagtatgtg 2640
tagtctgcta tgaaactatt agtaaaagctc aggcatttga aaggatgatg agtccaactg 2700
gttctaactc taagtctaata cattctgatg aatgtactac tgtccagcct cctcaggaga 2760
accaaacatc catataacct tcaccagcaa ctttgccagt ctacagcactt aaacaaccag 2820
gtgttggaag actatgttcc aaagaacaga agagagtatg gtttgcagat ggtatattgc 2880
ccaatggtga agttgcagat acaacaaaaat tatcatctgg aagtaaaaga tgttctgaag 2940
acttttagtcc tctctcacct gatgtgccta tgacagtaaa cacagtggat cattcccat 3000
ctactacagt ggaaaagcca acaatgaga caggagatat tacaagaaat gagataattc 3060
agagtcctat ttctcagggtt ccatcagtgg aaaaattgtc tatgaacaca ggaaatgagg 3120
ggttacctac ttctggttca tttacactag atgatgatgt ttttgagaa actgaagaac 3180
catctagtcc tactggtgtc ttagttaaca gcaatttacc tattgctagt atttcagatt 3240
ataggttact tgtgtatatt aacaagtatg tctgcaataa gattagttct ctacctaatg 3300
atgaggacag ttgccccca cttctggttg catctggaga aaagggatca gtgcctgtag 3360
tagaagaaca tccatctcat gagcagatca ttttgcttct tgaagggtga ggctttcatc 3420
ctgttacatt tgtcctaaat gctaattctac tctgtaattg caaattcata ttttattcct 3480

```

```

cagacaaata ttggtacttt tcaaccaatg gattgcatgg cttgggacag gcagaaatta 3540
ttattctatt gttatgtttg ccaaataaag atactattcc taaggacatc ttcagactat 3600
ttatcaccat atataaggat gctctaaaag gaaaatacat agaaaacttg gacaatatta 3660
cctttactga gagttttctc agtagcaagg atcacggagg attcctgttt attacaccta 3720
cttttcagaa acctgatgat ctctcattac caagtaatcc ttttctttgt ggaattctta 3780
tccagaagct tgagattccc tgggcaaagg ttttccctat gcgtttaatg ttgagattgg 3840
gtgcagaata taaagcatat cctgctcctc taacaagcat cagaggccga aaacctcttt 3900
ttggagaaat aggacacact attatgaact tacttgttga ccttcgaaat taccagtata 3960
ccttgcataa tatagatcaa ctgttgattc atatggaaat gggaaaaagc tgcataaaaa 4020
taccacggaa aaagtacagt gatgtaatga aagtactaaa ttcttccaat gagcatgtca 4080
ttagcattgg agcaagtttc agtacagaag cagattctca tctagtctgt atacagaatg 4140
atggaattta tgaacacacag gccaacagtg ccactggcca tcctagaaaa gtgacagggt 4200
caagttttgt ggtattcaat ggagctctaa aaacatcttc aggatttctt gctaagtcca 4260
gcatagttta agatggctta taactccaga gaccatgaat ggcttgccgc 4320
tagctttacg agaacagaaa gactttaaaa ttacatgtgg gaaagttgat gcagtagacc 4380
tgagagaata cgtggatata tgctgggtag atgctgaaga aaaaggaaac aaaggagtta 4440
tcagttcagt ggatggaata tcattacaag gatttccaag tgaaaaata aaactggaag 4500
cagattttga aaccgatgag aagattgtaa aatgtaccga ggtgttctac tttctaaagg 4560
accaggattt atctatttta tcaacttctt atcagtttgc aaaagaaata gccatggctt 4620
gtagtgctgc gctgtgccct cacctgaaaa ctctaaaaag taatgggatg aataaaattg 4680
gactcagagt ttccattgac actgatatgg ttgaatttca ggcaggatct gaaggccaac 4740
ttctgcctca gcattatcta aatgatcttg atagtctct gatacctgtg atccatggtg 4800
ggacctccaa ctctagttta ccattagaaa tagaattagt gtttttcatt atagaacatc 4860
tttttttagtg aaagaatgtg ccatattaca tattgcaacc taatttgtaa aaactaactc 4920
cagcactaaa gctgaaatgc cacaacact aaaagtataa atatgtctga tttttgaaac 4980
acataagctt tgctctttag gcaggaatga tcttttcaaa tcattagcac aatattttaa 5040
tatctaaaaa ttttaagagat ccatacttct tgtagcttta caattaattt aagtactaaa 5100
aagacaagga tttcttttaa gaaatttata gcatttactg tgttatttaa atgctaagcc 5160
aaagtatctg cacttaggta taaccttcta tgccaataat gattttaatg aaggctcttt 5220
tcagatgtaa ccttatgaag gaaatatctg ctttgtgtat atgccagtta gaatactggg 5280
ttctaaagtc tgtcaaattg tatttcagtg gcacaaaaac cagttttgag gtcttagact 5340
tataattctt tgaataaaac tgataactta tttgtataat tggagtggag acctacctcc 5400
ataattagat aaactctttt tggattataa tcagaatttt gccttttttc ttctcaaatt 5460
attacatatg tatgtattat atateccacat atatagtttt ccctgattaa atggatatta 5520
aaataattgc ggggtcttca ggactttttg ctctctatatt taagtatat gtttttatag 5580
caagaacata ttctgaatgt ttataaatac tttaataatt tatatgtagg taatattttt 5640
gtatcacaat gcattatttt ttttctctct ttccttccaa actataccac tgtatttacc 5700
acttctaaga gtgactgacg acgggccaga tgaccttga agtagtcatt atgtagcaat 5760
aaatgaagcc tgaaacaggt ttttttactt ccactttaat ccttagaaat ttcttgcaa 5820
cttgcgatat tttcattgac actgggtgat aagtataaat ttaaatgaac taattacttt 5880
tgcatatttt aaattcttta tatggtagtt attttttata acaggatatt aacataagtt 5940
aaatcctatg tatttgaat tggtacagag ctttctctt tacttcaaac agcaaaaaag 6000
tggggggcat attgtagtcc gttcatttaa gttatgtaaa aaatttaatc attattttga 6060
tgcttttaaac atttctcatgt gtaatatatg tttttgtatc aaaaacactc atatatattca 6120
agaaaaagaa attatgttaa atagccctgt tttaagaaaa atatttatga agcatctcaa 6180
cttgaagatc aagtcaaagt tataactcag gatctgaggt ctcaagctag gagagactga 6240
gaattttaat cagtttgagg atatagtttg gactgaatca catctgtagt acttagccaa 6300
agacaatttg gaggagaata tcagccctct ggaagttagt acttcctgaa caatgtaaag 6360
tgtgcagat attcaataaa atggcaacct gttataattt gtgaaattta ttgaaatggg 6420
gtaagatgaa aacaaattgca tatcaaacc aatttatgtt ttctaaatat agtgtagtga 6480
ttctgccatg taagtaattg aacagttctt aaataacc aaatctctaca atggtagagg gctgttccat 6540
gatgggacag ctttgatttt gttttcataa aatctctaca ttcaataaaa attggaatta 6600
tgtgcctgaa gtttgagggc acattttgaa gt 6632

```

<210> 4
 <211> 1539
 <212> PRT
 <213> Homo sapiens

 <400> 4

Met Asp Ser Tyr Phe Lys Ala Ala Val Ser Asp Leu Asp Lys Leu Leu
1 5 10 15

Asp Asp Phe Glu Gln Asn Pro Asp Glu Gln Asp Tyr Leu Gln Asp Val
20 25 30

Gln Asn Ala Tyr Asp Ser Asn His Cys Ser Val Ser Ser Glu Leu Ala
35 40 45

Ser Ser Gln Arg Thr Ser Leu Leu Pro Lys Asp Gln Glu Cys Val Asn
50 55 60

Ser Cys Ala Ser Ser Glu Thr Ser Tyr Gly Thr Asn Glu Ser Ser Leu
65 70 75 80

Asn Glu Lys Thr Leu Lys Gly Leu Thr Ser Ile Gln Asn Glu Lys Asn
85 90 95

Val Thr Gly Leu Asp Leu Leu Ser Ser Val Asp Gly Gly Thr Ser Asp
100 105 110

Glu Ile Gln Pro Leu Tyr Met Gly Arg Cys Ser Lys Pro Ile Cys Asp
115 120 125

Leu Ile Ser Asp Met Gly Asn Leu Val His Ala Thr Asn Ser Glu Glu
130 135 140

Asp Ile Lys Lys Leu Leu Pro Asp Asp Phe Lys Ser Asn Ala Asp Ser
145 150 155 160

Leu Ile Gly Leu Asp Leu Ser Ser Val Ser Asp Thr Pro Cys Val Ser
165 170 175

Ser Thr Asp His Asp Ser Asp Thr Val Arg Glu Gln Gln Asn Asp Thr
180 185 190

Ser Ser Glu Leu Gln Asn Arg Glu Ile Gly Gly Ile Lys Glu Leu Gly
195 200 205

Ile Lys Val Asp Thr Thr Leu Ser Asp Ser Tyr Asn Tyr Ser Gly Thr
210 215 220

Glu Asn Leu Lys Asp Lys Lys Ile Phe Asn Gln Leu Glu Ser Ile Val
225 230 235 240

Asp Phe Asn Met Ser Ser Ala Leu Thr Arg Gln Ser Ser Lys Met Phe
245 250 255

His Ala Lys Asp Lys Leu Gln His Lys Ser Gln Pro Cys Gly Leu Leu
260 265 270

Lys Asp Val Gly Leu Val Lys Glu Glu Val Asp Val Ala Val Ile Thr
275 280 285

Ala Ala Glu Cys Leu Lys Glu Glu Gly Lys Thr Ser Ala Leu Thr Cys
290 295 300

Ser Leu Pro Lys Asn Glu Asp Leu Cys Leu Asn Asp Ser Asn Ser Arg
305 310 315 320

Asp Glu Asn Phe Lys Leu Pro Asp Phe Ser Phe Gln Glu Asp Lys Thr

325	330	335
Val Ile Lys Gln Ser Ala Gln Glu Asp Ser Lys Ser Leu Asp Leu Lys		
340	345	350
Asp Asn Asp Val Ile Gln Asp Ser Ser Ser Ala Leu His Val Ser Ser		
355	360	365
Lys Asp Val Pro Ser Ser Leu Ser Cys Leu Pro Ala Ser Gly Ser Met		
370	375	380
Cys Gly Ser Leu Ile Glu Ser Lys Ala Arg Gly Asp Phe Leu Pro Gln		
385	390	400
His Glu His Lys Asp Asn Ile Gln Asp Ala Val Thr Ile His Glu Glu		
405	410	415
Ile Gln Asn Ser Val Val Leu Gly Gly Glu Pro Phe Lys Glu Asn Asp		
420	425	430
Leu Leu Lys Gln Glu Lys Cys Lys Ser Ile Leu Leu Gln Ser Leu Ile		
435	440	445
Glu Gly Met Glu Asp Arg Lys Ile Asp Pro Asp Gln Thr Val Ile Arg		
450	455	460
Ala Glu Ser Leu Asp Gly Gly Asp Thr Ser Ser Thr Val Val Glu Ser		
465	470	475
Gln Glu Gly Leu Ser Gly Thr His Val Pro Glu Ser Ser Asp Cys Cys		
485	490	495
Glu Gly Phe Ile Asn Thr Phe Ser Ser Asn Asp Met Asp Gly Gln Asp		
500	505	510
Leu Asp Tyr Phe Asn Ile Asp Glu Gly Ala Lys Ser Gly Pro Leu Ile		
515	520	525
Ser Asp Ala Glu Leu Asp Ala Phe Leu Thr Glu Gln Tyr Leu Gln Thr		
530	535	540
Thr Asn Ile Lys Ser Phe Glu Glu Asn Val Asn Asp Ser Lys Ser Gln		
545	550	555
Met Asn Gln Ile Asp Met Lys Gly Leu Asp Asp Gly Asn Ile Asn Asn		
565	570	575
Ile Tyr Phe Asn Ala Glu Ala Gly Ala Ile Gly Glu Ser His Gly Ile		
580	585	590
Asn Ile Ile Cys Glu Thr Val Asp Lys Gln Asn Thr Ile Glu Asn Gly		
595	600	605
Leu Ser Leu Gly Glu Lys Ser Thr Ile Pro Val Gln Gln Gly Leu Pro		
610	615	620
Thr Ser Lys Ser Glu Ile Thr Asn Gln Leu Ser Val Ser Asp Ile Asn		
625	630	635
Ser Gln Ser Val Gly Gly Ala Arg Pro Lys Gln Leu Phe Ser Leu Pro		
645	650	655

Ser	Arg	Thr	Arg	Ser	Ser	Lys	Asp	Leu	Asn	Lys	Pro	Asp	Val	Pro	Asp		
			660					665					670				
Thr	Ile	Glu	Ser	Glu	Pro	Ser	Thr	Ala	Asp	Thr	Val	Val	Pro	Ile	Thr		
		675					680					685					
Cys	Ala	Ile	Asp	Ser	Thr	Ala	Asp	Pro	Gln	Val	Ser	Phe	Asn	Ser	Asn		
	690					695					700						
Tyr	Ile	Asp	Ile	Glu	Ser	Asn	Ser	Glu	Gly	Gly	Ser	Ser	Phe	Val	Thr		
705					710					715					720		
Ala	Asn	Glu	Asp	Ser	Val	Pro	Glu	Asn	Thr	Cys	Lys	Glu	Gly	Leu	Val		
				725					730					735			
Leu	Gly	Gln	Lys	Gln	Pro	Thr	Trp	Val	Pro	Asp	Ser	Glu	Ala	Pro	Asn		
			740					745					750				
Cys	Met	Asn	Cys	Gln	Val	Lys	Phe	Thr	Phe	Thr	Lys	Arg	Arg	His	His		
	755						760					765					
Cys	Arg	Ala	Cys	Gly	Lys	Val	Phe	Cys	Gly	Val	Cys	Cys	Asn	Arg	Lys		
	770					775					780						
Cys	Lys	Leu	Gln	Tyr	Leu	Glu	Lys	Glu	Ala	Arg	Val	Cys	Val	Val	Cys		
785					790				795						800		
Tyr	Glu	Thr	Ile	Ser	Lys	Ala	Gln	Ala	Phe	Glu	Arg	Met	Met	Ser	Pro		
				805					810					815			
Thr	Gly	Ser	Asn	Leu	Lys	Ser	Asn	His	Ser	Asp	Glu	Cys	Thr	Thr	Val		
			820					825					830				
Gln	Pro	Pro	Gln	Glu	Asn	Gln	Thr	Ser	Ser	Ile	Pro	Ser	Pro	Ala	Thr		
		835					840						845				
Leu	Pro	Val	Ser	Ala	Leu	Lys	Gln	Pro	Gly	Val	Glu	Gly	Leu	Cys	Ser		
	850					855					860						
Lys	Glu	Gln	Lys	Arg	Val	Trp	Phe	Ala	Asp	Gly	Ile	Leu	Pro	Asn	Gly		
865					870					875					880		
Glu	Val	Ala	Asp	Thr	Thr	Lys	Leu	Ser	Ser	Gly	Ser	Lys	Arg	Cys	Ser		
				885					890					895			
Glu	Asp	Phe	Ser	Pro	Leu	Ser	Pro	Asp	Val	Pro	Met	Thr	Val	Asn	Thr		
			900					905					910				
Val	Asp	His	Ser	His	Ser	Thr	Thr	Val	Glu	Lys	Pro	Asn	Asn	Glu	Thr		
		915					920					925					
Gly	Asp	Ile	Thr	Arg	Asn	Glu	Ile	Ile	Gln	Ser	Pro	Ile	Ser	Gln	Val		
	930					935					940						
Pro	Ser	Val	Glu	Lys	Leu	Ser	Met	Asn	Thr	Gly	Asn	Glu	Gly	Leu	Pro		
945					950					955					960		
Thr	Ser	Gly	Ser	Phe	Thr	Leu	Asp	Asp	Asp	Val	Phe	Ala	Glu	Thr	Glu		
				965					970					975			

Glu Pro Ser Ser Pro Thr Gly Val Leu Val Asn Ser Asn Leu Pro Ile
980 985 990

Ala Ser Ile Ser Asp Tyr Arg Leu Leu Cys Asp Ile Asn Lys Tyr Val
995 1000 1005

Cys Asn Lys Ile Ser Leu Leu Pro Asn Asp Glu Asp Ser Leu Pro Pro
1010 1015 1020

Leu Leu Val Ala Ser Gly Glu Lys Gly Ser Val Pro Val Val Glu Glu
1025 1030 1035 1040

His Pro Ser His Glu Gln Ile Ile Leu Leu Leu Glu Gly Glu Gly Phe
1045 1050 1055

His Pro Val Thr Phe Val Leu Asn Ala Asn Leu Leu Val Asn Val Lys
1060 1065 1070

Phe Ile Phe Tyr Ser Ser Asp Lys Tyr Trp Tyr Phe Ser Thr Asn Gly
1075 1080 1085

Leu His Gly Leu Gly Gln Ala Glu Ile Ile Ile Leu Leu Leu Cys Leu
1090 1095 1100

Pro Asn Glu Asp Thr Ile Pro Lys Asp Ile Phe Arg Leu Phe Ile Thr
1105 1110 1115 1120

Ile Tyr Lys Asp Ala Leu Lys Gly Lys Tyr Ile Glu Asn Leu Asp Asn
1125 1130 1135

Ile Thr Phe Thr Glu Ser Phe Leu Ser Ser Lys Asp His Gly Gly Phe
1140 1145 1150

Leu Phe Ile Thr Pro Thr Phe Gln Lys Leu Asp Asp Leu Ser Leu Pro
1155 1160 1165

Ser Asn Pro Phe Leu Cys Gly Ile Leu Ile Gln Lys Leu Glu Ile Pro
1170 1175 1180

Trp Ala Lys Val Phe Pro Met Arg Leu Met Leu Arg Leu Gly Ala Glu
1185 1190 1195 1200

Tyr Lys Ala Tyr Pro Ala Pro Leu Thr Ser Ile Arg Gly Arg Lys Pro
1205 1210 1215

Leu Phe Gly Glu Ile Gly His Thr Ile Met Asn Leu Leu Val Asp Leu
1220 1225 1230

Arg Asn Tyr Gln Tyr Thr Leu His Asn Ile Asp Gln Leu Leu Ile His
1235 1240 1245

Met Glu Met Gly Lys Ser Cys Ile Lys Ile Pro Arg Lys Lys Tyr Ser
1250 1255 1260

Asp Val Met Lys Val Leu Asn Ser Ser Asn Glu His Val Ile Ser Ile
1265 1270 1275 1280

Gly Ala Ser Phe Ser Thr Glu Ala Asp Ser His Leu Val Cys Ile Gln
1285 1290 1295

Asn Asp Gly Ile Tyr Glu Thr Gln Ala Asn Ser Ala Thr Gly His Pro


```

agtttacaag ctttagatga tcaatcagtg aatattcaca atgaaaaaag tgttctgctc 480
gctgatggct ttccaccatg cagtagcccc aaaagtatta taaactttga ctgcttgacc 540
atggataacg aaatgccttt gcacagtcaa atgagtggtg atgacaatga caaagaaact 600
gtaacaatth cagtccttcc aacaatcata caggatacta gtaacgtaag cacagaccca 660
gctatcaata aacctggcac taaagaaccc catagagcat taaaggaaac cacatcagtt 720
attctgcctg aaataaaagcc ttactccaca tgtgctgccc ttctgtttga aaataacaat 780
aagggtccca gttatcaatt aaataataca aacctactca gogtttcacc agtggttgaa 840
gcatgtagtg agcagcagca aaaacataca tcttccttgc atgaagaaaa actttttgaa 900
ggtgtttctg caacggagtc ctttgcagcc actgctgcgg aaactgtact ggataatgag 960
gctctccgta gtgctgaatt ctttgacatt gttgtaaaga acttttctga ctcttggtgtg 1020
attaatggcg acttgactaa aagttgtggc ctctctcaag aaagcaatga aaagttttgt 1080
gcaagtaaaag agtttgaaag aggggtagat gctaattgtct tgttgaaaaa tgcattgtgt 1140
gtctataaaag aagcaatgaa ttgacctgaa gaaaatggaa ctaatgcacc aatgtctctg 1200
tacaatgggt gttatcccta tggaatgaaa aaccagccg tagctcaaaa ccaaaagaa 1260
ttaccttcaa aagaagattc tgtgacagaa gaaaaagaaa ttgaagaaag caagtcagaa 1320
tactatactg gtgtttatga acaacaaaga gaagatgatg ttacagagag aggtggactt 1380
ctgttaaagt ctaaggctga ccaaatgaag aacaatttgc atagtctttg taatcaggtt 1440
ccatccatgc atgggcaaac atcaccaaaa aagggcaaga ttgtgcaatc tctcagtggt 1500
ccatacgggt gagcacgcac taagcagcca actcatctca aactccatat tccaaagcca 1560
ttgtctgaaa tgttgacagc cgtctctcatt cctccaaatg ctggctgcag ctctaaatac 1620
aaaaatgaca tgttaaacaa atcaaatcag ggggataacc tgatttcaga atcactgctg 1680
gaggattctg cagtgccgag cctgtttact gatgctaatt gtgatttccc tggagaatac 1740
aggggacctg gcagcttggt ccttgacagt tctccagaca gccagacaa cgatctgctt 1800
gccgggcagt ttggggtagc catctctaag ccatttacta ctctagggga agtggctcca 1860
gtctgggtgc cagattccca agcaccaaac tgcattgaag gcgaggccag atttacattt 1920
acaaaaagga ggcattcactg ccgagcttgt ggaaaggtgt tctgtgctgc ttgttgacgt 1980
ctaaaatgca aactacagta catggataaa aaggaggtct gtgtgtgtgt tatttgtcat 2040
tctgtgctta tgaatgctca agcatgggag aacatgttaa gtgcacggt ccaaagccca 2100
aatccaaata atcctgctga atactgctca actatccctc cgatgcagca ggcacaagct 2160
tcaggagcac tgagttcccc acctccact gtcattggtg cagtgggtgt gttaaaacat 2220
ccaggaaactg aagggtcaca gtcaaaggaa cagcgcctg tttggtttgc tgatggaata 2280
ttaccaacg gagagactgc tgactcagat aatgcaaacg taactacagt ggctgggaca 2340
cttactgtgt cacataccaa caattccaca tcttcagagt ctgagaacac ctctggattc 2400
tgtggaagta taactcaggt tggcagtgca atgaacctta ttccagaaga tgggttctct 2460
cctatactaa tctctactgg agtaaaaagga gattaccgag ttgaggaacg ccttccag 2520
atgtctgtga tgcagcaact agaggaagga gaccagatc ctttggtttt tgttctaaat 2580
gcaaatcttt tggccatggt taagatcgtg aactatgtta acaggaaatg ctggtgcttt 2640
actacaaagg gaatgcattg agtgggcccag gctgagatcg taatcctgtt gcagtgcctg 2700
cctgatgaga agtgccctgc gagggacctg tttagccatt ttgttgagct gtatcaggag 2760
gcaattgcag gtaatgtagt ggggaacctg gggcattcct tctcagcca gagtttctct 2820
ggtagtaagg atcatggagg atttctttat gttgcaccaa cctaccagtc cctccaggac 2880
ctggttcttc ctgcagagcc gtacttggtt ggaactctta ttcaaaagtg ggagactcca 2940
tggccaaag tgttccccat tcggcttatg ctgcgtttag gtgcagaata cagattgtac 3000
ccatgtccac tcttcagtggt tcgatacaga aaacctctgt ttggggaaac cggacacacc 3060
atcattaatg ttctagccga ttccagaaac tatcagtata ctctgccagt ggtgcagggc 3120
ttggtggtgg atatggaagt cagaaaaact agcattaaaa tcccagcaa tagatacaat 3180
gagatgatga aagcaatgaa caaatccaat gagcatgtgt tggccatagg agcatgcttc 3240
aaccagatgg cagactctca ccttgtgtgt gtgcaaaacg atgatggcaa ttaccagacc 3300
caggcaatta gtatccacaa acaaccagct aaagtgcacg gggccagctt ctttgtcttc 3360
agtgggtcac taaagtcttc ttccggatag ctggccaaat ccagcatagt agaagatggg 3420
gtaatgggtc agatcacgc agagagcatg gatgccctca gacagtccct tcgggagatg 3480
aaggatttca ccattacatg tggaaaagct gatgcagagg agtcacagga acatgtctat 3540
gtccagtggtg tggaggatga caagaacttt aacaaaggag tttttagtcc aatcgatggc 3600
aatcaatgg agtctgtgac cagcgtcaag atttttcatg gctcagaata caaagctagt 3660
ggaaaaataa ttcgctggat agaggtcttc tttctggaca atgaggagca acagagtggc 3720
ctgagtgacc ctgctgatca cagccgactc actgaaaatg tggccaaagc attctgttta 3780
gcgctttgcc cacacctcaa gctactgaag gaagatggaa tgaccaggtt aggtctgcgg 3840
gtgtcactgg actcagacca ggttggtatc caagctggga gcaatgggca actcctgcct 3900
gcccagataa ccaatgattt ggatggtgct ttggtaccag tgatacacgg gggcacatgc 3960
cagttaaagt aagggcctgt cagtatggag ctgatatttt atatccttga gaacatctcc 4020
taggaaagac acatgtgtct cctcacaac tgccatcgcc caaaccattt gcactttaac 4080

```

cgcaaaagat tcattttttct tttctttttgc taacactagt attaggtcag ggtgcgagag 4140
gcagacacct gaactcttaa accttctatg cattttcaca gtaaggatca agctgcagct 4200
gggaatttcc tgttactaat ccaatgtggg acgttagaag tgatcgggtg cactgactat 4260
ctagctgttc aacctttctct ggctcctcta aggactctag tgccaggggg tgagacattc 4320
aagtttaaaa cgaaaactct aaataacaatc aggaatctca ctctgacctc atttaaatca 4380
tcactgcgac tttttttcct gctcgcatte tttattttgc atcttactca agtttacatt 4440
gtcaagacca gcctaagcct tcagtccttt ctcaattaaa ctactcgtgc atggcaagga 4500
gacttttcgt gcacagcctg aaatatacca atcacttccc aaaccacaag catgaatcca 4560
acgtttttcct gactggttgg ctctgctgtg aaagggacag caatattatt tttctacagt 4620
tgacaaaact tttgtctatg tctgtgtctc tcatggggga tttgttgccct gatgggcagc 4680
ctccggagag aagaattcca cccgtgtgta atatacagtc taagtgtatg gtctgctatg 4740
taacacctgt tgcgcagtg aaatgcactg actctctgga aggctataga gtttttaaaaa 4800
cggttagtct ttttaaaaaaa aaa 4823

<210> 6
<211> 1235
<212> PRT
<213> Xenopus

<400> 6
Met Pro Lys Met Val Ile Gly Asp Thr Ile Met Ala Glu Asp Ser Leu
1 5 10 15
Phe Asn Asn Thr Gly Pro Ser Glu Ile Val Cys Asn Pro Ser Thr Val
20 25 30
Glu Ser Gln Ser Leu Gln Ala Leu Asp Asp Gln Ser Val Asn Ile His
35 40 45
Asn Glu Lys Ser Val Leu Leu Ala Asp Gly Phe Ser Pro Cys Ser Ser
50 55 60
Pro Lys Ser Ile Ile Asn Phe Asp Cys Leu Thr Met Asp Asn Glu Met
65 70 75 80
Pro Leu His Ser Gln Met Ser Val Asp Asp Asn Asp Lys Glu Thr Val
85 90 95
Thr Ile Ser Val Leu Pro Thr Ile Ile Gln Asp Thr Ser Asn Val Ser
100 105 110
Thr Asp Pro Ala Ile Asn Lys Pro Gly Thr Lys Glu Pro His Arg Ala
115 120 125
Leu Lys Glu Thr Thr Ser Val Ile Leu Pro Glu Ile Lys Pro Tyr Ser
130 135 140
Thr Cys Ala Ala Leu Ser Phe Glu Asn Asn Asn Lys Val Pro Ser Tyr
145 150 155 160
Gln Leu Asn Asn Thr Asp Leu Leu Ser Val Ser Pro Val Val Glu Ala
165 170 175
Cys Ser Glu Gln Gln Lys His Thr Ser Ser Leu His Glu Glu Lys
180 185 190
Leu Phe Glu Gly Val Ser Ala Thr Glu Ser Phe Ala Ala Thr Ala Ala
195 200 205
Glu Thr Val Leu Asp Asn Glu Ala Leu Arg Ser Ala Glu Phe Phe Asp

210	215	220
Ile Val Val Lys Asn Phe Ser Asp Ser Cys Val Ile Asn Gly Asp Leu 225 230 235 240		
Thr Lys Ser Cys Gly Leu Ser Gln Glu Ser Asn Glu Lys Phe Cys Ala 245 250 255		
Ser Lys Glu Phe Glu Gly Gly Val Asp Ala Asn Val Leu Leu Glu Asn 260 265 270		
Ala Cys Val Ala Tyr Lys Glu Ala Ile Asp Leu Pro Glu Glu Asn Gly 275 280 285		
Thr Asn Ala Pro Met Ser Leu Tyr Asn Gly Cys Asp Ser Tyr Gly Met 290 295 300		
Lys Asn Pro Ala Val Ala Gln Asn Pro Lys Asn Leu Pro Ser Lys Glu 305 310 315 320		
Asp Ser Val Thr Glu Glu Lys Glu Ile Glu Glu Ser Lys Ser Glu Tyr 325 330 335		
Tyr Thr Gly Val Tyr Glu Gln Gln Arg Glu Asp Asp Val Thr Glu Arg 340 345 350		
Gly Gly Leu Leu Leu Asn Ala Lys Ala Asp Gln Met Lys Asn Asn Leu 355 360 365		
His Ser Leu Cys Asn Gln Val Pro Ser Met His Gly Gln Thr Ser Pro 370 375 380		
Lys Lys Gly Lys Ile Val Gln Ser Leu Ser Val Pro Tyr Gly Gly Ala 385 390 395 400		
Arg Thr Lys Gln Pro Thr His Leu Lys Leu His Ile Pro Lys Pro Leu 405 410 415		
Ser Glu Met Leu Gln Ser Asp Leu Ile Pro Pro Asn Ala Gly Cys Ser 420 425 430		
Ser Lys Tyr Lys Asn Asp Met Leu Asn Lys Ser Asn Gln Gly Asp Asn 435 440 445		
Leu Ile Ser Glu Ser Leu Arg Glu Asp Ser Ala Val Arg Ser Pro Val 450 455 460		
Thr Asp Ala Asn Gly Asp Phe Pro Gly Glu Tyr Arg Gly Pro Gly Ser 465 470 475 480		
Leu Cys Leu Ala Val Ser Pro Asp Ser Pro Asp Asn Asp Leu Leu Ala 485 490 495		
Gly Gln Phe Gly Val Pro Ile Ser Lys Pro Phe Thr Thr Leu Gly Glu 500 505 510		
Val Ala Pro Val Trp Val Pro Asp Ser Gln Ala Pro Asn Cys Met Lys 515 520 525		
Cys Glu Ala Arg Phe Thr Phe Thr Lys Arg Arg His His Cys Arg Ala 530 535 540		

Cys Gly Lys Val Phe Cys Ala Ala Cys Cys Ser Leu Lys Cys Lys Leu
 545 550 555 560
 Gln Tyr Met Asp Lys Lys Glu Ala Arg Val Cys Val Ile Cys His Ser
 565 570 575
 Val Leu Met Asn Ala Gln Ala Trp Glu Asn Met Leu Ser Ala Ser Val
 580 585 590
 Gln Ser Pro Asn Pro Asn Asn Pro Ala Glu Tyr Cys Ser Thr Ile Pro
 595 600 605
 Pro Met Gln Gln Ala Gln Ala Ser Gly Ala Leu Ser Ser Pro Pro Pro
 610 615 620
 Thr Val Met Val Pro Val Gly Val Leu Lys His Pro Gly Thr Glu Gly
 625 630 635 640
 Ser Gln Ser Lys Glu Gln Arg Arg Val Trp Phe Ala Asp Gly Ile Leu
 645 650 655
 Pro Asn Gly Glu Thr Ala Asp Ser Asp Asn Ala Asn Val Thr Thr Val
 660 665 670
 Ala Gly Thr Leu Thr Val Ser His Thr Asn Asn Ser Thr Ser Ser Glu
 675 680 685
 Ser Glu Asn Thr Ser Gly Phe Cys Gly Ser Ile Thr Gln Val Gly Ser
 690 695 700
 Ala Met Asn Leu Ile Pro Glu Asp Gly Leu Pro Pro Ile Leu Ile Ser
 705 710 715 720
 Thr Gly Val Lys Gly Asp Tyr Ala Val Glu Glu Arg Pro Ser Gln Met
 725 730 735
 Ser Val Met Gln Gln Leu Glu Glu Gly Gly Pro Asp Pro Leu Val Phe
 740 745 750
 Val Leu Asn Ala Asn Leu Leu Ala Met Val Lys Ile Val Asn Tyr Val
 755 760 765
 Asn Arg Lys Cys Trp Cys Phe Thr Thr Lys Gly Met His Ala Val Gly
 770 775 780
 Gln Ala Glu Ile Val Ile Leu Leu Gln Cys Leu Pro Asp Glu Lys Cys
 785 790 795 800
 Leu Pro Arg Asp Leu Phe Ser His Phe Val Glu Leu Tyr Gln Glu Ala
 805 810 815
 Ile Ala Gly Asn Val Val Gly Asn Leu Gly His Ser Phe Leu Ser Gln
 820 825 830
 Ser Phe Leu Gly Ser Lys Asp His Gly Gly Phe Leu Tyr Val Ala Pro
 835 840 845
 Thr Tyr Gln Ser Leu Gln Asp Leu Val Leu Pro Ala Glu Pro Tyr Leu
 850 855 860

Phe 865	Gly	Ile	Leu	Ile	Gln 870	Lys	Trp	Glu	Thr	Pro 875	Trp	Ala	Lys	Val	Phe 880
Pro	Ile	Arg	Leu	Met 885	Leu	Arg	Leu	Gly	Ala 890	Glu	Tyr	Arg	Leu	Tyr 895	Pro
Cys	Pro	Leu	Phe 900	Ser	Val	Arg	Tyr	Arg 905	Lys	Pro	Leu	Phe	Gly 910	Glu	Thr
Gly	His	Thr 915	Ile	Ile	Asn	Val	Leu 920	Ala	Asp	Phe	Arg	Asn 925	Tyr	Gln	Tyr
Thr	Leu 930	Pro	Val	Val	Gln	Gly 935	Leu	Val	Val	Asp	Met 940	Glu	Val	Arg	Lys
Thr 945	Ser	Ile	Lys	Ile	Pro 950	Ser	Asn	Arg	Tyr	Asn 955	Glu	Met	Met	Lys	Ala 960
Met	Asn	Lys	Ser 965	Asn	Glu	His	Val	Leu	Ala 970	Ile	Gly	Ala	Cys	Phe 975	Asn
Gln	Met	Ala	Asp 980	Ser	His	Leu	Val	Cys 985	Val	Gln	Asn	Asp	Asp 990	Gly	Asn
Tyr	Gln	Thr 995	Gln	Ala	Ile	Ser 1000	Ile	His	Lys	Gln	Pro 1005	Arg	Lys	Val	Thr
Gly 1010	Ala	Ser	Phe	Phe	Val	Phe 1015	Ser	Gly	Ala	Leu	Lys 1020	Ser	Ser	Ser	Gly
Tyr 1025	Leu	Ala	Lys	Ser	Ser 1030	Ile	Val	Glu	Asp	Gly 1035	Val	Met	Val	Gln	Ile 1040
Thr	Ala	Glu	Ser 1045	Met	Asp	Ala	Leu	Arg	Gln 1050	Ser	Leu	Arg	Glu	Met 1055	Lys
Asp	Phe	Thr 1060	Ile	Thr	Cys	Gly	Lys 1065	Ala	Asp	Ala	Glu	Glu	Ser 1070	Gln	Glu
His	Val 1075	Tyr	Val	Gln	Trp	Val	Glu 1080	Asp	Asp	Lys	Asn 1085	Phe	Asn	Lys	Gly
Val 1090	Phe	Ser	Pro	Ile	Asp	Gly 1095	Lys	Ser	Met	Glu	Ser 1100	Val	Thr	Ser	Val
Lys 1105	Ile	Phe	His	Gly 1110	Ser	Glu	Tyr	Lys	Ala 1115	Ser	Gly	Lys	Ile	Ile	Arg 1120
Trp	Ile	Glu	Val	Phe 1125	Phe	Leu	Asp	Asn	Glu 1130	Glu	Gln	Gln	Ser 1135	Gly	Leu
Ser	Asp	Pro 1140	Ala	Asp	His	Ser	Arg 1145	Leu	Thr	Glu	Asn	Val 1150	Ala	Lys	Ala
Phe	Cys 1155	Leu	Ala	Leu	Cys	Pro	His 1160	Leu	Lys	Leu	Leu	Lys 1165	Glu	Asp	Gly
Met	Thr 1170	Arg	Leu	Gly	Leu	Arg 1175	Val	Ser	Leu	Asp	Ser 1180	Asp	Gln	Val	Gly
Tyr	Gln	Ala	Gly	Ser	Asn	Gly	Gln	Leu	Leu	Pro	Ala	Arg	Tyr	Thr	Asn

Asp Leu Asp Gly Ala Leu Val Pro Val Ile His Gly Gly Thr Cys Gln
1205 1210 1215

Leu Ser Glu Gly Pro Val Ser Met Glu Leu Ile Phe Tyr Ile Leu Glu
1220 1225 1230

Asn Ile Ser
1235

<210> 7
<211> 2678
<212> DNA
<213> Xenopus

<400> 7
agttttatatt tcagaagacg ttgcatcttt attttaaaca ttaagtttca ctatgtagta 60
aaacattact gttgtatata cagtatgttg tagacatata acgtaactgt ttgctttgtg 120
ctttctttcc tctcagatg aaactgtctt tccaaagctg ttagatgcta agtggaatca 180
attcttagaa ccacattcgc ataaagtcaac tgataaacca gctcttgaca atgtctgtaa 240
atcaatcatt gctattgaag ctcatctcaa agtcagggtca cccagcttga cagcccttgc 300
aagggtccaca tatgtgaatg gagaagtagg tattgtgact cctgaaatgc ctaaaatggg 360
gataggagac accgatatgg cagaggattc actttttaac actgggtccct ctgaaattgt 420
atgcaactct attgtggaga gtcaaagttt agaagtttta gatgatgtac cagtgaagtat 480
taacaatgaa aaaagtgttc ttcttgatga tggattttct ccgtacagta gccccaaaag 540
tgttctaaac tctgcttgct tgaccatgaa taacggaaaag ccctcacacg gtcaaaaaat 600
tgttaatgac caagataaag aagctgtaac aatttcagtc cttccaatga tcatacagga 660
tactactaac gtaagcacag acccagcttt caataaatct ggcactgaag aagcttatag 720
tgcattaaaa caaaccacat cagttattct gcctgaaata aagccttatt ccatacaggc 780
tgccctttca tgtgaaaata tcaacaagat acccagatgt caattaaata atacagatct 840
actcagcatt tcaccagtgg ttgaagcatg tagtgagaag cagcaaaatc atacaacttc 900
cttgcatgaa aaaaaacttg cagctgtgtc tgcaactgcg ttctttccag tcaactgtgc 960
tgaaactgta aagctctcca tagtctgat ttttttgaca ttgttgtaaa 1020
gaacgtttct gactcgtgtg tgtttaatgg tgacctaaact agaactaatg gactctcaca 1080
agaaaacaat gaaatgtttt atgcaagtaa agagttggaa ggaggggtag atgctaatat 1140
cttattggaa gatgcatgca tagcttataa agaaagaata gatttgtctg aagaaaatgg 1200
aactaatgca ccaatgtatc tgtacaatgg gtgtgattcc tatggaatga aaaaccctgc 1260
tgtacgtcaa aacccaaaga atttaccatc aaaagaagat tctgtgacag aagaaaaaga 1320
aattgaagaa agcaagtcag aatactattc tgggtgtttat gaacaacaga aggaagatga 1380
cataactgag agaggtggag tcttggttaa tgccaagggt gaccaaataga agaacagttt 1440
gcatagtctt tataatccgg ttccatccat gcattgggcaa acctcaccaa aaaagggcaa 1500
gattgtgcaa tccctcagtg ttccatatgg tggagctcgc cccaagcagc caactcatct 1560
caaactcaat attccacagc cattgtctga aatgttacag tgtgatctca ttccgccaaa 1620
tgctggatgc agctctaaaa acaaaaatga catgttaaac aaatcaaatc ggggggataa 1680
cctgatttca gaatcactac gtgaggaagt gcacagccct gttactgata caaatgggtga 1740
agtccctcga gaaaacaggg gacctggcag cctgtgcctt gcagtgtctc cagacagccc 1800
tgacaatgat ctgctgtctg gacagtttg ggtaccatc tctaagccat ttactactct 1860
aggggatgtg gctccagctc gggtgccaga tccccagca ccaaactgca tgaagtgcga 1920
ggccagattt acatttacca aaaggaggca tcaactgccga gcttgtggaa aggtatgtaa 1980
agaaatgtgg tgtttcatca gggcaacagt aatcacggca aattattcat aacaaaatgt 2040
gttcagcaga ttcagttaaa gtagacttat aagttacaca gtaacaattc atctgctcag 2100
cctcattttg aagtagataa aatataatatt attaggaatc tctggggaga tataaggga 2160
agcttgccct aaagtagatg ttctgtatat tatttggtag tcaaagatga tttcatgaaa 2220
aaaagttatt tgtaaaaagt acaaaaatggg tagagactag acaataaaaa gtaaggagta 2280
aaaactaggt tatgtaacgt atattaaaat tatttttatga ttttaattatt tactgcacat 2340
tttctacagt gcagtgattt gtataacat gcaattatca aatgcttagt gccttcacac 2400
aaagtgcctt taataaaaaat tattttataa attatcatat tttctttata tgtagtcatc 2460
atcttttttg tctcatttct tgggaatcgt ctacttatgt tctactgata tgttttttac 2520
ccgagacctt tcttgcctc taaagtaatt ggcttgtcaa ctggctgtag ggggattttc 2580

agagttatag cttagtactg ttaatgagcc ataggttgaa atagtgtctc agattttacat 2640
gttgtacaac agttattgca atatgtgtag gggggggg 2678

<210> 8
<211> 561
<212> PRT
<213> Xenopus

<400> 8
Met Pro Lys Met Val Ile Gly Asp Thr Asp Met Ala Glu Asp Ser Leu
1 5 10 15
Phe Asn Thr Gly Pro Ser Glu Ile Val Cys Asn Ser Ile Val Glu Ser
20 25 30
Gln Ser Leu Glu Val Leu Asp Asp Val Pro Val Ser Ile Asn Asn Glu
35 40 45
Lys Ser Val Leu Leu Asp Asp Gly Phe Ser Pro Tyr Ser Ser Pro Lys
50 55 60
Ser Val Leu Asn Ser Ala Cys Leu Thr Met Asn Asn Gly Lys Pro Ser
65 70 75 80
His Gly Gln Lys Ile Val Asn Asp Gln Asp Lys Glu Ala Val Thr Ile
85 90 95
Ser Val Leu Pro Met Ile Ile Gln Asp Thr Thr Asn Val Ser Thr Asp
100 105 110
Pro Ala Phe Asn Lys Ser Gly Thr Glu Glu Ala Tyr Ser Ala Leu Lys
115 120 125
Gln Thr Thr Ser Val Ile Leu Pro Glu Ile Lys Pro Tyr Ser Ile Gln
130 135 140
Ala Ala Leu Ser Cys Glu Asn Ile Asn Lys Ile Pro Arg Cys Gln Leu
145 150 155 160
Asn Asn Thr Asp Leu Leu Ser Ile Ser Pro Val Val Glu Ala Cys Ser
165 170 175
Glu Lys Gln Gln Asn His Thr Thr Ser Leu His Glu Lys Lys Leu Ala
180 185 190
Ala Val Ser Ala Thr Ala Phe Phe Pro Val Thr Ala Ala Glu Thr Val
195 200 205
Leu Gly Asn Glu Ala Leu His Ser Ala Asp Phe Phe Asp Ile Val Val
210 215 220
Lys Asn Val Ser Asp Ser Cys Val Phe Asn Gly Asp Leu Thr Arg Thr
225 230 235 240
Asn Gly Leu Ser Gln Glu Asn Asn Glu Met Phe Tyr Ala Ser Lys Glu
245 250 255
Leu Glu Gly Gly Val Asp Ala Asn Ile Leu Leu Glu Asp Ala Cys Ile
260 265 270

Ala Tyr Lys Glu Arg Ile Asp Leu Ser Glu Glu Asn Gly Thr Asn Ala
275 280 285

Pro Met Tyr Leu Tyr Asn Gly Cys Asp Ser Tyr Gly Met Lys Asn Pro
290 295 300

Ala Val Arg Gln Asn Pro Lys Asn Leu Pro Ser Lys Glu Asp Ser Val
305 310 315 320

Thr Glu Glu Lys Glu Ile Glu Glu Ser Lys Ser Glu Tyr Tyr Ser Gly
325 330 335

Val Tyr Glu Gln Gln Lys Glu Asp Asp Ile Thr Glu Arg Gly Gly Val
340 345 350

Leu Leu Asn Ala Lys Val Asp Gln Met Lys Asn Ser Leu His Ser Leu
355 360 365

Tyr Asn Pro Val Pro Ser Met His Gly Gln Thr Ser Pro Lys Lys Gly
370 375 380

Lys Ile Val Gln Ser Leu Ser Val Pro Tyr Gly Gly Ala Arg Pro Lys
385 390 395 400

Gln Pro Thr His Leu Lys Leu Asn Ile Pro Gln Pro Leu Ser Glu Met
405 410 415

Leu Gln Cys Asp Leu Ile Pro Pro Asn Ala Gly Cys Ser Ser Lys Asn
420 425 430

Lys Asn Asp Met Leu Asn Lys Ser Asn Arg Gly Asp Asn Leu Ile Ser
435 440 445

Glu Ser Leu Arg Glu Glu Val His Ser Pro Val Thr Asp Thr Asn Gly
450 455 460

Glu Val Pro Arg Glu Asn Arg Gly Pro Gly Ser Leu Cys Leu Ala Val
465 470 475 480

Ser Pro Asp Ser Pro Asp Asn Asp Leu Leu Ala Gly Gln Phe Gly Val
485 490 495

Pro Ile Ser Lys Pro Phe Thr Thr Leu Gly Asp Val Ala Pro Val Trp
500 505 510


Val Pro Asp Ser Gln Ala Pro Asn Cys Met Lys Cys Glu Ala Arg Phe
515 520 525

Thr Phe Thr Lys Arg Arg His His Cys Arg Ala Cys Gly Lys Val Cys
530 535 540

Lys Glu Met Trp Cys Phe Ile Arg Ala Thr Val Ile Thr Ala Asn Tyr
545 550 555 560

Ser

United States Patent & Trademark Office
Office of Initial Patent Examination -- Scanning Division



Application deficiencies found during scanning:

☐ Page(s) _____ of _____ were not present
for scanning. (Document title)

☐ Page(s) _____ of _____ were not present
for scanning. (Document title)

** Scanned copy is best available. Drawing too dark.*